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ABSTRACT 
 Inflammation has been shown to play an integral role in a number of different disease 
processes.  There is evidence that measurements of the systemic immune/inflammatory 
response are associated with mortality in patients with certain malignancies, as well as those 
with atherosclerotic disease.  A variety of readily available inflammation-based prognostic 
scores, combining serum constituents of the systemic immune/inflammatory response, have 
been suggested for use in these patient groups.  However, it is unclear whether systemic 
inflammation-based scores are universally associated with mortality across all tumour types 
and whether this relationship persists in atherosclerotic conditions including cardiovascular 
and cerebrovascular disease.  The optimal constituents of such a score are also still to be 
determined.  The present thesis further examines these topics with specific reference to: 
1. The relationship between the presence of cancer, an inflammation-based prognostic score 
and biochemical parameters in a large group of unselected patients. 
2. The relationship between an inflammation-based prognostic score and cancer survival in 
patients with malignancies at a number of different sites. 
3. A comparison of commonly available inflammation-based prognostic scores in patients 
with cancer. 
4. The prognostic value of a derived neutrophil to lymphocyte ratio, commonly available in 
patients with cancer undergoing chemotherapy. 
5. The optimal serum constituents of the systemic inflammation-based Glasgow Prognostic 
Score (optimised) in patients with cancer. 
6. The optimal constituents and prognostic value of a systemic inflammation-based score for 
predicting cardiovascular, cerebrovascular and all-cause mortality. 
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1.0. INTRODUCTION 
1.1. THE IMMUNE/INFLAMMATORY RESPONSE 
1.1.1. The Local Immune/Inflammatory Response 
 The immune/inflammatory response, as a reaction to injury, infection, inflammatory 
conditions or malignancy, occurs at both a local and systemic level.  The local 
immune/inflammatory reaction is characterised by the four clinical signs of inflammation;   
erythema, heat, swelling and pain.  Erythema and increased tissue temperature occur as a 
result of mast cell degradation and cytokine mediated vasodilatation.  Similarly, swelling 
occurs as a result of cytokine mediated increased capillary permeability and subsequent 
accumulation of extravascular exudate and inflammatory cells.  During the local 
immune/inflammatory response, pain evoking proinflammatory mediators are also released 
[Chandrasoma and Taylor, 2005].  The local immune/inflammatory response, through 
complex immunological processes detailed below, can in turn initiate a global, systemic 
immune/inflammatory response. 
1.1.2. The Innate Immune System 
 Immunity can be broadly divided into the innate, humoral and adaptive systems 
[Abbas et al., 2005].  It is however worth noting that these definitions are arbitrary as the 
processes involved are interrelated and the distinctions between each system blurred at both 
the local and systemic levels (Figure 1.1).  The innate immune system is a non-specific, first 
line defence against insult or attack and aims to promote clearance of pathogens, wound 
healing and tissue repair.  Cells of the innate immune system have germline encoded 
recognition with the ability to detect non-self and are therefore integral in local and systemic 
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inflammatory processes [Janeway and Medzhitov, 2002].  At a local level, activation of the 
complement system stimulates mast cell release of histamine and protease, resulting in 
clinical signs of local inflammation [Reid and Porter, 1981;  Galli et al., 1993].  As illustrated 
in Figure 1.1, phagocytic cells initiate inflammatory pathways by releasing pro-inflammatory 
cytokines and activating the complement system, termed the humoral response [Laskin and 
Pendino, 1995;  Koj, 1996]. 
Figure 1.1. Interactions between the innate, humoral and adaptive immune systems [de 
Visser and Coussens, 2005] 
1.1.3. The Humoral Immune System 
 The humoral system refers to the non-cellular components of the immune system 
found in extracellular fluid, in particular the serum.  It is normally initiated by the innate 
immune-based local inflammatory response and triggers a cascade of immunological 
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processes that help link and co-ordinate the innate and adaptive immune/inflammatory 
responses (Figure 1.1).  It is composed of a number of blood based proteins including 
antibodies, constituents of the complement pathway, cytokines and opsonins that promote 
pathogen cell lysis and phagocytosis [Janeway et al., 2001].  Indeed, following tissue damage 
from infection, chemical injury, trauma, malignancy or immune based destruction, a wide 
variety of growth factors including colony stimulating, as well as a variety of chemotactic 
cytokines that attract monocytes and stimulate them to transform into macrophages, are 
released.  As well as the recruitment of innate and adaptive immune cells and promotion of 
pathogen death, humoral immunity also helps to drive the resulting systemic 
immune/inflammatory response [Baumann and Gauldie, 1994;  Janeway and Medzhitov, 
2002]. 
 
Figure 1.2. The temporal relationship between the innate and adaptive immune system 
[Abbas et al., 2005] 
1.1.4. The Adaptive Immune System 
 The adaptive immune system is predominantly composed of lymphocytes, and 
through the recognition of foreign antigens, aims to develop immunological memory and 
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speed the elimination of future pathogen attacks [Janeway and Medzhitov, 2002].  The 
adaptive immune system can be classified as antibody mediated (part of the humoral 
response) or cell mediated, although many of the processes are interrelated.  As illustrated in 
Figure 1.2, the antibody mediated response relies on phagocytic cells of the innate immune 
system, such as macrophages and neutrophils, as well as dendritic cells and B-lymphocytes, 
to present non-self peptides to T-lymphocytes and produce circulating antibodies [Unanue, 
2002].  Cell mediated immunity results in antigen-specific cytotoxic T-lymphocytes 
recognition and phagocytosis of previously exposed pathogens [Herberman and Holden, 
1978;  Santoni et al., 1979]. 
1.1.5. The Systemic Immune/Inflammatory Response  
 Following a local immune/inflammatory reaction, and activation of the innate, 
humoral and adaptive immune systems, circulating pro-inflammatory mediator can result in a 
subsequent systemic immune/inflammatory response.  Indeed, a correlation has been 
demonstrated between local cytokine production and systemic inflammation in patients with 
a variety of inflammatory processes [Vernooy et al., 2002;  Grigoryev et al., 2008].  While 
the immune system aims to promote healing and prevent further injury by destroying harmful 
or infectious agents, the systemic immune/inflammatory response, also referred to as the 
acute phase reaction, can influence neuroendocrine, haematopoietic, metabolic and hepatic 
regulation with a number of associated negative physiological outcomes (Table 1.1.) 
[Baumann and Gauldie, 1994;  Koj, 1996].  As part of the systemic immune/inflammatory 
response, circulating serum constituents of the fore-mentioned innate, humoral and adaptive 
immune systems, as well as a number of other physiological markers are altered.  The 
systemic immune/inflammatory response has often been overlooked during the study of 
inflammation, disease pathogenesis and progression, however it is becoming increasingly 
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evident that this process is closely associated with outcome.  This thesis will therefore 
concentrate on the systemic, opposed to the local immune/inflammatory response. 
Table 1.1. The acute phase phenomena 
Neuroendocrine 
Fever, somnolence, and anorexia 
Increased secretion of corticotropin-releasing hormone, corticotropin, and cortisol 
Increased secretion of arginine vasopressin 
Decreased production of insulin-like growth factor I 
Increased adrenal secretion of catecholamines 
Hematopoietic changes 
Anaemia of chronic disease 
Leukocytosis 
Thrombocytosis 
Metabolic changes 
Loss of muscle and negative nitrogen balance 
Decreased gluconeogenesis 
Cachexia and osteoporosis 
Increased hepatic lipogenesis 
Increased lipolysis in adipose tissue and decreased lipoprotein lipase activity in muscle and adipose tissue 
Hepatic changes 
Increased metallothionein, inducible nitric oxide synthase, heme oxygenase, manganese superoxide dismutase, 
and tissue inhibitor of metalloproteinase-1 
Decreased phosphoenolpyruvate carboxykinase activity 
Changes in non-protein plasma constituent 
Hypozincemia, hypoferremia, and hypercupremia 
Increased plasma retinol and glutathione concentrations 
[Gabay and Kushner, 1999] 
1.1.6. Acute Phase Proteins 
 During the systemic immune/inflammatory response, as a result of physiological 
changes in protein metabolism and distribution, serum protein levels fluctuate [Fleck, 1989].  
Acute phase protein have been defined as those demonstrating a plasma concentration change 
of at least 25% during an immune/inflammatory reaction [Kushner, 1982].  There are around 
forty acute phase proteins and these can be positive, (increasing in concentration) or negative 
(reducing in concentration) [Gabay and Kushner, 1999].  Immunomodulating cytokines, 
including IL-1, IL-6, IL8 and tumour necrosis factor α, are released from activated cells of 
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the innate immune system and, under glucocorticoid and growth factor regulatory control, act 
predominantly on the liver to synthesise positive acute phase proteins [Balkwill and Burke, 
1989;  Kulkarni and Karlsson, 1993;  Wigmore et al., 1997], some of which have 
immunological roles and function as part of the humoral immune system. 
 As shown in Figure 1.3, the majority of acute phase proteins are positive and increase 
in serum concentration during an immune/inflammatory response.  Examples of positive 
proteins include those of the complement system (C3, C4 and factor B), the coagulation and 
fibrinolytic  system  (fibrinogen,  plasminogen,  urokinase  and protein S),  antiproteases (α1-  
 
  
Figure 1.3. The temporal relationship of acute phase proteins [Gabay and Kushner, 
1999] 
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Antichymotrypsin and α1-Protease inhibitor), transport proteins (Haptoglobin) as well as 
many others including C-reactive protein and serum amyloid A [Gabay and Kushner, 1999].  
Examples of negative proteins include albumin, transferrin, alpha-fetoprotein and insulin-like 
growth factor I [Gabay and Kushner, 1999]. 
 In 1930, C-reactive protein was the first acute phase protein to be discovered [Tillett 
and Francis, 1930] and is now one of the most readily available markers of the systemic 
immune/inflammatory response.  C-reactive protein belongs to the pentraxin family of 
calcium-dependent ligand-binding plasma proteins.  It predominantly binds to 
phosphocholine residues found in necrotic and apoptotic cell walls [Thompson et al., 1999] 
but has also been shown to have an affinity for extrinsic ligands on bacterial, fungal and 
parasitic microorganism [Du Clos, 1996].  Binding of these ligands results in the aggregation 
and precipitation of such structures, initiation of the complement system and subsequent 
opsonisation and phagocytosis [Mold et al., 1999]. 
 C-reactive protein is currently one of the most commonly used markers of systemic 
inflammation in clinical practice with the median concentration of C-reactive protein having 
been found to be 0.8mg/l in healthy individuals.  It is also of interest that 90% of healthy 
people have a concentration of less than 3.0mg/l and 99% a concentration of less than 10mg/l 
[Shine et al., 1981].  As illustrated in Figure 1.3, serum concentrations peak around 48 hours 
following insult with a half life of around 19 hours [Vigushin et al., 1993].  It is also known 
to be one of the most sensitive acute phase proteins and can vary in magnitude by up to 1000 
times [Gabay and Kushner, 1999].  C-reactive protein levels in the general population tend to 
be stable with no seasonal change and only minor yearly variations [Macy et al., 1997;  Pepys 
and Hirschfield, 2003].  However, C-reactive protein concentrations are known to vary across 
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a number of parameters including body mass index (BMI) [Ford, 1999] and smoking [Wong 
et al., 2001]. 
 Serum albumin is also commonly sampled in clinical practice and is known to reduce 
in serum concentration during the acute phase response [Ritchie et al., 1999;  McMillan et al., 
2001].  Serum albumin is produced in the liver and accounts for the majority of hepatic 
protein synthesis [Williams and Scott, 1998] with serum levels being influenced by 
inflammatory cytokine regulation of hepatic production, as well as protein degradation and 
redistribution [Goldwasser and Feldman, 1997].  A number of conditions, including sepsis, 
malignancy and chronic disease, can result in increased vascular permeability, albumin 
redistribution into extra-vascular tissues and subsequent reduction in serum albumin levels 
[Fleck et al., 1985].  Factors known to influence serum albumin levels include gender 
[Ritchie et al., 1999], daily activity, muscle mass [Baumgartner et al., 1996] and smoking 
[Salive et al., 1992]. 
1.1.7. Liver Function Tests, Calcium and Inflammation 
 Commonly sampled serum biochemical parameters also affected during the systemic 
immune/inflammatory response include liver function tests and serum calcium levels.  A 
number of liver function tests have been shown to be associated with an inflammation 
associated C-reactive protein rise [Kerner et al., 2005;  Cheung et al., 2008] and alkaline 
phosphatase has been associated with altered levels of other acute phase proteins including 
albumin [Blayney et al., 2008].  Similarly, gamma-glutamyl transferase, thought to be an 
early marker of oxidative stress, has been associated with raised C-reactive protein levels 
[Lee and Jacobs, 2005].  Bilirubin, known to have endogenous antioxidant properties, has 
been found to have lower serum concentrations in the presence of an active leukocytosis 
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[Stocker et al., 1987;  Greabu et al., 2001].  There is also evidence that liver function tests are 
altered as part of the systemic immune/inflammatory response in conditions including lung 
and gastrointestinal cancer [Brown et al., 2007;  Roxburgh et al., 2009a].  Furthermore, it has 
been suggested that the systemic immune/inflammatory response and C-reactive protein have 
an effect on cellular calcium metabolism [Foldes-Filep et al., 1992]. 
1.1.8. The Chronic Systemic Immune/Inflammatory Response 
 If the precipitating factor leading to an acute phase response is persistent, this process 
can be prolonged and a chronic systemic immune/inflammatory state will occur [Gabay and 
Kushner, 1999].  Examples of chronic local immune/inflammatory conditions that may lead 
to a chronic systemic immune/inflammatory response include atherosclerotic lesions [Ross, 
1999], chronic infection [Cassell, 1998;  Moutsopoulos and Madianos, 2006], chronic 
pancreatitis [Nair et al., 2007] and malignancy [Rakoff-Nahoum, 2006].  This ongoing 
process is sometimes referred to as the "Systemic Inflammatory Response" that, in part, 
involves alterations of the pre-mentioned circulating constituents of the immune system and 
associated serum biochemical variables.  It is this phenomenon and its associations with 
outcome, predominantly in cancer but also in artheriosclerotic disease, that will be focused on 
in this thesis. 
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1.2. INFLAMMATION AND CANCER 
1.2.1. Cancer Incidence 
 In 2008, it was estimated that there were 12.4 million new cancer cases diagnosed 
worldwide.  Traditionally cancer has been a disease of Western, high income countries, 
however, this is changing.  As shown in Figure 1.4, over half of all newly detected cancers 
are now occurring in developing countries [Boyle and Levin, 2008]. 
 
Figure 1.4. Worldwide cancer incidence by region in 2008 [Boyle and Levin, 2008] 
 With a growing global population and increasing life expectancy, the current 
incidence figures are set to rise to at least 20 million by 2030 [Boyle and Levin, 2008].  This 
is expected to be a global phenomenon with a projected increase in European regions from 
4.1 million cases per annum in 2008 to at least 5.5 million per annum in 2030 [Boyle and 
Levin, 2008].  In the United Kingdom cancer incidence has also risen by approximately 25% 
between 1975 and 2004.  As a consequence, more than one in three people will develop 
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cancer during their lifetime [Cancer Research UK, 2008] with similar projected increases in 
the number of cases forecasted [Moller et al., 2007]. 
 Worldwide, lung cancer is the most commonly diagnosed tumour with approximately 
one million new cases in 2002.  The incidence of lung cancer varies from approximately 2 
per 100 000 in African women to 61 per 100 000 in North American men [Kamangar et al., 
2006], a difference largely attributable to cigarette smoking [Ezzati and Lopez, 2003].  Colon 
cancer is approximately 25 times more common in developed countries, a difference partially 
attributable to differences in meat, fat and fibre consumption [Trock et al., 1990;  Willett et 
al., 1990].  Female breast cancer is also more common in developed populations, a difference 
possibly due to an older population and increasing detection since the introduction of 
screening [Alberg and Singh, 2001]. 
         
Figure 1.5. Number of cancers diagnosed in the UK per year.  [Cancer Research UK, 
2008] 
 Of the 280 000 new cancers diagnosed each year in the United Kingdom (Figure 1.5), 
the majority occur in people over 60 years of age [Cancer Research UK, 2008].  During 2004 
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the commonest cancers diagnosed in males were prostate (34 986), lung (22 495), colorectal 
(19 657), gastroesophageal (10 100) and bladder (7168).  During the same time period, in 
females, the most commonly diagnosed malignancies were breast (44 335) followed by 
colorectal (16 452), lung (15 818), gynaecological (15 779) and gastroesophageal (5732). 
1.2.2. Cancer Mortality 
 Worldwide, in 2008 there were an estimated 7.6 million deaths attributed to cancer 
with projected figures to reach at least 12.9 million by 2030 [Boyle and Levin, 2008].  
Survival from common cancers including breast, colorectal and prostate, is generally better 
for those diagnosed in developed countries of western Europe, North America and Australia, 
when compared to less developed areas including eastern Europe, Algeria and Brazil 
[Coleman et al., 2008]. 
 In the United Kingdom cancer is the leading cause of death and responsible for 
approximately thirty percent of all mortality, equating to around 150,000 deaths per year 
[Cancer Research UK, 2007].  Most deaths occur in males and those over the age of 75 with 
an increased mortality rate in the socioeconomically deprived [Coleman et al., 2004].  The 
commonest cancers responsible for death are lung, bowel, breast and prostate with the 
relative five year survival of these, and other common cancers illustrated in Figure 1.6. 
 In recent decades there have been improvements of approximately ten percent in 
cancer mortality rates with these changes largely affecting people under the age of 75 with 
cancers of the stomach, lung, bladder, bowel and cervix [Cancer Research UK, 2006].  These 
improvements are likely due to better detection and treatment modalities, however, with 
increasing population age a rise of 40% in cancer deaths is expected by 2025 [Olsen et al., 
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2008].  This clearly has significant financial implications and will require a greater proportion 
of annual healthcare spending [Bosanquet and Sikora, 2004;  Boyle and Levin, 2008]. 
 
Figure 1.6. Relative 5 year survival in common tumour types in the UK. [Cancer 
Research UK, 2007] 
1.2.3. Patient Demographics and Cancer Survival 
 A number of patient based factors are known to be related to survival in patients with 
cancer.  Increasing age is associated with reduced survival when adjusted for other known 
factors in the majority of cancers [Sant et al., 2003;  Lam et al., 2007].  In part, this may be 
explained by inadequate staging and fewer treatment options in the elderly [de Rijke et al., 
1996;  Fentiman, 1996].  There are however certain tumour types, specifically lung, breast 
and prostate, that do not conform to this pattern with some evidence that older patients have 
an improved survival [Romano and Mark, 1992;  Merrill and Bird, 2002;  Chia et al., 2004;  
Mathew et al., 2004]. 
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 Male gender is also associated with reduced survival in variety of tumour types that 
can affect both sexes.  For example, male gender tends to be associated with a poorer 
outcome in patients with colorectal and lung cancer, as well as chronic lymphocytic 
leukaemia [Romano and Mark, 1992;  Diehl et al., 1999;  Wichmann et al., 2001;  McArdle et 
al., 2003;  Sant et al., 2003;  Visbal et al., 2004]. 
 Furthermore, increasing socioeconomic deprivation has been associated with reduced 
survival in a number of different tumour types including lung, breast, colorectal, bladder, 
prostate, uterine and cervical, independent of other prognostic factors [Schrijvers et al., 1995;  
Coleman et al., 2004].  In population studies, deprivation has traditionally been measured by 
the Carstairs index [Sloggett and Joshi, 1998], a postcode based score derived from a number 
of socioeconomic factors including car ownership, household crowding, head of household 
social class and male unemployment [Carstairs and Morris, 1991].  Currently, the 
recommended measurement of deprivation in Scotland is the (SIMD).  Similarly it 
categorises post code areas, however, a more detailed measurement of 37 indicators across 
seven domains including income, employment, education, housing, health, crime and 
geological area is used [Bishop et al., 2004].  Scotland is divided into 6,505 data zones with 
these ranked from 1 (least deprived) to 6,505 (most deprived).  These data zones have further 
been divided into quintiles of the Scottish population, with the present body of work using 
quintiles that range from 1 (least deprived) to 5 (most deprived).  As can be seen in Figure 
1.7, an increasing SIMD score has been shown to be associated with an increased cancer 
incidence as well as an increased cancer associated mortality in the Scottish population [The 
Scottish Government, 2008]. 
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Figure 1.7. Malignant neoplasm age-standardised incidence and mortality by SIMD 
Quintiles [The Scottish Government, 2008] 
1.2.4. Inherited Genetic Mutations and Carcinogenesis 
 The development of malignancy is a multi-step process depending on the inheritance 
or development of deoxyribonucleic acid (DNA) mutations that result in the interruption of 
tumour suppression or activation of pro-oncogenic pathways at a cellular level [Kinzler and 
Vogelstein, 1996].  Genetic mutations ultimately result in the development of several cellular 
characteristics, including invasion and the potential to metastasise, that are required for 
malignant transformation [Hanahan and Weinberg, 2000]. 
 It has long been accepted that cancer has a genetic basis with a variety of tumours 
noted to have potentially hereditary patterns [Easton, 1994].  In twin studies it has been 
estimated that genetic predispositions are a contributing factor in approximately 28% of 
gastric, 35% of colorectal, 27% of breast and 42% of prostate cancers [Lichtenstein et al., 
2000].  A number of genes have been identified as increasing cancer risk including BRCA1 
and 2 in breast cancer, APC, MSH2, MLH1 in colon cancer and MET in renal cell cancer. 
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1.2.5. Acquired Genetic Mutations and Carcinogenesis 
 DNA mutations, whether they result in the activation of oncogenes or the loss of 
tumour suppressor genes, can occur as a consequence of point mutations, insertions or 
deletions of base pairs, gain or loss of entire chromosomes, translocations and gene 
amplifications [Lengauer et al., 1998].  Acquired mutations are thought to be responsible for 
the majority of DNA mutations and can be secondary to oxidative stress or radiation 
[Lichtenstein et al., 2000;  Hemminki and Jiang, 2002].  Oxidative stress can occur as the 
result of contact with a number of carcinogens including those found in food [Wong et al., 
2001;  Straif et al., 2006;  Baan et al., 2007], cigarette smoke [Wogan et al., 2004] and other 
chemical compounds [Baan et al., 2008]. 
1.2.6. Inflammation and Carcinogenesis 
 There is growing evidence that a local inflammatory microenvironment encourages 
the development of malignancy with an increased prevalence of cancer in tissues 
experiencing chronic inflammation [Balkwill and Coussens, 2004;  Vakkila and Lotze, 2004;  
Lu et al., 2006].  Continued immune/inflammatory stimuli secondary to chemical irritation 
[Whitcomb, 2004], infection [Pagano et al., 2004] or immunological disorders [Itzkowitz and 
Yio, 2004] can result in the release of a variety tumour promoting cytokines [Lin and Karin, 
2007].  Increased tissue turnover, loss of tissue architecture and oxidative stress can result in 
DNA damage with subsequent risk of neoplastic transformation and eventual cancer 
development [Shacter and Weitzman, 2002;  Balkwill et al., 2005;  Colotta et al., 2009]. 
 Globally, approximately 17% of all cancers are attributed to infectious aetiology 
[Kuper et al., 2000;  Parkin, 2006].  For example, chronic viral hepatitis has been implicated 
in the pathogenesis of the majority of hepatocellular cancers [Kew, 1998] and the human 
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papilloma virus has been clearly associated with the development of cervical cancer [Bosch 
et al., 2002]. 
 Non-infective, autoimmune inflammatory conditions also predispose individuals to 
the development of neoplasia.  Colorectal cancer incidence increases by approximately 10 
fold in patients with chronic inflammatory conditions of the colon, such as ulcerative colitis 
[Itzkowitz and Yio, 2004].  Fibrotic and inflammatory lung conditions, including idiopathic 
pulmonary fibrosis and systemic sclerosis, have also been shown to increase risk the of 
developing cancer [Daniels and Jett, 2005].  Similarly, patients with systemic lupus 
erythematosus (SLE) have a higher incidence of cervical dysplasia [Blumenfeld et al., 1994]. 
1.2.7. Inflammation and Cancer Progression 
 It has been suggested that essential alterations in cell physiology, including self 
sufficiency in growth, sustained angiogenesis and the potential for tissue invasion and 
metastasis, are essential if tumours are to succeed in malignant growth [Hanahan and 
Weinberg, 2000;  Colotta et al., 2009].  It is becoming clear, as detailed in Figure 1.8, that the 
oncogenic process of tumour development and progression is influenced by the interaction of 
surrounding non-malignant cells [Hanahan and Weinberg, 2000;  Coussens and Werb, 2002] 
and it is therefore of interest that certain malignant tumours may consist of over 90% stromal 
and inflammatory cells [Mesker et al., 2007].  Moreover, this is consistent with growing 
evidence that suggests a pro-inflammatory tumour microenvironment is vital for the 
progression of malignancy [Balkwill and Coussens, 2004;  Mantovani et al., 2008;  DeNardo 
et al., 2008]. 
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Figure 1.8. Inflammation, carcinogenesis and neoplastic progression [de Visser et al., 
2006] 
 To achieve malignant growth, cancer cells hijack normal immunological and 
physiological processes to aid angiogenesis and stromal tissue development.  For example, 
infiltrating cells belonging to the innate immune system, including neutrophils, macrophages 
and mast cells will increase the angiogenic potential of a tumour and allow it to lay down a 
supportive connective tissue framework [Hanahan and Folkman, 1996;  Jackson et al., 1997;  
Imada et al., 2000;  Benitez-Bribiesca et al., 2001;  Kalluri and Zeisberg, 2006;  Joyce and 
Pollard, 2009]. 
 Tumour Associated Macrophages (TAMs) are the predominant tumour leukocyte 
infiltrate and have been implicated in both the destruction of tumour cells as well as the 
promotion, in part by cytokine production, of cancer progression and metastasis [Jonjic et al., 
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1992;  Mantovani et al., 2002;  Pollard, 2004].  Macrophages have also been shown to have 
an atrophic, remodelling role that contributes to tumour progression and cancer cell survival 
by increasing the proliferative potential, increasing cancer cell motility, intravasation and 
invasiveness as well as increasing angiogenesis, mediating immunosuppression and 
promoting extracellular matrix formation [Mantovani et al., 2002;  Lewis and Pollard, 2006;  
Nardin and Abastado, 2008].  While it remains a controversial issue, there is some 
corresponding evidence that TAMs are associated with reduced survival in certain tumour 
types [Leek et al., 1996;  Bingle et al., 2002]. 
 While there is evidence that a number of local inflammatory cells can promote tumour 
progression, conversely, an abundance of tumour margin lymphocytes has been associated 
with an improved outcome [Jass et al., 1987].  Indeed, this lymphocytic infiltrate has been, in 
colorectal, hepatocellular and gastroesophageal cancer, shown to correlate with improved 
survival [Ma et al., 1994;  Wada et al., 1998;  Ohashi et al., 2000;  Canna et al., 2005].  This 
is clearly a complex relationship as low intertumoral T regulatory cells, in the presence of 
high cytotoxic T cells (CD8+), have also been associated with improved survival [Gao et al., 
2007].  Moreover, it has been suggested that the inverse relationship between cytotoxic T cell 
infiltrate and survival may be due to the inhibition of micrometastasis [Chiba et al., 2004] and 
tumour induced modulation, at the lymph node level, may inhibit or down regulate the action 
of cytotoxic T-cells and therefore increase the potential for distal spread [Cochran et al., 
2006]. 
 Neutrophils produce cytotoxic substances, including proteinases, to defend the host 
from microorganism attack and promote healing [Smith, 1994].   They can also produce 
cytokines to drive the immune/inflammatory response with evidence to show that tumour 
associated neutrophils can play an active part in tumour angiogenesis and proliferation 
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[Nathan, 2006;  Tazzyman et al., 2009].  Neutrophilia is also known to occur as a result of 
cancer related production of myeloid growth factor, granulocyte colony stimulating factor 
and cytokine production [Ulich et al., 1987;  Lord et al., 1989]. 
 Platelets are also influenced by malignancy and can be activated by direct contact 
with tumour cells or via release of tumour based cytokines [Zucchella et al., 1989;  Grignani 
et al., 1989].  They have been shown to play a multifactorial role in angiogenesis, the pro-
coagulopathy observed in malignancy as well as tumour progression [Poggi et al., 1988;  
Sierko and Wojtukiewicz, 2004]. 
1.2.8. Cancer Stage and Indicators of Survival 
 Cancer staging is important as it currently helps identify those patients who will 
benefit from potentially curative interventions such as resectional surgery or oncological 
therapy.  It also provides an indication of prognosis and guides the requirement for 
surveillance following treatment.  The most commonly used staging system for malignant 
tumours is the TNM classification (Table 1.2) which is recommended by the Union for 
International  Cancer  Control (UICC),  Cancer  Research UK as well as the  American  Joint  
Table 1.2. Tumour Node Metastasis classification 
Primary Tumour 
T0 No evidence of malignant tumour 
Tis Carcinoma in situ (preinvasive) 
T1-T4 Size and/or extent of primary tumour 
Regional Lymph Nodes 
N0 No regional lymph node involvement 
N1-3 Degree of regional lymph node involvement (number and location) 
Distant Metastasis 
M0 No distant metastasis 
M1 Distant metastasis present 
[National Cancer Institute, 2009] 
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Committee on Cancer (AJCC).  TNM is based on the extent of the primary tumour (T), 
spread to the local lymph nodes (N) and the presence of distal metastasis (M) [Sobin and 
Wittekind, 2002].  It can be calculated by clinical means, including examination and 
radiological investigations, objective assessment of resected pathological specimens or a 
combination of these techniques.  A shortened TNM classification comprising five stages (0-
IV) is also commonly used, but differs in detail depending on the specific tumour type (Table 
1.3).  In colorectal cancer, this broadly corresponds to the Dukes classification where the 
more advanced the tumour, the shorter the expected survival [National Institute for Health 
and Care Excellence, 2009].  While the TNM system is used in the majority of tumour types, 
some central nervous system and haematological cancers do not comply and different 
systems are used. 
Table 1.3. Tumour stage classification 
Stage 0 Carcinoma in situ 
Stage I-III Higher number indicates more extensive disease.  Larger tumour size and/or spread 
of the cancer beyond the organ in which it first developed to nearby lymph nodes 
and/or tissue or organs adjacent to the location of the primary tumour. 
Stage IV Distal metastasis 
[National Cancer Institute, 2009] 
 While being considered the gold standard for staging prognosis, the TNM based 
classification has potential pitfalls.  It is clear that staging by clinical and radiological means 
may be open to a certain amount of subjective judgment and it has been shown that 
computerised tomography may provide different results from resected pathological 
specimens [Schlomer et al., 2006].  There are also concerns that inadequate pathological 
assessment, with regards to number of lymph nodes examined, may result in under staging 
and not effectively identify individuals who would benefit from adjuvant therapy [Tepper et 
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al., 2001;  Joseph et al., 2003;  Swanson et al., 2003].  These issues have compounded 
worries that while this system may be adequate for those at the extremes of the stage 
spectrum (I or IV), those in the middle may be getting inaccurately staged and under or over 
treated. 
 A number of other tumour related, pathological features are associated with outcome 
and survival in a variety of tumour types.  Tumour differentiation, as detailed in Table 1.4, is 
a measure of how abnormal tumour cells appears and a reflection of how rapidly a tumour is 
likely to grow and disseminate.  Tumour differentiation has been associated with outcome in 
the majority of neoplastic malignancies including gastroesophageal [Khan et al., 2004], breast 
[Bloom and Richardson, 1957], pancreatic [Lim et al., 2003] and colorectal [Mori et al., 
2006] cancers. 
Table 1.4. Grade of differentiation classification 
Grade 1 Well differentiated (low grade) 
Grade 2 Moderately differentiated (intermediate grade) 
Grade 3 Poorly differentiated (high grade) 
Grade 4 Undifferentiated (high grade) 
[National Cancer Institute, 2009] 
 While these methods are clearly important and provide a wealth of information 
regarding tumour status, they do little to estimate the host response to the malignant process.  
Performance status can be used as a potential indicator of host response and aims to measure 
physical function and gauge how malignancy impacts on a patient's daily life.  The Eastern 
Cooperative Oncology Group (ECOG) performance status score is a 5 point system that 
ranges from 0 (no symptoms/restriction to activity) to 5 (death) and is commonly used when 
making decisions as to whether a patient is fit enough to receive chemotherapy [Oken et al., 
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1982].  There have however been concerns that these subjective measures of patient function 
have been shown to have significant inter-observer variability [Ando et al., 2001].  As 
performance status is a measure of host function, and therefore a surrogate marker of cancer 
cachexia and muscle mass, it is also of no surprise that an association between the host 
systemic immune/inflammatory response and performance status has been demonstrated 
[Brown et al., 2007]. 
 Taken together, it is therefore expected that there is increasing interest in the "seed 
and soil" hypothesis that suggests patient outcome depends not only on tumour characteristics 
but also on the host immunological response to a malignant process [Fidler and Poste, 2008].  
It therefore stands that a measure of the pre-mentioned host immune/inflammatory response 
may offer a useful adjunct in the risk stratification of patients with cancer. 
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1.3. INFLAMMATION AND ATHEROSCLEROSIS 
1.3.1. Cerebrovascular and Cardiovascular Atherosclerotic Disease and Mortality 
 According to the World Health Organisation, cardiovascular and cerebrovascular 
disease are responsible for the majority of mortality worldwide.  In 2004, ischaemic heart 
disease was responsible for approximately 7.2 million deaths, thus accounting for over 12 
percent of all deaths worldwide.  The World Health organisation predict that this will 
increase to approximately 23 million by 2030 and concerns have been raised that 
cardiovascular disease may become the most common cause of death in the 21st century 
[Sporn, 1996;  Hansson, 2005].  Similarly, cerebrovascular disease was responsible for 
approximately 10 percent of all deaths worldwide in 2004 with this figure set to increase 
[Mathers et al., 2004].  In high income countries this pattern persisted with approximately 16 
percent of deaths being attributable to ischaemic heart disease and 9 percent as a result of 
cerebrovascular disease [Mathers et al., 2004].  These reported death rates are consistent with 
those published for the UK with approximately one third of all deaths being due to 
circulatory disease [Office for National Statistics, 2008;  McNiven D, 2010]. 
1.3.2. Atherosclerotic Disease and Inflammation 
 The link between atherosclerotic disease and inflammation is well recognised and has 
been shown to be independent of other arteriopathic risk factors including smoking and 
obesity [Kuller et al., 1996;  Tracy, 1998;  Ross, 1999;  Williams et al., 2004].  While the 
relationship between inflammation, C-reactive protein and atherosclerotic disease is not 
entirely clear, arterial wall lipoprotein retention and the subsequent formation of fatty streaks 
has been implicated [Ross, 1999;  Pepys and Hirschfield, 2003].  Once established, fatty 
streaks can encourage fibrous plaque formation, which in turn can rupture, precipitate 
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thrombus and result in a cardiac event [Ross, 1999].  Atherosclerotic vessel wall 
inflammatory infiltrate has been found to have increased levels of a number of inflammatory 
cells including lymphocytes and dendritic cells [Galkina and Ley, 2009].  Macrophages have 
also been implicated and, as illustrated in Figure 1.9, have been found to oxidise low density 
lipoproteins and drive an immune/inflammatory response [Jonasson et al., 1986;  Berliner et 
al., 1990].  Neutrophils and platelets are similarly involved in atherosclerotic disease and 
have been shown to have a pro-inflammatory role with the subsequent propagation of 
atheromatous plaque and potential rupture [Ross, 1993;  Massberg et al., 2002;  Kraaijeveld 
et al., 2007;  von Hundelshausen and Weber, 2007;  Zernecke et al., 2008].  These activated 
cells of  the  immune  system  involved  in  atheroma   development  also  produce   
inflammatory  
Figure 1.9. Low density lipoprotein, inflammation and atherosclerotic vessel wall 
infiltrate [Barter et al., 2004] 
cytokines including IL-1 and IL-6, and as a consequence, acute phase reactants including C-
reactive protein from the liver [Hansson et al., 1989;  Clinton and Libby, 1992;  Frostegard et 
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al., 1999].  As a result, both IL-6  and C-reactive protein levels have been shown to be 
elevated in patients with unstable angina and myocardial infarction [Liuzzo et al., 1994;  
Lindahl et al., 2000;  Danesh et al., 2008].  Traditionally, C-reactive protein levels of 10mg/l 
or less have been regarded as clinically unimportant, however smaller rises have since been 
classed as abnormal in those at risk, or with a history of ischaemic heart disease [Haverkate et 
al., 1997;  Gabay and Kushner, 1999].  It is likely that these small rises reflect the local 
inflammatory process in the artery, however, it is also possible that they represent 
inflammation at a distal site [Hansson, 2005].  It is also of interest that albumin, a negative 
acute phase protein, can reduce platelet adhesion and has an anti-oxidant effect that helps 
clearance of reactive oxygen species that are pathogenic in ischaemic heart disease [Halliwell 
and Gutteridge, 1990;  Porcellati et al., 1995]. 
1.3.3. Risk Stratification in Cardiovascular and Cerebrovascular Disease 
 A strategy that assists in the identification of those at increased risk can help 
individualise treatment and ensure that appropriate therapies are received by those who will 
benefit [Alderman, 1993].  The optimal prognostic tool would be of low financial cost, 
openly available  and easily interpreted with a high sensitivity and specificity [Parikh and 
Vasan, 2007]. 
 The extensively validated Framingham Risk Score can be used to calculate the 
probability of an individual having a major cardiac event and the requirement for therapy 
[Kannel et al., 1976;  Anderson et al., 1991;  Brindle et al., 2003;  Greenland et al., 2010].  It 
includes gender, total cholesterol, HDL cholesterol, smoking status as well as systolic blood 
pressure and is recommended by European and American cardiac societies [Wood et al., 
1998;  Grundy et al., 1999]. 
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 A similar score, the CHADS2, is used in the risk stratification for future 
cerebrovascular events in patients with atrial fibrillation.  It looks at the presence of 
congestive heart failure, hypertension, age, diabetes and a history of prior cerebrovascular 
events and indicates the requirement for anticoagulation therapy [Gage et al., 2004]. 
 As inflammation is pathologically related to atherosclerotic disease, C-reactive 
protein as a measure of the systemic immune/inflammatory response, is currently 
recommended by the American Heart Association for cardiovascular screening and statin 
management [Greenland et al., 2010].  It therefore stands that that other simple, easily 
obtainable measures of the systemic immune/inflammatory response may also predict 
outcome in patients with cardiovascular and cerebrovascular disease. 
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1.4. SERUM MARKERS OF SYSTEMIC INFLAMMATION AND MORTALITY 
1.4.1. C-reactive Protein 
 A number of markers of the systemic immune/inflammatory response have been 
associated with all-cause mortality.  In 274,515 incidentally sampled patients, Marsik and co-
workers, demonstrated that a raised baseline serum C-reactive protein concentration was 
associated with mortality from cancer, cardiovascular and cerebrovascular disease [Marsik et 
al., 2008].  This study was noted to be particularly robust as patient cause of death was 
confirmed by a post mortem in approximately 35% of cases.  Also, when 22,962 patients with 
subacute C-reactive protein measurements (<10mg/l) were studied, high sensitivity 
measurements were found to have additional value to the traditional thresholds (>10mg/l), 
when predicting all-cause mortality [Currie et al., 2008]. 
 Serum C-reactive protein levels have also been associated with both the risk of 
developing cancer and a reduced survival in patients with cancer.  In a cohort of 22,887 
patients, a baseline elevated C-reactive protein level was associated with a greater risk of 
developing colorectal cancer, with similar studies demonstrating comparative findings for 
lung cancer [Erlinger et al., 2004; Allin et al., 2009].  Elevated levels of C-reactive protein 
have also been associated with survival in a number of malignancies including colorectal 
[Nozoe et al., 1998], oesophageal [Guillem and Triboulet, 2005; Crumley et al., 2006a], 
pancreatic [Falconer et al., 1995; Jamieson et al., 2005], ovarian [Hefler et al., 2008], 
endometrial [Schmid et al., 2007], cervical [Polterauer et al., 2007], breast [Albuquerque et 
al., 1995], renal cell [Casamassima et al., 2005; Komai et al., 2007] and hepatocellular 
[Hashimoto et al., 2005; Nagaoka et al., 2007] cancer. 
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 Correlations between C-reactive protein concentrations and atherosclerotic disease 
have also been found.  Koenig and co-workers demonstrated, in 936 healthy men, that a 
raised C-reactive protein was independently associated with an increased risk of developing 
cardiovascular disease [Koenig et al., 1999].  Also, meta-analysis of 1953 coronary events 
demonstrated a relative risk of 2.0 for the development of future coronary events if a patient's 
C-reactive protein was in the top tertile (>2.4mg/l Vs <1mg/l) [Danesh et al., 2000].  
Moreover, many other studies have shown similar associations with a raised C-reactive 
protein, in patients with unstable angina or myocardial infarction, and future cardiac events 
and death [Liuzzo et al., 1994; Ridker et al., 2000; Ridker et al., 2001; Danesh et al., 2004]. 
 In patients with cerebrovascular disease, C-reactive protein has been found to have 
prognostic value in both identifying patients at risk of developing the condition, as well as 
those who are likely to die as a result.  In a cohort of 7901 healthy Japanese men, those with 
raised C-reactive protein measurements were more likely to have a cerebrovascular event, as 
well as die from all-cause mortality [Makita et al., 2009].  Similar associations between a 
raised C-reactive protein and cerebrovascular related mortality have been noted in other 
studies [Di Napoli et al., 2001; den Hertog et al., 2009]. 
1.4.2. Albumin 
 Hypoalbuminaemia has been shown, in 7735 randomly enrolled men, to be associated 
with an increased risk of all-cause mortality independent of other risk factors [Phillips et al., 
1989].  Similarly, hypoalbuminaemia was found to be a risk factor associated with all-cause 
mortality in the American National Health and Nutrition Examination Survey (NHANES) 
longitudinal follow-up survey [Gillum and Makuc, 1992] as well as in other large cohorts 
[Goldwasser and Feldman, 1997; Grimm et al., 2009; Desai et al., 2009]. 
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 Hypoalbuminaemia has also long been associated with reduced survival in patients 
with  a variety of cancers [Phillips et al., 1989; Lam et al., 2007; Penel et al., 2008].  A 
number of studies have demonstrated a link between hypoalbuminaemia and survival in lung 
cancer.  These include work carried out by Maeda and co-workers demonstrating this 
relationship in 261 patients with advanced Non-small Cell Lung Cancer (NSCLC) [Maeda et 
al., 2000] as well as a number of other studies with similar results [Hespanhol et al., 1995; 
Maestu et al., 1997; Tas et al., 1999].  In 1367 patients undergoing surgical treatment for 
colorectal cancer, hypoalbuminaemia was shown to be independently associated with a 
reduced survival [Sun et al., 2009] with comparable results being found in other operable and 
palliative cohorts [Heys et al., 1998; Schindl et al., 2005; Cengiz et al., 2006].  This 
association, between hypoalbuminaemia and reduced survival, has been shown to persist in a 
number of solid organ malignancies including gastric [Lien et al., 2004; Alici et al., 2006; 
Onate-Ocana et al., 2007], oesophageal [Di Fiore et al., 2007; Wang et al., 2009], 
hepatocellular cancer [Nagaoka et al., 2007; Takahashi et al., 2008; Choi et al., 2008], 
pancreatic [Siddiqui et al., 2007], ovarian [Gupta et al., 2009] and breast cancer [Wyld et al., 
2003; Lis et al., 2003].  Similar studies have also shown this association to occur in 
haematological malignancies including, Non-Hodgkin's Lymphoma [Alici et al., 2003]. 
 Serum albumin is also known to be associated with cardiovascular mortality in 
unselected patients and in those with pre-existing renal disease [Goldwasser and Feldman, 
1997; Grimm et al., 2009].  Similarly, hypoalbuminaemia has been shown to be associated 
with an increased risk of death from cardiovascular disease independent of other risk factors 
[Phillips et al., 1989].  These findings were further confirmed in the American National 
Health and Nutrition Examination Survey (NHANES) [Gillum and Makuc, 1992] with 
several other studies also demonstrated this relationship [Kuller et al., 1991; Corti et al., 
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1996; Weijenberg et al., 1997].  Hypoalbuminaemia has also been shown, after controlling 
for stroke risk factors, to predict cerebrovascular incidence as well as mortality in subjects of 
NHANES epidemiological follow-up study [Gillum et al., 1994]. 
1.4.3. Liver Function Tests and Calcium 
 Liver function tests have similarly been associated with outcome and survival.  
Bilirubin, a potential antioxidant, has been associated with a reduction in the incidence of 
coronary artery disease [Schwertner et al., 1994].  Higher levels of bilirubin, in 
approximately 10 000 unselected patients, has been linked with improved all-cause, cancer 
and cardiovascular survival [Temme et al., 2001].  Conversely, an elevated alkaline 
phosphatase has been associated with a reduced survival in patients with kidney disease, 
cardiovascular disease and in the general population [Blayney et al., 2008; Tonelli et al., 
2009].  Furthermore, it is of interest that γ-glutamyl transferase (GGT) and serum calcium 
have also been reported to predict cancer and non-cancer outcomes [Leifsson and Ahren, 
1996; Kazemi-Shirazi et al., 2007]. 
1.4.4. White Cell Count 
 A white blood cell count has likewise been shown to have prognostic value in 
previously health individuals.  When 2011 men were followed up for an average of thirteen 
years, their initial white cell count corrected for lifestyle risk factors, was shown to predict 
all-cause mortality [de Labry et al., 1990].  In addition, a study of 13,555 individuals 
demonstrated positive correlation between white cell count and all-cause mortality, as well as 
risk of stroke and cardiovascular disease [Gillum et al., 2005] with a number of other studies 
demonstrating similar relationships [Tamakoshi et al., 2007]. 
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 In cancer cohorts, an elevated white cell count has been shown to have prognostic 
significance in a range of advanced malignancy including lung [Tibaldi et al., 2008], 
colorectal [Kohne et al., 2002], pancreatic [Engelken et al., 2003] and other gastrointestinal 
cancers [O'Gorman et al., 2000].  While these reported associations between a white count 
and mortality in both cancer and non-cancer groups is of interest, it remains to be seen 
whether a particular cell type, for example neutrophils, are predominantly responsible for this 
relationship. 
1.4.5. Neutrophil Count 
 Elevated neutrophil counts have been associated with a reduced survival in renal cell 
and Non-Small Cell Lung cancer [Donskov, 2007; Teramukai et al., 2009].  In addition, the 
NHANES epidemiological follow-up study of approximately 5000 patients demonstrated a 
link between neutrophil count and all-cause and cardiovascular mortality [Gillum et al., 
2005]. 
1.4.6. Lymphocyte Count 
 Conversely, a raised lymphocytes count seems to be of prognostic benefit and in 
elderly populations, lymphocytosis has been shown to reduce all-cause mortality [Bender et 
al., 1986; Izaks et al., 2003; Lukito et al., 2004].  Similarly, an increased lymphocyte count 
has been associated with an improved survival in patients with metastatic renal cell 
[Fumagalli et al., 2003], pancreatic cancer [Fogar et al., 2006] and sarcoma [Ray-Coquard et 
al., 2009].  The prognostic value of a low lymphocyte count has also been studied in patients 
with cardiac disease and congestive heart failure and has been found to be associated with 
increased mortality [Acanfora et al., 2001]. 
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1.4.7. Platelet Count 
 Thrombocytosis, in patients with renal disease, has been shown to be associated with 
presence of coronary artery disease [Sokunbi et al., 1994].  It has also been linked with both 
tumour stage [Ito et al., 2006] and prognosis in renal cell carcinoma [O'Keefe et al., 2002; 
Erdemir et al., 2007] with similar associations in colon [Abbasciano et al., 1995] and lung 
cancer [Teramukai et al., 2009]. 
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2.0. SUMMARY AND AIMS 
2.1. SUMMARY 
 Local inflammation occurs as a response to injury, infection, autoimmune conditions 
or malignancy.  Through complex pathways involving the innate, humoral and adaptive 
immune systems, the local immune/inflammatory reaction can result in a systemic 
immune/inflammatory response.  As well as exhibiting clinical manifestations including 
pyrexia, anorexia and cachexia, the systemic response is also associated with alterations in a 
number of serum markers of inflammation.  These include components of the innate and 
adaptive immune systems, for example the constituents of a differential white cell count and 
acute phase reactants such as C-reactive protein, as well as other biochemical parameters 
including albumin and liver function tests. 
 Worldwide, approximately 12.4 million new cases of cancer are diagnosed each year 
with 7.6 million people dying as a result.  In the United Kingdom, around one in three people 
will develop cancer during their lifetime with breast, followed by lung and colorectal 
malignancies being the most common.  Increasing age, male gender and socioeconomic 
deprivation have been shown to be associated with a reduced survival in the majority of 
malignancies.  Deoxyribonucleic acid (DNA) mutations that result in the interruption of 
tumour suppression or the activation of pro-oncogenic pathways can occur secondary to a 
genetic predisposition.  However, the majority of genetic mutations are acquired and it is 
recognised that a local inflammatory microenvironments can lead to DNA damage, neoplastic 
transformation and cancer development.  It has also been shown that cancer progression, and 
subsequent metastasis, is dependent on complex interactions with the inflammatory tumour 
microenvironment involving the innate, humoral and adaptive immune systems.  The Tumour 
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Node Metastasis (TNM) staging system utilises evidence of local invasion and distal tumour 
spread in the risk stratification of patients with cancer.  It is however recognised that this 
system may be open to an element of subjectivity and therefore, there is increasing interest in 
the study of the host immune/inflammatory response in predicting outcome in patients with 
malignancy. 
 Cardiovascular and cerebrovascular atherosclerotic disease is responsible for 
approximately a third of all deaths in the United Kingdom.  Atherosclerotic plaques have a 
significant inflammatory cell infiltrate and clear relationship between inflammation and 
vascular disease has been established.  Patient risk stratification tools, such as the 
Framingham Score and CHADS2, are composed of a variety of risk factors including patient 
age, high density lipoproteins and systolic blood pressure.  These scores can be used to 
individualise therapies in patients with cardiovascular or cerebrovascular disease and help 
ensure that treatment is received by those who will benefit.  Similarly, C-reactive protein as a 
measure of the systemic immune/inflammatory response, is recommended in the assessment 
of patients with cardiovascular disease.  This therefore raises the possibility that other, widely 
available serum markers of inflammation may also predict outcome. 
 A number of commonly sampled serum markers of the systemic 
immune/inflammatory response have been associated with cancer, cardiovascular, 
cerebrovascular and all-cause mortality.  Serum C-reactive protein levels have been widely 
studied and shown to be predictive of outcome in a variety of cancers including colorectal, 
gastroesophageal and pancreatic, with similar associations demonstrated in patients with 
cardiovascular and cerebrovascular disease.  Comparative associations with survival in 
similar cohorts have been reported when other serum inflammatory markers including 
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albumin, liver function tests and the constituents of a differential white cell count have been 
studied. 
 There has therefore been increasing interest in systemic inflammation-based scores 
that combine these commonly sampled markers of the systemic immune/inflammatory 
response and whether they can be used to predict outcome in patients with a range of 
diseases.  A variety of scores have been suggested including the Glasgow Prognostic Score 
(GPS), the modified Glasgow Prognostic Score, the Neutrophil Lymphocyte Ratio (NLR), the 
Platelet Lymphocyte Ratio (PLR) and the Prognostic Nutritional Index (PNI).  There has 
however been little work to investigate directly the effect that the presence of cancer has on 
these markers of systemic inflammation and whether their relationship with survival is a 
universal phenomenon in all tumour types.  It is also unclear as to the optimal constituents of 
such an inflammation-based prognostic score and whether these would differ for cancer, 
atherosclerotic disease or all-cause mortality. 
2.2. AIMS 
To investigate the areas detailed above, in a single cohort of incidentally sampled patients, 
studies were carried out: 
1. To explore the relationship between the presence and site of cancer, an inflammation-
based prognostic score and biochemical parameters. 
2. To investigate whether an inflammation-based prognostic score can predict cancer 
survival independent of tumour site and assess any derangement of associated biological 
parameters. 
3. To compare the previously suggested inflammation-based prognostic scores in patients 
with cancer with regard to their universal utility and predictive value. 
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4. To investigate whether an inflammation-based score using variables available in large 
oncological data sets, specifically a white cell and neutrophil count, can be used to 
predict cancer survival. 
5. To investigate the optimal constituents of an inflammation-based prognostic score for 
use in patients with cancer. 
6. To explore whether a similar inflammation-based score can be used to predict 
cardiovascular, cerebrovascular and all-cause mortality. 
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3.0. SYSTEMIC INFLAMMATION-BASED PROGNOSTIC SCORES 
3.1. ABSTRACT 
Introduction:  As disease associated inflammation is increasingly recognised as a key 
determinant of prognosis in patients with cancer, cardiovascular disease and stroke, there has 
been significant interest in measurements of the systemic immune/inflammatory response in 
an attempt to help predict patient outcome. 
Methods:  A systematic review was carried out looking at all published literature between 
September 1999 and September 2009 in the Pubmed database.  The following search term 
were entered ("glasgow prognostic score" OR "modified glasgow prognostic score" OR 
"neutrophil lymphocyte ratio" OR "neutrophil to lymphocyte ratio" OR "platelet lymphocyte 
ratio" OR "platelet to lymphocyte ratio" OR "prognostic index" OR "prognostic nutritional 
index" AND (survival OR mortality)). 
Results:  1095 studies were returned in the pubmed search but only 31 investigated the 
relationship between inflammation-based scores and mortality. The majority of these (n=19) 
investigated the prognostic value of the Glasgow Prognostic Score (GPS/mGPS). 
Conclusion:  The results indicate that good evidence exists demonstrating an association 
between inflammation-based scores and mortality in certain cancer types as well as 
cardiovascular disease.  It is however unclear as to whether this is a universal phenomenon in 
all cancers and whether these scores could be utilised in patients with other atherosclerotic 
conditions such as cerebrovascular disease. 
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3.2. INTRODUCTION 
 As disease associated inflammation is increasingly recognised as a key determinant of 
prognosis in patients with cancer, cardiovascular disease and stroke, there has been 
significant interest in measurements of the systemic immune/inflammatory response in an 
attempt to help predict patient outcome.  Furthermore, it has been suggested that an optimal 
biomarker should have a standardised assay, be universally available in clinical practice and 
financially viable for widespread use [Paoletti et al., 2004].  While single measures of 
commonly sampled parameters, such as an isolated C-reactive protein, white cell count or 
albumin, have been shown to have prognostic significance there has been a move towards 
combining these markers in order to create inflammation-based prognostic scores with 
improved sensitivity and specificity.  Inflammation-based scores that quantify the systemic 
immune/inflammatory response associated with a disease process have the potential to 
provide important prognostic information and allow the risk stratification of patients.  It is 
also recognised that the optimal constituents of a score may change depending on the clinical 
situation.  For example, in patients entering large chemotherapeutic trials that routinely 
record only a differential white cell count, a score consisting of these constituents would be 
optimal.  It is with all this in mind that the main focus of this thesis will be on systemic 
inflammation-based scores that utilise commonly sampled markers of inflammation including 
C-reactive protein, liver function tests and the constituents of a differential white cell count. 
 On review of the current literature, it is evident that there are a number of regularly 
studied inflammation-based prognostic scores that incorporate multiple, routinely available, 
markers of the systemic immune/inflammatory response and have been shown to be 
associated with mortality.  The Glasgow Prognostic Score (GPS, Table 2.1), a combination of 
acute phase proteins namely C-reactive protein and albumin using standard thresholds (C-
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reactive protein >10mg/L, albumin <35g/L) has been shown to have prognostic value in 
certain cancers [Forrest et al., 2003; McMillan et al., 2007].  The GPS was subsequently 
refined to form the modified Glasgow Prognostic Score (mGPS Table 2.1) [McMillan et al., 
2007] when, in patients with primary operable colorectal cancer, hypoalbuminaemia alone 
was found to have similar prognostic value as a GPS of 0.  Several studies have reported the 
mGPS to have independent prognostic value in patients with a number of different cancers in 
a variety of clinical scenarios [McMillan, 2009].  Other commonly sampled markers of the 
systemic immune/inflammatory response have also been combined to form inflammation-
based prognostic scores associated with survival in patients with cancer, atherosclerotic 
disease and all-cause mortality (Table 3.1).  These include the Neutrophil Lymphocyte Ratio 
(NLR), a combination of circulating neutrophil and lymphocyte counts, the Platelet 
Lymphocyte Ratio (PLR), a combination of circulating platelet and lymphocyte counts, the 
Prognostic Index (PI), a combination of C-reactive protein and white cell count and finally, 
Onodera’s Prognostic Nutritional Index (PNI), a combination of albumin and lymphocyte 
count. 
 The aim of the present Chapter was to examine the relationship between 
inflammation-based prognostic scores and survival in cancer and non-cancer cohorts. 
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Table 3.1. Systemic Inflammation-Based Prognostic Scores. 
The Glasgow Prognostic Score Score 
C-reactive protein ≤10 mg/l and albumin ≥35 g/l  0 
C-reactive protein ≤10 mg/l and albumin <35 g/l  1 
C-reactive protein >10 mg/l and albumin ≥35 g/l 1 
C-reactive protein >10 mg/l and albumin <35 g/l  2 
The modified Glasgow Prognostic Score  
C-reactive protein ≤10 mg/l and albumin ≥35 g/l  0 
C-reactive protein ≤10 mg/l and albumin <35 g/l  0 
C-reactive protein >10 mg/l and albumin ≥35 g/l 1 
C-reactive protein >10 mg/l and albumin <35 g/l  2 
Neutrophil Lymphocyte Ratio  
Neutrophil count:lymphocyte count <5:1  0 
Neutrophil count:lymphocyte count ≥5:1  1 
Platelet Lymphocyte Ratio  
Platelet count:lymphocyte count <150:1  0 
Platelet count:lymphocyte count 150–300:1  1 
Platelet count:lymphocyte count >300:1  2 
Prognostic Nutritional Index  
Albumin (g/l) + 5 × total lymphocyte count ×10
9
/l >45 0 
Albumin (g/l) + 5 × total lymphocyte count ×10
9
/l <45 1 
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3.3. MATERIALS AND METHODS 
 A systematic review was carried out looking at all published literature between 
September 1999 and September 2009 in the Pubmed database.  The following search term 
were entered ("glasgow prognostic score" OR "modified glasgow prognostic score" OR 
"neutrophil lymphocyte ratio" OR "neutrophil to lymphocyte ratio" OR "platelet lymphocyte 
ratio" OR "platelet to lymphocyte ratio" OR "prognostic index" OR "prognostic nutritional 
index" AND (survival OR mortality)) and 1095 results were returned. 
 Abstracts were searched to identify appropriate citations with subsequent paper 
acquisition for those manuscripts included.  Only papers in English, or those that had been 
translated into English were included.  Only original articles were considered with all reviews 
being excluded.  Multiple papers from the same cohort were included if the comparative 
findings differed.  Any scores including variables other than commonly available serum 
markers of inflammation were excluded.  Only those articles with death as a primary or 
secondary endpoint were considered and only those reporting disease specific or overall 
survival were included.  Overall survival was preferentially  reported,  otherwise  disease free 
survival noted.  If only "survival" was mentioned then this was taken to be overall survival. 
Articles that grouped other events with survival (i.e. Major Adverse Cardiac Events) were 
disregarded.  Only studies using multivariate statistical model analysis or relative survival to 
control for confounding factors (including age and gender) were included.  As tumour stage 
is a major predictor of survival in patients with cancer, only papers correcting for this were 
included.  Hazard ratios, probability values and, where available, 95% confidence intervals 
were included.  Categorical Hazard Ratios (HR) were included where available, otherwise 
single continuous variables were presented.  If tertile or quartile based results were presented 
then, where available, the HR from the first to the last were presented.  HRs were shortened 
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to two decimal places and P-values to 3 decimal places.  In patients with malignancy, where 
stated in the original paper, the stage of disease was reported.  Where stage was not 
absolutely stated but could be accurately defined from the text/tables then stage is marked * 
to show implied.  If stage could not be accurately identified then this was marked as "stage 
not defined."  Patients with resectional/operable tumours were taken to be stage I-III and 
denoted with a * unless otherwise stated (excluding ovarian).  Each paper's main conclusion 
or details of original findings were noted.  If a score was independent to other factors this was 
noted.  If other factors in a multivariate model did not retain statistical significance then a 
score was stated to be a superior measure. 
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3.4. RESULTS - Table 3.2 Systemic review of inflammation-based prognostic scores 
Reference Site N Score Threshold HR 
(95% CI) 
P-
value 
Stage Survival Comments 
Breast 
[Al Murri et 
al., 2006] 
- 96 GPS 0/1/2 2.26 
(1.45-3.52) 
<0.001 IV Cancer GPS independent of palliative chemotherapy and radiotherapy 
Gynaecological 
[Sharma et al., 
2008] 
Ovarian 154 GPS 0/1/2 Not Stated <0.05 III-IV Overall Treated with systemic chemotherapy with or with-out surgery 
GPS superior to performance status 
[Cho et al., 
2009a] 
Ovarian 192 NLR >2.60 6.05 
(1.77-20.71) 
0.004 I-IV Overall Treated with surgery 
NLR Independent of cell type and grade of tumour 
Gastroesophageal 
[Nozoe et al., 
2002] 
Oesophageal 258 PNI >46 1.80 
(1.16-2.81) 
0.009 I-IV Cancer Treated with surgery 
PNI independent to lymphatic and vascular invasion 
[Crumley et 
al., 2006b] 
Gastro-
oesophageal 
258 GPS 0/1/2 1.51 
(1.22-1.86) 
<0.001 I-IV Cancer Treated with palliative intent 
GPS independent of palliative adjuvant therapy 
[Han-Geurts 
et al., 2006] 
Oesophageal 400 PNI Per single 
unit 
increase 
- ns I-III* Overall Treated with resection with or without neoadjuvant therapy 
PNI not independently significant 
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[Crumley et 
al., 2008] 
Gastro-
oesophageal 
65 GPS 0/1/2 1.65 
(1.10-2.47) 
<0.05 III-IV Cancer Treated with palliative chemotherapy 
GPS superior to ECOG-Performance Status 
[Kobayashi et 
al., 2008] 
Oesophageal 48 GPS 1-2/0 0.17 
(0.06-0.52) 
0.002 I-III Cancer Treated with surgery and neoadjuvant chemoradiotherapy 
GPS independent of lymphatic and venous invasion 
Renal 
[Ramsey et 
al., 2007] 
- 119 GPS 0/1/2 2.93 
(1.88-4.55) 
<0.001 IV Cancer Treated with immunotherapy 
GPS independent of MSKCC and MRCCPS scores 
Ramsey et al., 
2008] 
- 23 GPS 0/1-2 2.23 
(1.09-4.57) 
0.029 IV Cancer Treated with immunotherapy 
GPS superior to interleukin 6 
Colorectal 
[Read et al., 
2006] 
Colorectal 48 mGPS 0/1/2 2.27 
(1.09-4.73) 
0.028 IV Overall Treated with palliative therapy with or without previous 
therapies 
mGPS independent of performance status, nutritional 
assessment tool (PGSGA) and LFTs 
[McMillan et 
al., 2007] 
Colorectal 123 mGPS 0/1/2 1.74 
(1.20-2.51) 
<0.001 II Cancer Treated with resection with or without adjuvant therapy 
mGPS superior to tumour site and delivery of adjuvant therapy 
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[Leitch et al., 
2007] 
Colorectal 149 
Primary 
Operable 
mGPS 0/1/2 2.08 
(1.32-3.28) 
0.002 I-III Overall Treated with colorectal resection, or palliative procedure or 
chemotherapy or radiotherapy 
mGPS superior to NLR, deprivation and independent to 
constituents of the differential white cell count NLR >5 - ns 
84 
Hepatic 
Mets 
mGPS 0/1/2 1.44 
(1.01-2.04) 
0.043 IV Cancer 
NLR >5 - ns 
[Ishizuka et 
al., 2007] 
Colorectal 315 GPS 1-2/0 0.17 
(0.04-0.73) 
0.018 I-IV Overall Treated only with surgery with-out adjuvant therapy 
GPS superior to tumour markers (CEA, CA19-9, CA72-4) 
[Halazun et 
al., 2008] 
Colorectal 440 NLR >5 2.28 
(1.65-3.13) 
<0.001 IV Overall Treated with colonic surgery then liver surgery and adjuvant 
chemotherapy 
NLR superior to positive margin and tumour number 
[Leung et al., 
2008] 
Colorectal 53 mGPS 0/1/2 2.12 
(1.34-3.35) 
0.001 IV Cancer Treated with chemotherapy or supportive care 
mGPS independent of lipid-soluble antioxidant vitamins 
[Crozier et al., 
2009] 
Colorectal 188 mGPS 0/1/2 2.22 
(1.06-4.74) 
0.039 II Cancer Treated with surgery with or without neoadjuvant 
chemotherapy. 
mGPS superior to presentation (emergency/elective), 
deprivation and adjuvant therapy 
[Neal et al., 
2009] 
Colorectal 174 NLR >5 - ns IV Overall Treated with resection of liver metastasis with or without 
chemotherapy 
NLR not independently significant 
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[Kishi et al., 
2009] 
Colorectal 290 NLR >5 2.00 
(1.30-3.30) 
0.005 IV Overall Colorectal with liver metastasis with chemotherapy with or 
without resection 
NLR independent to number and size of metastasis, history of 
previous treatment and positive margins 
[Roxburgh et 
al., 2009a] 
Colorectal 244 mGPS 0/1/2 2.34 
(1.65-3.31) 
<0.001 I-III Cancer Treated with surgery without or without adjuvant therapy 
mGPS independent of high risk pathological Petersen's Index 
[Roxburgh et 
al., 2009b] 
Colorectal 287 mGPS 0/1/2 2.56 
(1.66-4.25) 
<0.001 I-III Cancer Treated with surgery without or without adjuvant therapy 
mGPS superior to nodes sampled, adjuvant therapy and Jass 
criteria and independent to Klintrup criteria 
[Ishizuka et 
al., 2009] 
Colorectal 112 mGPS 0/1/2 6.07 
(1.63-22.68) 
0.007 II-IV Cancer Treated with surgery then palliative chemotherapy 
mGPS superior to liver function tests (AST, ALT, GGT) and 
tumour markers (CEA, CA19-9, CA 72-4) 
[Roxburgh et 
al., 2009c] 
colon 245 mGPS 0/1/2 1.56 
(1.03-2.38) 
0.038 I-III Cancer Treated with surgery with or without adjuvant therapy 
mGPS superior to adjuvant therapy and independent to Klintrup 
criteria 
rectum 140 1.76 
(1.00-3.10) 
0.033 
Hepatocellular 
[Glen et al., 
2006] 
Pancreatic 187 GPS 0/1/2 1.72 
(1.40-2.11) 
<0.001 III-IV Overall Treated with or without palliative bypass 
GPS superior to bilirubin 
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[Clark et al., 
2007] 
Pancreatic 44 NLR >5 - ns NS Overall Treated with surgery 
NLR not independently significant 
[Gomez et al., 
2008a] 
HCC 96 NLR >5 - ns NS Overall Treated with surgery 
NLR not independently significant 
[Smith et al., 
2009] 
Pancreatic 110 NLR Per single 
unit 
increase 
- ns NS Overall Treated with surgery with or without adjuvant therapy 
PLR superior to NLR, positive margin, differentiation and 
independent of lymph node ratio 
PLR Per single 
unit 
increase 
1.00 
(1.00-1.01) 
<0.001 
[Halazun et 
al., 2009] 
HCC 150 NLR >5 6.10 
(2.29-16.29) 
<0.001 NS Overall Treated with liver transplant with or without adjuvant therapy 
NLR superior to, tumour grade, vascular invasion and 
independent to AFP 
Lung 
[Forrest et al., 
2005] 
NSCLC 101 GPS 0/1/2 2.32 
(1.52-3.54) 
<0.001 III-IV Overall  Treated with or without palliative chemotherapy or radiotherapy 
GPS independent of treatment 
[Sarraf et al., 
2009] 
NSCLC 177 NLR Per single 
unit 
increase 
1.10 
(1.03-1.17) 
0.005 I-IV Overall Treated with surgery 
NLR independent to total white cell count 
[Teramukai et 
al., 2009] 
NSCLC 388 NLR >4.74 1.56 
(1.09-2.24) 
0.011 IIIb-
IV 
Overall Treated with palliative chemotherapy 
NLR independent to smoking history and ECOG performance 
status 
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Cardiovascular 
[Duffy et al., 
2006] 
CVD 1046 NLR Tertile      
1 vs 3 
1.60 
(1.00-2.55) 
0.048  Overall Patients undergoing PCA 
[Gibson et al., 
2007] 
CVD 1938 NLR Per single 
unit 
increase 
1.09 
(1.03-1.16) 
0.004  Overall Patients undergoing elective CABG 
[Nunez et al., 
2008] 
CVD 470 NLR Quintile    
1 vs 5 
4.2 
(1.72-10.21) 
0.002  Overall Patients with STEMI 
[Papa et al., 
2008] 
CVD 422 NLR >2.42 8.13 
(1.42-46.57) 
0.0186  Cardiac Consecutive patients with stable coronary artery disease 
[Tamhane et 
al., 2008] 
CVD 2833 NLR Tertile      
1 vs 3 
3.88 
(3.19-8.06) 
<0.001  Overall Patients admitted with ACS 
[Poludasu et 
al., 2009] 
CVD 372 NLR >3.5 2.11 
(1.11-4.02) 
0.023  Overall Patients treated with PCI 
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3.5. DISCUSSION 
 The results of the current chapter show that the presence of a systemic 
immune/inflammatory response, as evidenced by a number of inflammation-based scores, can 
predict mortality in both cancer and cardiovascular disease.  A number of different scores, 
that all incorporate multiple, routinely available, markers of the systemic 
immune/inflammatory response have been suggested for use.  These include the Glasgow 
Prognostic Score (GPS and mGPS), Neutrophil Lymphocyte ratio (NLR), Platelet 
Lymphocyte Ratio (PLR) and Onodera’s Prognostic Nutritional Index (PNI). 
 The majority of studies (n=31) to date (September 2009) have investigated the 
relationship between inflammation-based scores and cancer.  Over half of these (n=18) 
include patients with malignancies of the alimentary tract including colorectal and 
gastroesophageal cancer.  However, there is also good evidence that inflammation-based 
scores have a predictive role in pancreatic, hepatobiliary, renal and ovarian cancers.  Of these 
scores the Glasgow Prognostic Score (GPS/mGPS) is the most widely validated with 19 
studies all showing a statistically significant association with mortality.  The NLR has also 
been extensively investigated in a variety of tumour types with varying associations with 
mortality demonstrated.  The PLR and PNI have only been included in one study each but, 
never the less, have also been reported to be to be associated with mortality.  Indeed, it is 
likely that, while some scores may be more sensitive than others, they are essentially 
measuring the same process. There have been six studies looking at cardiovascular disease, 
all of which have demonstrated a positive correlation between the NLR and mortality. 
 This chapter has detailed evidence demonstrating that inflammation-based scores 
have predictive value in certain cancer types as well as cardiovascular disease.  It is however 
unclear whether this is a universal phenomenon in all cancers and if these scores could be 
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utilised in patients with other atherosclerotic conditions such as cerebrovascular disease.  The 
optimal constituents of an inflammation-based score for use in cancer and non-cancer cohorts 
is yet to be determined. 
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4.0. THE RELATIONSHIP BETWEEN THE PRESENCE AND SITE OF CANCER, 
AN INFLAMMATION-BASED PROGNOSTIC SCORE AND BIOCHEMICAL 
PARAMETERS 
4.1. ABSTRACT 
Introduction:  Biochemical parameters, such as C-reactive protein and liver function tests, 
have been associated with mortality.  The aim of the present chapter was to examine the 
relationship between the presence and site of cancer, an inflammation-based prognostic score 
(mGPS) and biochemical parameters. 
Methods:  Patients (n=223,303) who had a single incidental sample taken for C-reactive 
protein, albumin, calcium and serum liver function tests where available, between 2000 and 
2008 were studied.  Those with a pathological diagnosis of cancer (n=22,715) were also 
identified. 
Results:  The strongest associations (Spearman’s correlation > 0.3) in both the non-cancer 
and cancer groups were found between albumin, C-reactive protein and Alk phos, AST and 
ALT, AST and GGT and ALT and GGT (all p<0.001).  On multivariate analysis, age, 
deprivation, C-reactive protein, albumin, adjusted calcium, Alk phos and GGT were 
associated with the presence of cancer (all p<0.01).  When cancer diagnoses were ranked 
from those with the lowest proportion of mGPS 1 or 2 to those with the highest, the 
percentage of cases with a mGPS of 1 or 2 ranged from 21% in breast cancer to 68% in 
pulmonary cancer. 
Conclusion:  The results indicate that the systemic inflammatory response is increased by the 
presence of cancer.  There is a striking parallel between the proportions of cases with a 
mGPS of 1 or 2 and reported survival rates in these tumours. 
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4.2. INTRODUCTION 
 In the West of Scotland there has been a longstanding interest in the role of the 
systemic immune/inflammatory response in determining outcome in cancer [McMillan, 2008; 
McMillan, 2009; Roxburgh and McMillan, 2010].  Although, as detailed in Chapter 1, it is 
recognised that the development of cancer has a genetic basis, there is increasing evidence 
that host immune/inflammatory responses play a pivotal role in the development and 
progression of cancer [Balkwill and Mantovani, 2001; Coussens and Werb, 2002; Mantovani 
et al., 2008; Colotta et al., 2009; McDonald et al., 2009].  This is consistent with the 
hypothesis that chronic exposure to inflammatory processes, either through infection, social 
conditions or lifestyle, enhances the ageing process [Finch and Crimmins, 2004]. 
 As has also been detailed in Chapter 1, the presence of a systemic 
immune/inflammatory response as evidenced by an elevated C-reactive protein concentration 
sampled incidentally in a large hospital based cohort, was associated with a shorter duration 
of cancer and non-cancer survival [Marsik et al., 2008].  Goldwasser and Feldman, amongst 
others, have reported a similar relationship in a systematic review of the prognostic value of 
albumin [Goldwasser and Feldman, 1997].  These acute phase proteins, produced exclusively 
in the liver, have been shown to be a major factor in the progressive nutritional and functional 
decline of patients with cancer [McMillan, 2008].  Also, C-reactive protein and albumin 
concentrations have been combined to form the modified Glasgow Prognostic Score (mGPS) 
and have been reported to be independently associated with reduced survival in patients with 
a variety of cancers as detailed in Table 3.2 [McMillan, 2009; Roxburgh and McMillan, 
2010]. 
 It is also of interest that liver function tests such as bilirubin [Temme et al., 2001], 
alkaline phosphatase [Tonelli et al., 2009] and γ-glutamyl transferase [Kazemi-Shirazi et al., 
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2007] as well as serum calcium [Leifsson and Ahren, 1996], have also been reported to 
predict cancer and non-cancer outcome (Chapter 1.).  There is also some evidence that liver 
function tests are altered as part of the systemic immune/inflammatory response in patients 
with lung and gastrointestinal cancer [Brown et al., 2007; Roxburgh et al., 2009a]. 
 The aim of the present Chapter was to examine the effect of cancer on markers of 
systemic inflammation induced by the liver (mGPS) and on these variables (bilirubin, 
alkaline phosphatase, aspartate transaminase, alanine transaminase, γ-glutamyl transferase 
and adjusted calcium). 
4.3. MATERIALS AND METHODS 
 This cohort includes patients who have had a single sample taken for C-reactive 
protein, albumin and calcium between the 1st of January 2000 and the 1st of November 2008 
in the North of Glasgow.  The samples were taken incidentally and if more than one set of 
measurements were available for a given patient, only the initial set was used.  Where 
available, serum liver function tests, including bilirubin and alkaline phosphatase (Alk phos) 
were recorded.  Patients were excluded if they did not have a complete set of identifying 
details (name, gender, date of birth and hospital number).  The limit of detection of C-
reactive protein was a concentration of less than 5mg/L.  The mGPS was constructed, using 
C-reactive protein and albumin, as follows;   patients with both an elevated C-reactive protein 
(>10 mg/L) and low albumin (<35 g/L) were allocated a score of 2;   patients in whom only 
C-reactive protein was elevated (>10 mg/L) were allocated a score of 1 and those with a 
normal C-reactive protein were allocated a score of 0 [McMillan et al., 2007].  The rationale 
and basis of the mGPS has been previously described [McMillan, 2008].  Serum C-reactive 
protein, albumin and liver function tests, including bilirubin, Alk phos, AST, ALT and GGT, 
as well as calcium adjusted for albumin [Ashby et al., 1986], were classified in accordance 
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with the NHS Greater Glasgow and Clyde biochemistry laboratory reference ranges.  These 
analytes were measured using identical standard operating procedures on identical automated 
platforms using reagents from the same manufacturer (Abbot Diagnostics).  Analysis was 
carried out in three linked laboratories in the North of Glasgow which take part in external 
quality assurance schemes for routine biochemical analysis.  All samples were refrigerated, as 
stable for a number of days in these conditions, and analysed within 6 hours. 
 All patient records fulfilling these criteria were then cross referenced with the local 
pathology database to identify those in whom a tissue diagnosis of cancer had been made 
either before or after their initial blood sample (Appendix 1).  Systematized Nomenclature of 
Medicine – Clinical Terms (SNOMED CT) codes, which share certain codes with the 
International Classification of Diseases, contained in the pathology database were used to 
identify the site and type of tumour in those with a tissue diagnosis of cancer.  Patients were 
then grouped into those with a pathological diagnosis of cancer and those without.  The 
cancer group were then grouped into those patients with a clear primary cancer diagnosis, 
those with multiple tumours or those with no clear indication of the primary tumour site.  
Patients with incomplete identifying details (name, date of birth and hospital number), under 
16 years of age, or those with multiple malignancies, metastatic disease or cancer of an 
unknown origin were excluded.  For the purpose of analysis, cancers were grouped according 
to tumour site;   bladder, breast, colorectal, dermatological, endocrinological, 
gastroesophageal, gynaecological, haematological, head and neck, hepatocellular, 
musculoskeletal and soft tissue, pancreaticobiliary, pulmonary, prostatic, renal and testicular.  
The study was approved by the Research Ethics Committee, North Glasgow NHS Trust. 
 The Scottish Index of Multiple Deprivation (SIMD) 2006, as detailed in Chapter 1. 
and recommended by the ISD on behalf of NHS Scotland and the Scottish Government 
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Department of Health, was used to measure deprivation with the least deprived being scored 
as 1 to the most deprived scoring 5 [Bishop J et al., 2004]. 
 SNOMED CT codes were used to identify the site and type of tumour in those with a 
tissue diagnosis of cancer.  Each pathology sample had two SNOMED CT codes, one for 
type of tumour (morphology) and one for site of tumour (topography).  Examples of 
SNOMED CT cancer morphology codes, of which there are over 400, include metastatic 
carcinoma (M80106), large cell carcinoma (M80123), small cell carcinoma (M80413-
M80416), squamous cell carcinoma (M80703-M80763), adenocarcinoma (M81402-
M81406), cholangiocarcinoma (M81603), renal cell carcinoma (M83123-M83126), 
intraductal carcinoma (M85002-M85003), malignant melanoma (M87202-M87433), 
mesothelioma (M90501-M90503), lymphoma (M95903-M97003) and leukaemia (M98003-
M99403).  Examples of SNOMED CT topography codes include bladder (T74000-T74400), 
breast (T04000-T04400), colorectal (colon T67000- T67995, rectum T68000-T68200, anus 
T69000-T69200) dermatological (T02100-02870), endocrine (adrenal T93000-T93100, 
thyroid T96000-T97800), gastroesophageal (oesophagus T62000-T62910, stomach T63000-
T63700), gynaecological (uterus with or without cervix T82000- T82900, uterus and ovaries 
T82920-T82922, cervix T83000-T83300, endometrium T84000-T85000, ovary T86920-
T87800), haematological (bone marrow: T06000-T06600, lymph node T08000-T09600), 
head and neck (pharynx T60000-T61300, upper respiratory tract T21000-T24920, mouth and 
salivary glands T51000-T55550), liver (T56000-T56020), musculoskeletal and soft tissue 
(skeletal bone T10000-T12720, skeletal muscle T13000) pancreaticobiliary (gallbladder 
T57000, bile duct T57600-T58500, pancreas and ampulla T58700-T59300) 
pulmonary(T26000-T29900), prostatic (T77000-T77350), renal (T71000-T72000) testicular 
(T78000-T78020).  The combination of SNOMED CT morphology and topography codes 
were used to identify the tumour type and site. 
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 With regards to statistical analysis, the relationships between patient demographics, 
the presence of cancer, biochemical parameters, the mGPS, tumour site and other 
biochemical parameters were analysed using the Pearson’s chi-square test (linear by linear 
association).  Spearman’s rank correlation was used to measure the strength of the 
relationship between age and biochemical parameters and the interrelationships between 
biochemical parameters.  The relationship between the presence of cancer and patient 
demographics and biochemical parameters was examined using Cox proportional hazards 
model multivariate regression analysis;   only patients who had a diagnosis of cancer made 
within two years following their blood test were included in this analysis.  This was based on 
the premise that this group of patients were likely to have had an ongoing malignant process.  
Analysis was performed using SPSS software (SPSS Inc., Chicago, IL, USA). 
4.4. RESULTS 
 In total 223,303 patients were studied.  The majority, 144,900 (65%), were under 65 
years of age.  There were 120,115 (54%) females and 103,188 (46%) males.  Of those 
patients with an identifiable postcode (86%), the majority were from the Greater Glasgow 
area (88%).  In this cohort, when measured by the SIMD 2006, 14% of cases were from 
affluent areas (least deprived quintile of the Scottish population) and 45% from deprived 
areas (most deprived quintile of the Scottish population). 
 The demographics of non-cancer and cancer patients are shown in Table 4.1.  Patients 
with cancer, when compared to those without a diagnosis of cancer were older and more 
likely to be female (p<0.001).  The cancer group had a higher proportion of cases from less 
deprived areas than those in the non-cancer group (p<0.001). 
 Of 22,715 with a diagnoses of cancer 19,476 (86%) had a single primary tumour 
while 1299 (6%) had multiple malignancies.  In 1940 (8%) cases SNOMED CT codes gave 
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no definitive indication of the primary site of malignancy.  Examples of this include: 1497 
cases were SNOMED CT codes stated lung carcinoma, lung adenocarcinoma or lung 
metastatic carcinoma;   269 cases were SNOMED CT codes stated liver carcinoma, liver 
adenocarcinoma or liver metastatic carcinoma;   209 cases had SNOMED CT codes stating 
lymph node carcinoma, lymph node adenocarcinoma or lymph node metastatic carcinoma 
and 160 cases had SNOMED CT codes stating metastatic carcinoma at other sites. 
 When the cancer group was categorised (n=22,715) into different tumour sites the 
following main groups were observed;   bladder (n=939, 4%), breast (n=3849, 17%), 
colorectal (n=1899, 8%), dermatological (n=4907, 22%), endocrinological (n=303, 1%), 
gastroesophageal (n=1018, 5%), gynaecological (n=1136, 5%), haematological (n=1165, 
5%), head and neck (n=610, 3%), hepatocellular (n=55, 0%), musculoskeletal and soft tissue 
(n=164, 1%), pancreaticobiliary (n=456, 2%), prostate (n=957, 4%), pulmonary (n=1393, 
6%), renal (n=527, 2%) and testicular (n=97, 1%). 
 The relationship between markers of the systemic immune/inflammatory response, 
biochemical parameters and the presence of cancer is shown in Table 4.2.  There were higher 
circulating concentrations of C-reactive protein and lower albumin levels (and thus a higher 
proportion of mGPS 1 or 2), in those patients with cancer (all p<0.001).  Patients in the 
cancer group were also found to have lower AST and ALT levels but higher adjusted 
calcium, Alk phos and GGT levels compared with the non-cancer cohort (all p<0.001). 
 The interrelationships between markers of the systemic immune/inflammatory 
response and biochemical parameters in patients without and with cancer are shown in Tables 
4.3 and 4.4.  In the non-cancer cohort age was significantly associated with all biochemical 
parameters (all p<0.001) (Table 4.3).  Similarly, all biochemical parameters were 
significantly associated with each other (all p<0.001).  In the non-cancer cohort the strongest 
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associations (Spearman’s correlation > 0.3) were between C-reactive protein and albumin, C-
reactive protein and Alk phos, AST and ALT, AST and GGT and ALT and GGT. 
 There were similar interrelationships in the cancer cohort (Table 4.4) with the 
strongest associations (Spearman’s correlation > 0.3) existing between C-reactive protein and 
albumin, C-reactive protein and Alk phos, bilirubin and AST, Alk phos and GGT, AST and 
ALT, AST and GGT and ALT and GGT. 
 The temporal relationships between the date of blood samples and cancer diagnoses 
are shown in Table 4.5.  In order to give a clearer indication of the alterations that occur in 
biochemical parameters around the diagnosis of cancer only patients with a diagnosis within 
two years of their blood sample were included in the analysis, pre-diagnosis (n=8083) and 
post-diagnosis (n=5971).  Compared with those patients who had pre-diagnosis levels, post-
diagnosis patients were more likely to be female and affluent (all p<0.001). Patients 
following a diagnosis of cancer had lower albumin levels and thus higher mGPS (p<0.001).  
Also, post diagnosis patients were more likely to have lower adjusted calcium, bilirubin, Alk 
Phos, AST, ALT and GGT levels (all p<0.05). 
 The relationship between patient demographics, biochemical parameters and the 
absence (n= 200,588) or presence (n= 8083) of cancer within two years pre-diagnosis group 
is shown in Table 4.6.  On univariate analysis, those over 65 years of age and living in least 
deprived areas were more likely to have cancer (all p <0.001).  Patients with an elevated C-
reactive protein, adjusted calcium, Alk phos and GGT levels or low albumin levels were 
more likely to have cancer (all p<0.001).  On multivariate analysis, these associations with 
the presence of cancer persisted in age, deprivation, C-reactive protein, albumin, adjusted 
calcium, Alk phos and GGT (all p<0.01). 
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 The relationships between the mGPS and tumour site in the two year pre-diagnosis 
group is shown in cancers with more than 50 cases in Table 4.7.  The cancers are ranked from 
those with the highest proportion of mGPS 0 to those with the lowest.  The percentage of 
cases with a mGPS of 1 or 2 ranges from 21% in breast cancer, to 46% in prostate cancer and 
to 68% in pulmonary cancer.  Compared with breast cancer the mGPS was significantly 
higher in dermatological, bladder, endocrinological, gynaecological, prostate, 
musculoskeletal, gastroesophageal, haematological, renal, colorectal, head and neck, 
pancreaticobiliary and pulmonary cancers (all p<0.001). 
4.5. DISCUSSION 
 The results of the current Chapter show that the presence of a systemic 
immune/inflammatory response, as evidenced by an elevated C-reactive protein concentration 
(>10mg/l), was present in 40% and hypoalbuminaemia (<35g/l) was present in 14% of 223 
303 patients who were incidentally sampled.  Adjusted calcium was elevated in 2.2% (1.8% 
unadjusted), Alk phos was elevated in 12%, ALT was elevated in 11% and GGT was 
elevated in 26% of patients studied. 
 These results are consistent with previous studies including an Austrian cohort of 
approximately 280,000 patients, in whom 35% had an elevated C-reactive protein 
concentration [Marsik et al., 2008] and 13% had hypoalbuminaemia [Grimm et al., 2009].  
They also reported that 33% had an elevated GGT concentration [Kazemi-Shirazi et al., 
2007].  In a Swedish population based cohort of 33,346 patients, 1% were found to have an 
elevated unadjusted serum calcium  [Leifsson and Ahren, 1996].  In a North American cohort 
of 18,835 patients approximately 9% had an elevated Alk phos [Tonelli et al., 2009].  
Another population based cohort from the United States of 14,950 patients reported an 
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elevated ALT level in 14% of patients [Ruhl and Everhart, 2009].  Therefore, the results of 
the present Chapter are similar to those previously reported in other large cohort studies.   
 In the present cohort there were more females in the cohort as a whole, more females 
in the cancer group and more females had measurements taken post cancer diagnosis.  
However, gender was not significantly associated with the presence of cancer.  The present 
Chapter shows that when compared with non-cancer, the presence of cancer was associated 
with a significantly higher proportion of cases with an elevated C-reactive protein (>10mg/L, 
47% vs 39%) and lower albumin (<35g/L, 19% vs 14%) concentrations, higher adjusted 
calcium (>2.60mmol/L, 4% vs 2%), Alk phos (>280U/L, 16% vs 12%) and GGT (>40U/L in 
females, >70U/L in males, 29% vs 25%), and lower ALT levels (>50U/L, 10% vs 12%).  
Furthermore, when samples taken following a diagnosis of cancer were compared with those 
taken prior to a diagnosis of cancer the proportion of cases with albumin (>35g/L, 74% vs 
81%) adjusted calcium (>2.60mmol/L, 3% vs 5%), Alk phos (>280U/L, 15% vs 18%), ALT 
(>50U/L, 10% vs 11%). and GGT (>40U/L, in females, >70U/L in males 29% vs 31%) levels 
were all lower.  When these biochemical parameters together with bilirubin, and ALT were 
regressed against the presence of cancer, C-reactive protein, albumin, adjusted calcium, Alk 
phos and GGT were all shown to be independently associated with the presence of cancer.  
These results would suggest that the presence of cancer influences a number of biochemical 
parameters that have been previously associated with all-cause mortality [Leifsson and 
Ahren, 1996; Kazemi-Shirazi et al., 2007; Marsik et al., 2008; Grimm et al., 2009; Tonelli et 
al., 2009].  
 The present Chapter also showed that all these biochemical parameters were 
significantly associated.  In particular, C-reactive protein was associated with albumin and 
Alk phos and GGT associated with AST and ALT in both cancer and non-cancer cohorts.  
Recently the combination of C-reactive protein and albumin, termed the mGPS, was shown 
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to be associated in a similar manner in patients with lung cancer [Brown et al., 2007] and 
predict cancer specific survival in a number of operable [Roxburgh and McMillan, 2010] and 
inoperable cancers [McMillan, 2009].  These results raise the question of whether the above 
reported association of these biochemical parameters and all-cause mortality are indeed 
independent of each of other.  Further studies using this cohort will aim to address this 
question.  
 In the present Chapter the proportions of mGPS 1 or 2 were greater following a 
diagnosis of cancer.  This appears to be secondary to a reduction in albumin which may be 
secondary to a number of factors including operative management, adjuvant oncological 
therapies or tumour progression, a pattern recognised in previous studies within specific 
tumour types [McMillan et al., 2003; Jamieson et al., 2005].  Interestingly in patients who 
had blood tests taken following a diagnosis of cancer, adjusted calcium, bilirubin and Alk 
phos, AST, ALT and GGT levels were all more likely to be within normal limits.  The 
reasons for this are unclear but it is possible that removal or treatment of the underlying 
malignant process in a proportion of these patients may be responsible. 
 In the present Chapter it was also of interest to note that, prior to diagnosis, there were 
significant variations in the proportions of cases with a mGPS of 1 or 2.  Indeed, the 
proportion of patients with an elevated mGPS varied from 21% in breast cancer, to 46% in 
prostate cancer and to 68% in pulmonary cancer.  There is a striking parallel between the 
proportions of cases with a mGPS of 1 or 2 and reported survival rates in these tumours as 
detailed in Chapter 1[Cancer Research UK, 2007].  For example, the five year survival rate 
for breast cancer is approximately 84% and the proportion of patients in the present Chapter 
with a mGPS of 0 was 79%.  In contrast the 5 year survival for lung cancer is 8% and the 
proportion of patients in the present Chapter with a mGPS of 0 was 32%.  These results may 
suggest that, in addition to the mGPS having prognostic value within tumour types 
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[McMillan, 2009] it may also have prognostic value across tumour types.  Further work is 
required to confirm this hypothesis.  
 The present cohort has a number of limitations.  The patients were selected on the 
basis that measurements of C-reactive protein, albumin and calcium had been performed and 
were therefore not necessarily representative of all non-cancer and cancer patients treated in 
the North Glasgow area and therefore gives no meaningful information on cancer prevalence.  
Similarly, as this cohort was not a true representation of the North of Glasgow population, a 
direct comparison between SIMD measured deprivation and previously reported cancer 
incidence (figure 1.7) was not possible.  Furthermore, sampling was incidental and not 
performed at a standard time during the course of the disease in the cancer group.  It is also 
recognised that patients in both groups may have concurrent morbidity causing a rise in their 
C-reactive protein and derangement of their albumin and other biochemical parameters.  As 
inclusion in the cancer cohort was dependent on a pathological diagnosis of cancer it is 
acknowledged that a small number in the non-cancer group may have had a clinical diagnosis 
of malignancy.  In order to provide more detailed follow up with regards to survival it is 
important to link the present data with patient outcomes. 
 In summary, the results of the present Chapter indicate that the systemic 
immune/inflammatory response is common in a large patient cohort, increased by the 
presence of cancer and associated with the perturbation of a number of biochemical 
parameters previously reported to be associated with mortality.  Taken together with the 
myriad effects of the systemic immune/inflammatory response on host metabolism [Gabay 
and Kushner, 1999] these results have a number of clinical implications particularly for 
clinical epidemiological studies.  Future studies should incorporate a measure of the systemic 
immune/inflammatory response, such as C-reactive protein or the mGPS, in the study design, 
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analysis and interpretation.  This is required to account for the likely confounding effect of 
this response on the other measured variables and their relationship with outcomes. 
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Table 4.1. The relationship between patient demographics and the presence of cancer 
 
 
n=223,303 
 
Non-Cancer  
n (%) 
200,588 
 
Cancer  
n (%) 
22,715 
 
p value 
Age <65 years 135,531 (67) 9369 (41)  
 
<0.001 
65-74 years 31,593 (16) 6412 (28) 
>75 years 33,464 (17) 6934 (31) 
Sex Male 93,313 (46) 9875 (43)  
<0.001 Female 107,275 (54) 12,840 (57) 
SIMD 2006 1 (least deprived) 22,902 (14) 3233 (15)  
 
 
 
<0.001 
2 18,693 (11) 2578 (12) 
3 21,148 (12) 2771 (13) 
4 30,850 (18) 3872 (18) 
5 (most deprived) 77,448 (45) 8844 (42) 
 
  86 
Table 4.2. The relationship between markers of the systemic immune/inflammatory 
response, biochemical parameters and cancer 
 
n=223 303 
 
Non-Cancer  
n (%) 
200,588 
 
Cancer  
n (%) 
22,715 
 
p value 
C-reactive protein <10mg/l 122,317 (61) 12,050 (53)  
<0.001 >10mg/l 78 ,271 (39) 10,665 (47) 
Albumin <35g/l 27,515 (14) 4275 (19)  
<0.001 >35g/l 173,073 (86) 18,440 (81) 
mGPS 0 122,317 (61) 12,050 (53)  
 
<0.001 
1 56,357 (28) 7033 (31) 
2 21,914 (11) 3632 (16) 
Adjusted calcium <2.10mmol/l 4963 (3) 577 (2)  
 
<0.001 
2.10-2.60mmol/l 191,429 (95) 21,323 (94) 
>2.60mmol/l 4196 (2) 815 (4) 
Bilirubin <20μmol/l 170,447 (88) 19,322 (88)  
0.008 >20μmol/l 24,258 (12) 2593 (12) 
Alkaline phosphatase <80U/l 28,168 (14) 2463 (11)  
 
<0.001 
80-280U/l 148,245 (74) 16,626 (73) 
>280U/l 23,954 (12) 3603 (16) 
Aspartate 
transaminase 
<40U/l 162,269 (84) 18,676 (86)  
<0.001 >40U/l 30,531 (16) 3129 (14) 
Alanine transaminase <50U/l 144,468 (88) 15,872 (90)  
<0.001 >50U/l 19,043 (12) 1740 (10) 
γ-glutamyl transferase M <70 U/l, F <40U/l 145,658 (75) 15,689 (71)  
<0.001 M >70U/l, F >40U/l 49,393 (25) 6325 (29) 
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Table 4.3. The interrelationships between markers of the immune/inflammatory response and biochemical parameters in patients 
without cancer 
 
n=200,588 
C-reactive 
protein 
Albumin Adjusted 
Calcium 
Bilirubin Alkaline 
phosphatase 
Aspartate 
transaminase 
Alanine 
transaminase 
γ-glutamyl 
transferase 
Age 0.199*** -0.286*** 0.052*** 0.099*** 0.177*** 0.078*** -0.047*** 0.148*** 
C-reactive protein  -0.362*** -0.108*** 0.167*** 0.320*** 0.103*** 0.040*** 0.193*** 
Albumin   -0.060*** 0.040*** 0.022*** 0.009*** 0.072*** -0.116*** 
Adjusted calcium    -0.077*** -0.147*** -0.081*** -0.028*** 0.077*** 
Bilirubin     0.143*** 0.297*** 0.216*** 0.169*** 
Alkaline phosphatase      0.225*** 0.152*** 0.243*** 
Aspartate transaminase       0.736*** 0.437*** 
Alanine transaminase        0.550*** 
***p<0.001 
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Table 4.4. The interrelationships between markers of the immune/inflammatory response and biochemical parameters in patients with 
cancer 
n=22,715 
 
C-reactive 
protein 
Albumin Adjusted 
Calcium 
Bilirubin Alkaline 
phosphatase 
Aspartate 
transaminase 
Alanine 
transaminase 
γ-glutamyl 
transferase 
Age 0.103*** -0.203*** 0.024*** 0.127*** 0.079*** 0.020** -0.162*** -0.062*** 
C-reactive protein  -0.439*** -0.078*** 0.166*** 0.308*** 0.104*** 0.034*** 0.239*** 
Albumin   -0.086*** 0.004 0.028*** 0.007 0.073*** -0.123*** 
Adjusted calcium    -0.095*** -0.087*** -0.053*** -0.013 0.106*** 
Bilirubin     0.166*** 0.307*** 0.225*** 0.177*** 
Alkaline phosphatase      0.253*** 0.213*** 0.346*** 
Aspartate transaminase       0.720*** 0.403*** 
Alanine transaminase        0.505*** 
***p<0.001 
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Table 4.5. The relationship between time of diagnosis and biochemical parameters in patients 
with cancer 
n=14,054  Pre–diagnosis 
n (%) 
8083 
Post-diagnosis 
n (%) 
5971 
p value 
Age <65 years 3516 (43) 2690 (45)  
 
0.732 
65-74 years 2413 (30) 1626 (27) 
>75 years 2154 (27) 1655 (28) 
Sex Male 3806 (47) 2482 (42)  
<0.001 Female 4277 (53) 3489 (58) 
SIMD 2006 1 (least deprived) 1140 (15) 951 (17)  
 
 
 
<0.001 
2 958 (12) 724 (13) 
3 1080 (14) 802 (15) 
4 1428 (19) 1003 (18) 
5 (most deprived) 3042 (40) 2011 (37) 
C-reactive protein <10mg/l 4082 (51) 2963 (50)  
0.304 >10mg/l 4001 (49) 3008 (50) 
Albumin <35g/l 1566 (19) 1545 (26)  
<0.001 >35g/l 6517 (81) 4426 (74) 
mGPS 0 4082 (50) 2963 (50)  
 
<0.001 
1 2666 (33) 1643 (27) 
2 1335 (17) 1365 (23) 
Adjusted Calcium <2.10mmol/l 183 (2) 151 (3)  
 
<0.001 
2.10-2.60 7501 (93) 5614 (94) 
>2.60mmol/l 399 (5) 206 (3) 
Bilirubin <20μmol/l 6844 (87) 5163 (90)  
<0.001 >20μmol/l 994 (13) 587 (10) 
Alkaline phosphatase <80U/l 788 (10) 743 (12)  
 
0.003 
80-280U/l 5805 (72) 4324 (73) 
>280U/l 1482 (18) 898 (15) 
Aspartate 
transaminase 
<40U/l 6614 (85) 4941 (86)  
0.030 >40U/l 1175 (15) 788 (14) 
Alanine transaminase <50U/l 5729 (89) 4215 (90)  
0.004 >50U/l 734 (11) 450 (10) 
γ-glutamyl transferase M<70 U/l, F<40U/l 5440 (69) 4100 (71)  
0.012 M>70U/l, F>40U/l 2432 (31) 1667 (29) 
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Table 4.6. The relationship between patient demographics, biochemical parameters and the 
presence of cancer 
 
n=208,671 
Univariate analysis Multivariate analysis 
Odds 
Ratio 
95% CI p-value Odds 
Ratio 
95% CI p-value 
Age <65/  1  <0.001 1  <0.001 
65-74 2.94 2.79-3.12 <0.001 2.60 2.46-2.75 <0.001 
>75 2.48 2.35-2.62 <0.001 2.17 2.05-2.30 <0.001 
Sex Male 1  0.317    
Female 0.98 0.94-1.02 0.317    
SIMD 5 (most deprived) 1  <0.001 1  <0.001 
4 1.18 1.11-1.26 <0.001 1.16 1.09-1.24 <0.001 
3 1.30 1.21-1.40 <0.001 1.32 1.22-1.42 <0.001 
2 1.31 1.21-1.41 <0.001 1.36 1.26-1.46 <0.001 
1 (least deprived) 1.27 1.18-1.36 <0.001 1.27 1.18-1.36 <0.001 
C-reactive 
protein 
<10mg/l 1  <0.001 1  <0.001 
>10mg/l 1.53 1.47-1.60 <0.001 1.22 1.16-1.28 <0.001 
Albumin <35g/l 1.51 1.43-1.60 <0.001 1.11 1.04-1.19 0.002 
>35g/l 1  <0.001 1  0.002 
Adjusted 
calcium 
<2.10mmol/l 0.94 0.81-1.09 0.425    
2.10-2.60mmol/l 1  <0.001   <0.001 
>2.60mmol/l 2.43 2.18-2.70 <0.001 1.90 1.70-2.21 <0.001 
Bilirubin <20μmol/l 1  0.558    
>20μmol/l 1.02 0.95-1.09 0.558    
Alkaline 
phosphatase 
<80U/l 0.71 0.66-0.77 <0.001 0.81 0.75-0.87 <0.001 
80-280U/l 1  <0.001 1  <0.001 
>280U/l 1.58 1.49-1.68 <0.001 1.30 1.22-1.39 <0.001 
Aspartate 
transaminase 
<40U/l 1  0.075    
>40U/l 0.94 0.89-1.01 0.075    
Alanine 
transaminase 
<50U/l 1  0.477    
>50U/l 0.97 0.90-1.05 0.477    
γ-glutamyl 
transferase 
M<70 U/l,F<40U/l 
M>70U/l, F>40U/l 
1  <0.001 1   
1.32 1.26-1.38 <0.001 1.09 1.03-1.15 0.003 
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Table 4.7. The relationship between tumour site and an inflammation-based prognostic 
score sampled prior to diagnosis 
Tumour Site Total 
n 
mGPS  
n (%) 
p value* 
0 
 
1 
 
2 
 
 
Breast 1199 950 
(79) 
207 
(17) 
42 
(4) 
 
Dermatological 1126 693 
(62) 
310 
(27) 
123 
(11) 
 
<0.001 
Bladder 296 174 
(59) 
76 
(26) 
46 
(15) 
 
<0.001 
Endocrinological 145 84 
(58) 
41 
(28) 
20 
(14) 
 
<0.001 
Gynaecological 197 108 
(55) 
60 
(30) 
29 
(15) 
 
<0.001 
Prostate 267 145 
(54) 
91 
(34) 
31 
(12) 
 
<0.001 
Musculoskeletal 78 41 
(53) 
15 
(19) 
22 
(28) 
 
<0.001 
Gastroesophageal 503 249 
(50) 
162 
(32) 
92 
(18) 
 
<0.001 
Haematological 499 245 
(49) 
157 
(32) 
97 
(19) 
 
<0.001 
Renal 294 132 
(45) 
105 
(36) 
57 
(19) 
 
<0.001 
Colorectal 784 342 
(44) 
250 
(32) 
192 
(24) 
 
<0.001 
Head and neck 156 67 
(43)  
58 
(37) 
31 
(20) 
 
<0.001 
Pancreaticobiliary 321 122 
(38) 
101 
(31) 
98 
(31) 
 
<0.001 
Pulmonary 820 260 
(32) 
387 
(47) 
173 
(21) 
 
<0.001 
*compared with breast cancer 
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5.0. AN INFLAMMATION-BASED PROGNOSTIC SCORE (mGPS) PREDICTS 
CANCER SURVIVAL INDEPENDENT OF TUMOUR SITE 
5.1. ABSTRACT 
Introduction:  The modified Glasgow Prognostic score (a combination of C-reactive protein 
and albumin) as well as liver function tests including bilirubin, alkaline phosphatase and γ-
glutamyl transferase have been reported to predict cancer survival.  The aim of the present study 
was to examine the relationship between the mGPS, biochemical parameters and survival. 
Methods:  Patients (n=21,669) sampled between 2000 and 2006 for C-reactive protein, albumin, 
liver function tests where available, as well as a diagnosis of cancer were identified.  Of this 
group 9608 patients who had an ongoing malignant process were studied (sampled within two 
years following diagnosis). 
Results:  On follow up, there were 6005 (63%) deaths of which 5122 (53%) were cancer deaths.  
The median time from blood sampling to diagnosis was 1.4 months.  Increasing age, male 
gender, and increasing deprivation was associated with reduced 5 year overall and cancer 
specific survival (all p<0.001).  An elevated mGPS, adjusted calcium, bilirubin, Alk phos, AST, 
ALT and GGT were associated with a reduced 5 year overall and cancer specific survival, 
independent of age, sex and deprivation (all p<0.001).  An increasing mGPS was predictive of a 
reduced cancer specific survival in all cancers (all p<0.001). 
Conclusion:  The results of the present study indicate that the mGPS is a powerful prognostic 
factor when compared with other biochemical parameters and independent of tumour site in 
patients with cancer. 
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5.2. INTRODUCTION 
 As detailed in Chapter 3, measurement of the systemic immune/inflammatory response 
has been refined using a selective combination of C-reactive protein and albumin (termed the 
modified Glasgow Prognostic score, mGPS) and has been shown to have prognostic value, 
independent of tumour stage, in lung, gastrointestinal and renal cancers [McMillan, 2008; 
McMillan, 2009].  As has been detailed in Chapter 1, it is also of interest that liver function tests 
such as bilirubin [Temme et al., 2001], alkaline phosphatase [Tonelli et al., 2009] and γ-glutamyl 
transferase [Kazemi-Shirazi et al., 2007] as well as serum calcium [Leifsson and Ahren, 1996], 
have also been reported to predict cancer and non-cancer mortality in large cohort studies. 
 In Chapter 4 it has been demonstrated, in a large cohort of more than 200,000 patients, 
that the mGPS is elevated in patients with cancer when compared to those without cancer 
[Proctor et al., 2010].  Moreover, there were significant interrelationships between the above 
biochemical parameters, including the constituents of the mGPS [Proctor et al., 2010].  The 
question is therefore raised whether the mGPS and other routine biochemical parameters have 
independent prognostic value in patients with cancer and whether this applies across different 
tumour sites. 
 The aim of the present Chapter was to examine the relationship between an inflammation 
based prognostic score (mGPS), biochemical parameters, tumour site and survival in patients 
with cancer. 
5.3. MATERIALS AND METHODS 
 From a cohort previously described in Chapter 4 [Proctor et al., 2010], patients in North 
Glasgow who were sampled incidentally for the pre-mentioned markers of the systemic 
immune/inflammatory response as well as liver function tests between the 1st January 2000 and 
the 31st December 2006 to correspond with Cancer Registry follow-up data, were identified.  
  94 
Only patients with blood samples taken within two years following their cancer diagnosis were 
included.  This was done with the premise that a prognostic score would be of clinical use during 
this time period.  Biochemical variable thresholds were categorised as detailed in Chapter 4 
[Proctor et al., 2010]. 
 Cancer diagnosis was established through linkage with the Scottish Cancer Registry 
using exact matches of patients’ forename, surname and date of birth followed by a Soundex 
phonetic matching algorithm if initial exact matching was unsuccessful (Appendix 2).  At the 
time of data collection the Scottish Cancer Registry held complete pathological and clinical 
cancer diagnosis records from the 1st of January 1980 until 31st December 2006 and mortality 
follow-up until 30th June 2009.  In those who had died, cancer specific deaths were classified as 
patients whose primary cause of death matched their primary cancer diagnosis.  All other deaths 
were classed as non-cancer specific deaths.  Only patients who had complete Cancer Registry 
follow-up were included.  Patient numbers in this Chapter differ from those in Chapter 4 as the 
matching process was through the cancer registry and not the North of Glasgow pathology 
database.  
 Cancers were coded in accordance with the International Classification of Disease 10 and 
broadly grouped according to tumour site.  These include breast (C50), bladder (C67), 
gynaecological (C51-57), prostate (C61), gastroesophageal (C15-16), haematological (C81-96), 
renal (C64-65), colorectal (C18-20), head and neck (C00-14, C30-32), hepatopancreaticobiliary 
(C22-25) and pulmonary (C34, C45) cancer.  These groups were listed in order of the magnitude 
of their inflammatory status as shown previously [Proctor et al., 2010].  Deprivation was 
measured with the Scottish Index of Multiple Deprivation (SIMD) as detailed in Chapter 1 with 
the least deprived scoring 1 and the most deprived scoring 5. 
 Statistical analysis was carried out as follows.  Survival, overall and cancer specific, was 
calculated from the time of cancer diagnosis to death.  Cancer groups with less than 150 cancer 
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specific deaths were excluded to ensure statistical power.  Analysis was carried on all cancer 
patients as well as on a sub-group of patients who had a blood sample taken within 2 months of 
their cancer diagnosis.  This was carried out in order to examine the relationships between the 
mGPS, biochemical parameters and survival in all patients with a history of malignancy (patients 
sampled within 2 years following a diagnosis of cancer) and those at the time of diagnosis 
(patients sampled within 2 months following a diagnosis of cancer).  When investigating the 
prognostic value of the systemic immune/inflammatory response and associated biochemical 
variables only blood samples taken after a diagnosis of cancer were included.  This was carried 
out under the premise that it would be within this time period that the prognostic value of these 
variable would be of clinical utility.  The mGPS and biochemical proportionality assumptions 
were explored using log-log plots and were found to be satisfactory.  Kaplan-Meier estimator 
was used to analyse the relationship between patient characteristics, mGPS, biological 
parameters, tumour site and overall and cancer specific survival (Tables 5.3 and 5.4) as well as 
the relationship between mGPS and survival (Figure 5.2 and Table 5.9).  Cox proportional 
hazards model multivariate regression analysis (stratified by tumour site) was used to determine 
the relationship between patient characteristics, the mGPS, and each biochemical parameter and 
survival (Tables 5.5, 5.6, 5.7, 5.8).  Chi square (linear by linear) association was used to analyse 
the relationship between the mGPS, patient characteristics and biochemical parameters (Table 
5.9).  Due to the number of statistical comparisons a P value of less than 0.01 was considered 
significant.  Analysis was performed using SPSS software (SPSS Inc., Chicago, IL, USA).  The 
study was approved by the Research Ethics Committee, North Glasgow NHS Trust. 
 
5.4. RESULTS 
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 From Glasgow Inflammation Outcome Study of 223,303 patients originally described 
(Proctor et al, 2010), 21,668 patients were identified as having a diagnosis of cancer in the 
Scottish Cancer Registry and a blood sample taken between January 2000 and December 2006.  
There were 9608 patients in this group who had been sampled within two years following a 
diagnosis of cancer and included in the present Chapter.  The majority, 7516 (78%), were under 
75 years of age.  There were 5116 (53%) females and 4492 (47%) males.  All patients had an 
identifiable post code corresponding to a SIMD 2006 score with 15% of cases being from 
affluent areas (least deprived quintile of the Scottish population) and 38% being from deprived 
areas (most deprived quintile of the Scottish population).  The minimum follow-up was 29 
months and the maximum 112 months (median 61 months for survivors). 
 The relationship between patient characteristics, tumour site, mGPS, biochemical 
parameters and mortality in patients with blood samples taken within two years, as well as 
within two months, following a diagnosis is shown in Table 5.1 and Table 5.2.  In those sampled 
within two years (n=9608), there were 5122 (53%) cancer deaths and the median time from 
blood sample to diagnosis was 1.4 months.  In those sampled within two months (n=5397), there 
were 2993 (56%) cancer deaths and the median time from blood sample to diagnosis was 0.4 
months.  Breast and lung cancer were among the most common tumour types studied. 
 The relationship between the mGPS, biochemical parameters, tumour site and five year 
survival in patients with blood samples taken within two years, as well as two months, following 
a diagnosis of cancer is shown in Table 5.3, Table 5.4 and Figure 5.1.  Increasing age, male 
gender and increasing deprivation was associated with reduced 5 year overall and cancer specific 
survival (all p<0.001).  An elevated mGPS, adjusted calcium, bilirubin, Alk phos, AST, ALT 
and GGT were associated with a reduced 5 year overall and cancer specific survival (all 
p<0.001).  These tables demonstrate the dramatic survival difference between tumours at 
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different sites as well as in those with raised markers of the systemic immune/inflammatory 
response. 
 In the present cohort sampled within two years, the majority of patients with a low 
albumin concentration (n=2701) also had an elevated C-reactive protein concentration (n=2419, 
90%).  Few patients had a low albumin but a C-reactive protein concentration in the normal 
range (n=282).  A low albumin concentration alone was not significantly associated with cancer 
specific survival in bladder (p=0.913), gynaecological (p=0.737), prostate (p=0.500), 
gastroesophageal (p=0.893), renal (p=0.945), colorectal (p=0.133), head and neck (p=0.740), 
and hepatopancreaticobiliary (p=0.209) cancers.  In Cox multivariate regression analysis the 
relationship between a mGPS of 2 and cancer specific survival (HR 3.01, p<0.001) was stronger 
than that between C-reactive protein alone and cancer specific survival (HR 2.29, p<0.001). 
 The relationship between the mGPS and cancer specific survival in breast (n=1956), 
bladder (n=466), gynaecological (n=533), prostate (n=491), gastroesophageal (n=869), 
haematological (n=974), renal (n=424), colorectal (n=1065), head and neck (n=501), 
hepatopancreaticobiliary (n=605) and pulmonary (n=1724) cancers are shown in Figures 5.2. 
 The relationship between the mGPS, biochemical parameters and survival in patients 
sampled within two years, as well as two months, following cancer diagnosis, adjusted for age, 
sex, deprivation and stratified by tumour site, is shown in Table 5.5 and Table 5.6.  On survival 
analysis, a raised mGPS, adjusted calcium, bilirubin, Alk phos, AST, ALT and GGT were all 
associated with increased overall and cancer specific mortality independent of age, sex and 
deprivation (all p<0.001). These tables illustrate the associations between markers of the 
systemic immune/inflammatory response, biochemical variables and survival and highlight the 
relative strength of the mGPS as a predictive factor. 
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 The relationship between the mGPS, patient demographics and survival in patients 
sampled within two years, as well as within two months, following cancer diagnosis is shown in 
Table 5.7 and 5.8.  On multivariate survival analysis, stratified by tumour site, increasing age 
and mGPS were associated with increased overall and cancer specific mortality (all p<0.001).  
Patients in the most deprived quintile (5) had a reduced overall and cancer specific survival 
(both p<0.01) but a significant linear relationship across deprivation categories was not 
observed.  These tables illustrate the associations between the mGPS, patient demographics and 
survival and highlight the relative strength of the mGPS, when compared to patient 
characteristics, as a predictive factor. 
 In the present cohort of patients sampled within two months following cancer diagnosis, 
only a limited number of patients had staging information available from the Scottish Cancer 
Registry.  Tumour staging was available in 533 (39%) patients with breast cancer, 430 (76%) 
patients with colorectal cancer and 158 (13%) patients with pulmonary cancer.  All other cancer 
groups had no staging available.  Therefore, only in colorectal cancer was staging available in 
over 50% of patients.  In these colorectal cancer patients there were 30 Dukes A, 113 Dukes B, 
131 Dukes C and 156 Dukes D and 236 died of their cancer.  When Dukes stage was included in 
the multivariate analysis, both Dukes stage (HR 3.59, 95% CI 2.95-4.39, p<0.001) and mGPS 
(HR 1.49, 95% CI 1.26-1.76, p<0.001) remained independently associated with survival. 
 The associations between an activated systemic immune/inflammatory response, as 
measured by an elevated mGPS. and other biochemical parameters in patients with blood 
samples taken within two years following a diagnosis of cancer is shown in Table 5.9.  An 
increasing mGPS was also associated with increasing age, male gender, increasing adjusted 
calcium, bilirubin, Alk phos, AST, ALT and GGT (all p<0.001).  An increasing mGPS was 
shown to be associated with a reduction in overall and cancer specific survival (both p<0.001).  
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This table illustrates the correlation between an activated systemic immune/inflammatory 
response and derangement of a number of other biochemical variables. 
 Figure 5.2 illustrates the relationship between the mGPS and cancer specific survival 
(p<0.001) in each tumour site.  This clearly demonstrates that the mGPS is predictive of survival 
independent of tumour site. 
5.5. DISCUSSION 
 Previously, in large cohort studies, a number of biochemical parameters (other than C-
reactive protein and albumin that compose the mGPS) including bilirubin [Temme et al., 2001], 
Alk phos [Tonelli et al., 2009], GGT [Kazemi-Shirazi et al., 2007] and calcium [Leifsson and 
Ahren, 1996], have been reported to predict overall and cancer specific survival. 
 In the present Chapter, the mGPS and the above biochemical parameters were shown to 
have prognostic value in all patients with a history of malignancy as well as those around the 
time of diagnosis.  Moreover, a mGPS of 2 was associated with an approximate 160% reduction 
in both overall and cancer specific survival independent of tumour site.  In contrast, an increase 
in adjusted calcium was associated with an approximate 130% reduction in both overall and 
cancer specific survival;   an increase in bilirubin was associated with an approximate 50% 
reduction in both overall and cancer specific survival;   an increase in Alk phos was associated 
with an approximate 110% reduction in both overall and cancer specific survival: an increase in 
AST was associated with an approximate 70% reduction in both overall and cancer specific 
survival;   an increase in ALT was associated with an approximate 40% increase in both overall 
and cancer specific survival and an increase in GGT was associated with an approximate 80% 
reduction in both overall and cancer specific survival.  These results indicate that the mGPS and 
the biochemical parameters measured have prognostic significance in the tumour sites studied.  
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Moreover, the results show that a raised mGPS is most closely associated with a reduction in 
both overall and cancer specific survival, independent of tumour site. 
 The GPS was originally developed, from the combination of C-reactive protein and 
albumin, in a cohort of patients with advanced non-small lung cancer [Forrest et al., 2004].  In 
this Chapter, they were combined to give a score of 0 for both a normal C-reactive protein and 
albumin, 1 for either an abnormal C-reactive protein alone or albumin alone and 2 for both an 
abnormal C-reactive protein and albumin.  It was clear from this analysis that a low albumin 
alone was uncommon, accounting for less than 10% of all observations, and raised the 
possibility that this was not associated with a reduced survival.  When examined in a cohort of 
patients undergoing potentially curable resection for colorectal cancer [McMillan et al., 2007] 
the results showed that the relationship between an abnormal albumin alone and cancer specific 
survival was similar to that of a normal albumin.  Therefore, the GPS was modified (mGPS) to 
give a score of 1 only for an elevated C-reactive protein concentration.  In the present Chapter, 
in a much larger cohort, a low albumin alone was associated with poor survival in some tumours 
(breast, haematological and pulmonary) but not others (bladder, gynaecological, prostate, 
gastroesophageal, renal, colorectal, head and neck, hepatopancreaticobiliary).  Therefore, the 
present results would suggest the greater consistency of the mGPS and suggest its general use 
rather than that of the GPS. 
 In the present Chapter we examined the relationship between the mGPS, biochemical 
parameters and survival in all patients with cancer as well as a sub group of patients who were 
sampled within two months following a diagnosis of cancer.  This was carried out with the 
premise that patients sampled within two years following a diagnosis would have a mGPS 
associated with disease prognosis and those sampled within two months would have a mGPS 
associated with their cancer diagnosis.  With reference to the mGPS, the hazard ratios associated 
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with survival remained consistent in both analyses and confirms the temporal utility of this 
inflammation-based prognostic score. 
 To date the mGPS has been shown to have prognostic value, independent of TNM stage, 
in lung, gastrointestinal and renal cancers [McMillan, 2008; McMillan, 2009].  In the present 
Chapter there was insufficient staging information available on all cancer groups, apart from 
colorectal, to demonstrate that the mGPS is universally prognostic independent of stage.  
However, the results of the present and previous studies as detailed in Chapter 3  would suggest 
that the mGPS might also have independent prognostic in other cancer types [McMillan, 2009; 
Roxburgh and McMillan, 2010].  Further detailed studies, including tumour stage, in breast, 
bladder, gynaecological, prostate, haematological, head and neck, and hepatopancreaticobiliary 
cancers are required to confirm this hypothesis.  Nevertheless, if this were to prove to be the 
case, then similar to the TNM staging system, the mGPS may be implemented universally in the 
assessment of cancer patients.  Moreover, that they (TNM stage and mGPS) may be combined in 
a single staging system which would not only account for tumour stage but also the host 
systemic immune/inflammatory response. 
 The present cohort has a number of limitations.  The patients were selected on the basis 
that measurements of C-reactive protein, albumin and calcium had been performed and were 
therefore not necessarily representative of all cancer patients diagnosed and treated in the North 
Glasgow area.  It is also recognised that patients with cancer may have concurrent morbidity 
causing a rise in their C-reactive protein and derangement of their albumin and other 
biochemical parameters.  Moreover, a rise in inflammatory markers may have occurred as a 
result of the initiation of oncological treatments including resectional surgery, radiotherapy and 
chemotherapy. 
 In summary, the results of the present Chapter indicate that, in a large patient cohort, the 
systemic immune/inflammatory response, as evidenced by the mGPS, is common and that the 
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mGPS is a powerful prognostic factor compared with other biochemical parameters, independent 
of tumour site in patients with cancer. 
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Table 5.1. The relationship between patient characteristics, mGPS, biochemical parameters, tumour 
site and mortality in patients sampled within two years following cancer diagnosis 
 Patients 
n= 9608 (%) 
All deaths 
n= 6005 
Cancer deaths 
n=5122 
Age <65 years 4577 (48) 2258 2056 
65–74 years 2936 (30) 2041 1729 
≥ 75 years 2095 (22) 1706 1337 
Sex  Male 4492 (47) 3269 2794 
Female 5116 (53) 2736 2328 
SIMD 2006 1 (least deprived) 1419 (15) 722 616 
2 1198 (13) 631 543 
3 1445 (15) 850 739 
4 1858 (19) 1222 1038 
5 (most deprived) 3688 (38) 2580 2186 
Tumour site Breast  1956 (20) 452 328 
Bladder  466 (5) 250 155 
Gynaecological  533 (6) 298 256 
Prostate  491 (5) 244 165 
Gastroesophageal  869 (9) 772 719 
Haematological  974 (10) 539 418 
Renal  424 (5) 265 229 
Colorectal  1065 (11) 673 571 
Head and Neck  501 (5) 316 220 
Hepatopancreaticobiliary  605 (6) 563 536 
Pulmonary  1724 (18) 1633 1525 
Inflammation 
based score 
mGPS 0 3985 (42) 1647 1315 
1 3204 (33) 2325 2039 
2 2419 (25) 2033 1768 
Biochemical 
parameters 
Adjusted 
calcium 
<2.10mmol/l 329 (4) 229 177 
2.10-2.60mmol/l 8856 (92) 5399 4601 
>2.60mmol/l 423 (4) 377 344 
Bilirubin <20μmol/l 7936 (83) 4693 3978 
>20μmol/l 1342 (14) 1071 942 
Alkaline 
phosphatase 
<80U/l 177 (2) 56 48 
80-280U/l 6846 (71) 3704 3068 
>280U/l 2569 (27) 2236 1999 
Aspartate 
transaminase 
<40U/l 7609 (18) 4439 3734 
>40U/l 1678 (79) 1340 1206 
Alanine 
transaminase 
<50U/l 6350 (66) 3588 3036 
>50U/l 992 (10) 741 677 
γ-glutamyl 
transferase 
M<70 U/l, F<40U/l 6082 (63) 3336 2765 
M>70U/l, F>40U/l 3264 (34) 2488 2212 
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Table 5.2. The relationship between patient characteristics, mGPS, biochemical parameters, tumour 
site and mortality in patients sampled within two months following cancer diagnosis 
 Patients 
n= 5397 (%) 
All deaths 
n= 3405 
Cancer deaths 
n= 2993 
Age <65 years 2452 (46) 1192 1093 
65–74 years 1686 (31) 1172 1035 
≥ 75 years 1259 (23) 1041 865 
Sex  Male 2315 (43) 1829 1620 
Female 3082 (57) 1576 1373 
SIMD 2006 1 (least deprived) 802 (15) 392 335 
2 685 (13) 344 304 
3 766 (14) 429 388 
4 974 (18) 648 572 
5 (most deprived) 2170 (40) 1592 1394 
Tumour site Breast  1383 (26) 235 166 
Bladder  181 (3) 97 60 
Gynaecological  188 (3) 129 108 
Prostate  159 (3) 106 75 
Gastroesophageal  456 (8) 400 371 
Haematological  427 (8) 255 211 
Renal  179 (3) 117 107 
Colorectal  569 (11) 363 309 
Head and Neck  191 (4) 130 94 
Hepatopancreaticobiliary  486 (9) 455 438 
Pulmonary  1178 (22) 1118 1054 
Inflammation 
based score 
mGPS 0 2243 (41) 890 743 
1 1815 (34) 1385 1252 
2 1339 (25) 1130 998 
Biochemical 
parameters 
Adjusted 
calcium 
<2.10mmol/l 165 (3) 116 91 
2.10-2.60mmol/l 4971 (92) 3058 2685 
>2.60mmol/l 261 (5) 231 217 
Bilirubin <20μmol/l 4366 (81) 2558 2230 
>20μmol/l 855 (16) 720 655 
Alkaline 
phosphatase 
<80U/l 98 (2) 28 25 
80-280U/l 3788 (70) 2039 1746 
>280U/l 1502 (30) 1333 1217 
Aspartate 
transaminase 
<40U/l 4191 (78) 2409 2084 
>40U/l 1034 (19) 876 812 
Alanine 
transaminase 
<50U/l 3740 (69) 2127 1847 
>50U/l 636 (12) 514 483 
γ-glutamyl 
transferase 
M<70 U/l, F<40U/l 3393 (63) 1841 1581 
M>70U/l, F>40U/l 1867 (35) 1472 1338 
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Table 5.3. The relationship between patient characteristics, mGPS, biochemical parameters, 
tumour site and five year survival in patients sampled within two years following cancer diagnosis 
 
n=9608 
5 year overall 
survival % 
p-value 5 year cancer 
survival % 
 
p-
value 
Age <65 years 50 
<0.001 
54 
<0.001 
65–74 years 30 38 
≥ 75 years 19 30 
Sex  Male 27 
<0.001 
34 
<0.001 Female 47 53 
SIMD  1 (least deprived) 50 
<0.001 
55 
<0.001 
2 47 52 
3 41 46 
4 34 41 
5 (most deprived) 30 37 
Tumour site Breast  77 
<0.001 
83 
<0.001 
Bladder  57 64 
Gynaecological  44 52 
Prostate  50 64 
Gastroesophageal  11 13 
Haematological  46 54 
Renal  39 38 
Colorectal  37 43 
Head and Neck  34 50 
Hepatopancreaticobiliary  6 7 
Pulmonary  5 7 
Inflammation 
based score 
mGPS 0 59 
<0.001 
65 
<0.001 
1 28 34 
2 15 21 
Biochemical 
parameters 
Adjusted 
calcium 
<2.10mmol/l 30 
<0.001 
41 
<0.001 
2.10-2.60mmol/l 39 45 
>2.60mmol/l 10 14 
Bilirubin <20μmol/l 41 
<0.001 
47 
<0.001 >20μmol/l 20 25 
Alkaline 
phosphatase 
<80U/l 62 
<0.001 
66 
<0.001 
80-280U/l 46 53 
>280U/l 13 17 
Aspartate 
transaminase 
<40U/l 42 
<0.001 
48 
<0.001 >40U/l 20 24 
Alanine 
transaminase 
<50U/l 43 
<0.001 
50 
<0.001 >50U/l 25 28 
γ-glutamyl 
transferase 
M<70 U/l, F<40U/l 45 
<0.001 
52 
<0.001 M>70U/l, F>40U/l 23 28 
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Table 5.4. The relationship between patient characteristics, mGPS, biochemical parameters, tumour 
site and five year survival in patients sampled within two months following cancer diagnosis 
 
n=5397 
5 year overall 
survival % 
p-value 5 year cancer 
survival % 
 
p-value 
Age <65 years 51 
<0.001 
54 
<0.001 
65–74 years 30 35 
≥ 75 years 18 26 
Sex  Male 21 
<0.001 
26 
<0.001 Female 49 54 
SIMD  1 (least deprived) 52 
<0.001 
57 
<0.001 
2 50 54 
3 43 47 
4 32 38 
5 (most deprived) 27 32 
Tumour site Breast  83 
<0.001 
87 
<0.001 
Bladder  48 63 
Gynaecological  33 39 
Prostate  32 46 
Gastroesophageal  12 15 
Haematological  40 47 
Renal  35 39 
Colorectal  37 43 
Head and Neck  29 43 
Hepatopancreaticobiliary  5 6 
Pulmonary  5 7 
Inflammation 
based score 
mGPS 0 60 
<0.001 
65 
<0.001 
1 24 29 
2 15 20 
Biochemical 
parameters 
Adjusted 
calcium 
<2.10mmol/l 29 
<0.001 
39 
<0.001 
2.10-2.60mmol/l 38 43 
>2.60mmol/l 10 13 
Bilirubin <20μmol/l 41 
<0.001 
47 
<0.001 >20μmol/l 15 19 
Alkaline 
phosphatase 
<80U/l 68 
<0.001 
69 
<0.001 
80-280U/l 46 52 
>280U/l 11 14 
Aspartate 
transaminase 
<40U/l 42 
<0.001 
48 
<0.001 >40U/l 15 18 
Alanine 
transaminase 
<50U/l 43 
<0.001 
48 
<0.001 >50U/l 19 21 
γ-glutamyl 
transferase 
M<70 U/l, F<40U/l 46 
<0.001 
51 
<0.001 M>70U/l, F>40U/l 20 25 
  
  107 
Table 5.5. The relationship between the mGPS, biochemical parameters and survival in 
patients sampled within two years following cancer diagnosis.  Adjusted for age, sex, 
deprivation and stratified by tumour site 
n=9608 Overall survival Cancer specific survival 
HR p value 
 
HR p value 
mGPS 0 1 <0.001 1 <0.001 
1 1.79 <0.001 1.92 <0.001 
2 2.87 <0.001 3.01 <0.001 
Adjusted 
calcium 
<2.10mmol/l 1.25 0.001 1.15 0.070 
2.10-2.60mmol/l 1 <0.001 1 <0.001 
>2.60mmol/l 2.30 <0.001 2.38 <0.001 
Bilirubin <20μmol/l 1 <0.001 1 <0.001 
>20μmol/l 1.53 <0.001 1.55 <0.001 
Alkaline 
phosphatase 
<80U/l 0.71 0.012 0.74 0.037 
80-280U/l 1 <0.001 1 <0.001 
>280U/l 2.12 <0.001 2.19 <0.001 
Aspartate 
transaminase 
<40U/l 1 <0.001 1 <0.001 
>40U/l 1.66 <0.001 1.73 <0.001 
Alanine 
transaminase 
<50U/l 1 <0.001 1 <0.001 
>50U/l 1.36 <0.001 1.39 <0.001 
γ-glutamyl 
transferase 
M<70 U/l, F<40U/l 1 <0.001 1 <0.001 
M>70U/l, F>40U/l 1.85 <0.001 1.85 <0.001 
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Table 5.6. The relationship between the mGPS, biochemical parameters and survival in 
patients sampled within two months following cancer diagnosis. Adjusted for age, sex, 
deprivation and stratified by tumour site 
n=5397 
 
Overall survival Cancer specific survival 
HR p value HR 
 
p value 
mGPS 0 1 <0.001 1 <0.001 
1 1.67 <0.001 1.74 <0.001 
2 2.36 <0.001 2.40 <0.001 
Adjusted 
calcium 
<2.10mmol/l 1.17 0.107 1.07 0.530 
2.10-2.60mmol/l 1 <0.001 1 <0.001 
>2.60mmol/l 1.96 <0.001 2.04 <0.001 
Bilirubin <20μmol/l 1 <0.001 1 <0.001 
>20μmol/l 1.49 <0.001 1.49 <0.001 
Alkaline 
phosphatase 
<80U/l 0.78 0.016 0.68 0.053 
80-280U/l 1 <0.001 1 <0.001 
>280U/l 1.93 <0.001 1.96 <0.001 
Aspartate 
transaminase 
<40U/l 1 <0.001 1 <0.001 
>40U/l 1.66 <0.001 1.71 <0.001 
Alanine 
transaminase 
<50U/l 1 <0.001 1 <0.001 
>50U/l 1.34 <0.001 1.37 <0.001 
γ-glutamyl 
transferase 
M<70 U/l, F<40U/l 1 <0.001 1 <0.001 
M>70U/l, F>40U/l 1.79 <0.001 1.79 <0.001 
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Table 5.7. The relationship between patient characteristics, mGPS and survival in patients 
sampled within two years following cancer diagnosis.  Multivariate analysis stratified by tumour 
site 
 
n=9608 
Overall survival Cancer specific survival 
HR 95 % CI p value 
 
HR 95 % CI p value 
Age <65 years 1  <0.001 1  <0.001 
65–74 years 1.35 1.26-1.43 <0.001 1.20 1.13-1.29 <0.001 
≥ 75 years 1.93 1.80-2.06 <0.001 1.59 1.48-1.70 <0.001 
Sex Male 1  0.037 1  0.132 
Female 0.94  0.037 0.95  0.132 
SIMD 1 (least deprived) 1  <0.001 1  0.003 
2 1.02  0.684 1.02  0.773 
3 1.09  0.090 1.09  0.136 
4 1.16 1.06-1.27 0.002 1.12  0.025 
5 (most deprived) 1.22 1.12-1.33 <0.001 1.17 1.06-1.28 0.001 
mGPS 0 1  <0.001 1  <0.001 
1 1.79 1.68-1.91 <0.001 1.92 1.79-2.06 <0.001 
2 2.87 2.68-3.08 <0.001 3.01 2.79-3.24 <0.001 
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Table 5.8. The relationship between patient characteristics, mGPS and survival in patients 
sampled within two months following cancer.  Multivariate analysis stratified by tumour site 
 
n=5397 
Overall survival Cancer specific survival 
 
HR 95 % CI p value 
 
HR 95 % CI p value 
Age <65 years 1  <0.001 1  <0.001 
65–74 years 1.31 1.20-1.42 <0.001 1.22 1.12-1.33 <0.001 
≥ 75 years 1.92 1.76-2.10 <0.001 1.70 1.55-1.87 <0.001 
Sex Male 1  0.340 1  0.507 
Female 0.96  0.340 0.97  0.507 
SIMD 1 (least deprived) 1  <0.001 1  <0.001 
2 1.05  0.503 1.08  0.364 
3 1.07  0.342 1.11  0.179 
4 1.20 1.06-1.36 0.005 1.20 1.05-1.38 0.008 
5 (most deprived) 1.30 1.16-1.45 <0.001 1.28 1.14-1.45 <0.001 
mGPS 0 1  <0.001 1  <0.001 
1 1.67 1.53-1.83 <0.001 1.74 1.59-1.91 <0.001 
2 2.36 2.15-2.59 <0.001 2.40 2.17-2.65 <0.001 
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Table 5.9. The relationship between the mGPS, patient characteristics, biochemical parameters 
and survival in patients sampled within two years following cancer diagnosis 
 
n=9608 
 
mGPS p value 
0 
n (%) 
1 
n (%) 
2 
n (%) 
 
Age 
 
<65 years 2193 (55) 1464 (46) 920 (38) 
<0.001 
65–74 years 1091 (27) 1007 (31) 838 (35) 
≥ 75 years 701 (18) 733 (23) 661 (27) 
Sex  Male 1516 (38) 1672 (52) 1304 (54) 
<0.001 Female 2469 (62) 1532 (48) 1115 (46) 
SIMD 2006 1 (least deprived) 739 (19) 383 (12) 297 (12) 
<0.001 
2 592 (15) 342 (11) 264 (11) 
3 633 (16) 460 (14) 352 (15) 
4 727 (18) 613 (19) 518 (21) 
5 (most deprived) 1294 (32) 1406 (44) 988 (41) 
Adjusted 
calcium 
<2.10mmol/l 76 (2) 87 (3) 166 (7) 
<0.001 
2.10-2.60mmol/l 3835 (96) 2972 (93) 2049 (85) 
>2.60mmol/l 74 (2) 145 (4) 204 (8) 
Bilirubin <20μmol/l 3564 (92) 2621 (85) 1751 (76) 
<0.001 >20μmol/l 324 (8) 466 (15) 552 (24) 
Alkaline 
phosphatase 
<80U/l 93 (2) 16 (0) 68 (3) 
<0.001 
80-280U/l 3428 (86) 2163 (68) 1255 (52) 
>280U/l 457 (12) 1020 (32) 1092 (45) 
Aspartate 
transaminase 
<40U/l 3491 (90) 2501 (81) 1617 (70) 
<0.001 >40U/l 399 (10) 593 (19) 686 (30) 
Alanine 
transaminase 
<50U/l 3016 (91) 1982 (85) 1352 (79) 
<0.001 >50U/l 301 (9) 337 (15) 354 (21) 
γ-glutamyl 
transferase 
M<70 U/l, F<40U/l 3071 (79) 1875 (60) 1136 (49) 
<0.001 M>70U/l, F>40U/l 839 (21) 1242 (40) 1183 (51) 
     
Overall survival in months (mean, CI) 70 (68-72) 37 (36-39) 22 (21-24) <0.001 
Cancer specific survival in months (mean, CI) 77 (75-79) 43 (41-45) 27 (26-29) <0.001 
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Number at risk 
Alive 
 
9608 5492 4566 3710 2732 1845 
Overall deaths 
 
0 4116 5042 5898 6876 7763 
Cancer deaths 0 3658 4452 4795 4961 5052 
 
Figure 5.1. The relationship between tumour site and cancer specific five year survival.  
Tumours from top to bottom;   breast, gynaecological, bladder, prostate, haematological, head 
and neck, colorectal, renal, gastroesophageal, pulmonary and hepatopancreaticobiliary 
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Figure 5.2. The relationship between the mGPS - 0 (top, small dash line), mGPS 1 
(middle, large dash line) and mGPS 2 (bottom, solid line) - and cancer specific survival 
(p<0.001) in each tumour site 
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6.0. A COMPARISON OF INFLAMMATION-BASED PROGNOSTIC SCORES IN 
PATIENTS WITH CANCER 
6.1. ABSTRACT 
Introduction:  Components of the systemic inflammatory response, combined to form 
inflammation-based prognostic scores including the modified Glasgow Prognostic Score 
(mGPS), Neutrophil Lymphocyte Ratio (NLR), Platelet Lymphocyte Ratio (PLR), Prognostic 
Index (PI) and Prognostic Nutritional Index (PNI), have been associated with cancer specific 
survival.  The aim of the present chapter was to compare the prognostic value of these scores. 
Methods:  Patients (n=27,031) who had an incidental blood sample taken between 2000 and 
2007 for C-reactive protein, albumin, white cell, neutrophil, lymphocyte and platelet counts, 
as well as a diagnosis of cancer (Scottish Cancer Registry) were identified.  Of this group 
8759 patients who had been sampled within two years following their cancer diagnosis were 
studied. 
Results:  On follow up there were 5163 deaths, 4417 (86%) of which were cancer related.  
The median time from blood sampling to diagnosis was 1.7 months.  An elevated mGPS, 
NLR, PLR, PI and PNI were predictive of a reduced cancer specific survival independent of 
age, sex and deprivation and tumour site (all p<0.001).  The area under the receiver operator 
curves was greatest for mGPS and PI.  Specifically, in colorectal cancer, an elevated mGPS 
and PI were predictive of a reduced cancer specific survival independent of age, sex, 
deprivation and tumour stage (both p<0.001). 
Conclusion:  The results of the present study show that systemic inflammation-based scores, 
in particular the mGPS and PI, have prognostic value in cancer independent of tumour site. 
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6.2. INTRODUCTION 
 As has been detailed in Chapter 1, while the development of cancer has a genetic 
basis, there is increasing evidence that the host immune/inflammatory response plays an 
important role in the development and progression of cancer [Coussens and Werb, 2002; 
Mantovani et al., 2008; Colotta et al., 2009; McDonald et al., 2009; Tenesa et al., 2010].  The 
modified Glasgow Prognostic Score (mGPS) has been shown to have prognostic value, 
independent of tumour stage, in a number of tumour types including lung, gastrointestinal 
and renal cancers [McMillan, 2008; McMillan, 2009].  As shown in Table 3.1, it is also of 
interest that other haematological components of the systemic immune/inflammatory 
response have been combined to form inflammation-based prognostic scores that have been 
associated with survival in patients with cancer.  In addition to those detailed in Chapter 3, 
the Neutrophil Lymphocyte Ratio (NLR), a combination of circulating neutrophil and 
lymphocyte counts, has been associated with survival in colorectal [Chua et al., 2011a], lung 
[Sarraf et al., 2009; Kao et al., 2010a] and ovarian [Cho et al., 2009b] cancers.  The Platelet 
Lymphocyte Ratio (PLR), a combination of circulating platelet and lymphocyte counts, has 
been associated with survival in patients with pancreatic cancer [Smith et al., 2009].  The 
combination of C-reactive protein and white cell count in a Prognostic Index (PI) has been 
associated with survival in patients with lung cancer [Kasymjanova et al., 2010].  Finally, 
Onodera’s Prognostic Nutritional Index (PNI) has also been associated with survival in 
patients with pancreatic [Kanda et al., 2011] and gastric [Nozoe et al., 2010] cancer. 
 In Chapter 4 and 5, it has been shown that the mGPS is elevated in patients with 
cancer [Proctor et al., 2010] and predictive of survival across all tumour sites studied 
independent of age, sex and deprivation [Proctor et al., 2011b].  Therefore, it is of 
considerable interest to compare the prognostic value of the mGPS, NLR, PLR, PI and PNI 
across different tumour sites. 
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 The aim of the current Chapter was to compare the prognostic value of the mGPS, 
NLR, PLR, PI and PNI adjusted for age, sex, deprivation and tumour site in the Glasgow 
Inflammation Outcome Study. 
6.3. MATERIALS AND METHODS 
 From a cohort previously described in Chapter 4. [Proctor et al., 2010], patients in the 
North Glasgow who were sampled incidentally for C-reactive protein, albumin, calcium, 
white cell, neutrophil, lymphocyte and platelet counts between the 1st January 2000 and the 
31st December 2007 were included.  This time period differed from previous Chapters to 
correspond with the available follow-up data from the Scottish Cancer Registry at the time of 
analysis.  The limit of detection of C-reactive protein was a concentration of less than 5mg/L.  
The mGPS, NLR, PLR, PI and PNI were constructed as described in Table 6.1. 
 Cohort linkage, with the Scottish Cancer Registry, classification of deaths and cancer 
coding were carried out as described in Chapter 5 and only those patients who had complete 
Cancer Registry follow-up were included [Proctor et al., 2011b].  Survival was calculated as 
described in Chapter 5 with cancer registry follow-up available until June the 30th 2009 
[Proctor et al., 2011b].  Cancer groups with less than 150 cancer specific deaths were 
excluded to ensure statistical power.  Analysis was carried on all cancer patients who had a 
blood sample taken within two years of diagnosis as well as on a sub-group of patients who 
had a sample taken within two months of a diagnosis of cancer.  This was carried out in order 
to examine the relationships between the mGPS, NLR, PLR, PI, PNI and survival in all 
patients with a recently diagnosed malignancy (patients sampled within two years following a 
diagnosis of cancer) and those at the time of diagnosis (patients sampled within two months 
following a diagnosis of cancer).  Cancer stage was extracted from the registry where 
available. 
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 Deprivation was measured with the Scottish Index of Multiple Deprivation (SIMD) as 
detailed in Chapter 1.  Patients with incomplete identifying details (name, date of birth and 
hospital number), under 16 years of age, or those with multiple malignancies, metastatic 
disease or cancer of an unknown origin or those without all haematological variables 
available were excluded.  Overall patient numbers were different in this Chapter, when 
compared to previous, as the inclusion time period was longer as extended cancer registry 
follow-up was available.  The study was approved by the Research Ethics Committee, North 
Glasgow NHS Trust. 
 Statistical analysis was carried out as follows.  The mGPS, NLR, PLR, PI, PNI 
proportionality assumptions were explored using log-log plots and were found to be 
satisfactory.  Kaplan-Meier estimator was used to analyse the relationship between patient 
characteristics, mGPS, NLR, PLR, PI, PNI, tumour site and overall and cancer specific 
survival (Table 6.2, Figures 6.1, 6.2).  Cox proportional hazards model multivariate 
regression analysis (stratified by tumour site) was used to correct for age, sex and deprivation 
and determine the relationship between patient characteristics, mGPS, NLR, PLR, PI, PNR 
and survival (Tables 6.3, 6.4). To determine whether one of the independently significant 
variables was more predictive than the other, the area under the receiver operating 
characteristic (ROC) curve was calculated.  Analysis was performed using SPSS software 
(SPSS Inc., Chicago, IL, USA). 
6.4. RESULTS 
 From the Glasgow Inflammation Outcome Study of 223,303 patients originally 
described in Chapter 4. [Proctor et al., 2010], 27,031 patients were identified as having a 
diagnosis of cancer in the Scottish Cancer Registry and a blood sample for taken for C-
reactive protein, albumin, white cell, neutrophil, lymphocyte and platelet counts between 
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January 2000 and December 2007.  Within this group there were 8759 patients who had been 
sampled for all these variables within two years following a diagnosis of cancer and were 
included in the present study.  The majority, 6857 (78%), were under 75 years of age.  There 
were 4644 (53%) females and 4115 (47%) males.  Fifteen per cent of patients lived in 
affluent areas (least deprived quintile of the Scottish population) and 36% in deprived areas 
(most deprived quintile of the Scottish population).  The minimum follow-up from cancer 
diagnosis was 18 months and the maximum 115 months (median 51 months for survivors). 
 The relationship between patient characteristics, tumour site, inflammatory-based 
prognostic scores and survival is shown in Table 6.2 and Figure 6.1.  In total 8759 patients 
were studied.  On follow-up, there were 5163 deaths of which 4417 (86%) were cancer 
deaths.  The median time from diagnosis to blood sampling was 1.7 months, suggesting that 
most scores reflect status at diagnosis rather that at a later stage.  Increasing age, male gender, 
and increasing deprivation were associated with reduced 5 year overall and cancer specific 
survival (all p<0.001).  An elevated mGPS, NLR, PLR, PI and PNI were also associated with 
a reduced 5 year overall and cancer specific survival (all p<0.001).  When this analysis was 
repeated on a subgroup of patients (n=4674) who were sampled within two months following 
their cancer diagnosis (median time to diagnosis 0.5 months) the above proportions remained 
similar and the associations significant (all p<0.001).  The relationship between the mGPS, 
NLR, PLR, PI and PNI and cancer specific survival in individual tumour groups is shown in 
Figure 6.2.  All were predictive of cancer specific survival in bladder, breast, colorectal, 
gastroesophageal, gynaecological, prostate, pulmonary and renal cancer (all p<0.001).  
Additionally, the mGPS, NLR, PI and PNI were predictive of cancer specific haematological, 
head and neck, and hepatopancreaticobiliary cancer survival (all p<0.001). 
 The relationship between inflammation-based prognostic scores and survival, adjusted 
for age, sex and deprivation and stratified by tumour site is shown in Table 6.3.  On survival 
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analysis of all patients (n=8759), a raised mGPS, NLR, PLR, PI and PNI were associated 
with reduced overall and cancer specific survival independent of age, sex and deprivation (all 
p<0.001).  When this analysis was repeated on a subgroup of patients (n=4674) who were 
sampled two months following their cancer diagnosis the above proportions remained similar 
and the associations significant (all p<0.001). 
 In all patients, using overall mortality at as an endpoint, the area under the receiver 
operator curve was for the mGPS 0.718 (95% CI, 0.707-0.729, p<0.001);   NLR 0.650 (95% 
CI, 0.638-0.661, p<0.001);   PLR 0.632 (95% CI, 0.620-0.644, p<0.001);   PI 0.715 (95% CI, 
0.704-0.726, p<0.001) and PNI 0.678 (95% CI, 0.666-0.689, p<0.001).  Using cancer-
specific mortality at as an endpoint, the area under the receiver operator curve was for the 
mGPS 0.698 (95% CI, 0.687-0.709, p<0.001);   NLR 0.632 (95% CI, 0.620-0.643, p<0.001);   
PLR 0.632 (95% CI, 0.620-0.644, p<0.001);   PI 0.694 (95% CI, 0.682-0.705, p<0.001) and 
PNI 0.660 (95% CI, 0.649-0.672, p<0.001). 
 When this analysis was repeated on a subgroup of patients (n=4674) who were 
sampled within two months following their cancer diagnosis, using overall mortality as an 
endpoint, the area under the receiver operator curve was for the mGPS 0.730 (95% CI, 0.715-
0.745, p<0.001);   NLR 0.657 (95% CI, 0.641-0.672, p<0.001);   PLR 0.644 (95% CI, 0.628-
0.660, p<0.001);   PI 0.724 (95% CI, 0.724-0.753, p<0.001) and PNI 0.692 (95% CI, 0.677-
0.708, p<0.001).  Using cancer-specific mortality as an endpoint, the area under the receiver 
operator curve was for the mGPS 0.712 (95% CI, 0.697-0.727, p<0.001);   NLR 0.640 (95% 
CI, 0.624-0.656, p<0.001);   PLR 0.638 (95% CI, 0.622-0.654, p<0.001);   PI 0.719 (95% CI, 
0.704-0.733., p<0.001) and PNI 0.673 (95% CI, 0.658-0.689, p<0.001).  
 In the present cohort only a limited number of patients had staging information 
available from the Scottish Cancer Registry.  Of those patients sampled within two months 
  120 
following cancer diagnosis, tumour staging was available in 470 (35%) patients with breast 
cancer, 374 (75%) patients with colorectal cancer and 108 (12%) patients with pulmonary 
cancer.  All other cancer groups had no staging available.  Therefore, only in colorectal 
cancer was staging available in over 50% of patients.  In this group there were 31 Dukes A, 
113 Dukes B, 113 Dukes C and 117 Dukes D with 227 dying of their cancer on follow-up.  
The relationship between inflammation-based prognostic scores and survival in colorectal 
cancer patients sampled within two months following cancer diagnosis adjusted for age, sex, 
deprivation and Dukes stage is shown in Table 6.4.  Given the small numbers of Dukes A, 
Dukes A and B were grouped together.  On survival analysis (n=374), only a raised mGPS 
and PI were associated with reduced overall and cancer specific survival independent of age, 
sex, deprivation and Dukes stage (all p<0.001). 
 As mGPS and PI both contain C-reactive protein, the prognostic value of a low 
albumin (<35g/l) or high white cell count (>11×109/l), independent of each other was of 
interest.  On Cox-regression multivariate survival analysis of the same group of patients 
(n=374), both a high white cell count (HR 1.57, p=0.011) and low albumin (HR 1.59, 
p=0.004) were predictive of cancer specific survival independent of age, sex, deprivation and 
Dukes stage. 
6.5. DISCUSSION 
 The results of the present Chapter show clearly that systemic inflammation-based 
prognostic scores, whether it be the mGPS, NLR, PLR, PI or PNI, predict cancer specific 
outcome in most cancers.  Moreover, scores including C-reactive protein (mGPS and PI) 
were superior, in terms of differentiating good from poor prognostic groups, to those based 
on components of the circulating white cell count (NLR, PLR) or in combination with 
albumin (PNI).  Therefore, any further development of prognostic scores, based on the 
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systemic immune/inflammatory response, should include the prototypical acute phase protein 
[Gabay and Kushner, 1999], C-reactive protein.  Also, based on the present results and the 
existing validation literature [McMillan, 2009], the mGPS should be included in the routine 
assessment of all patients with cancer. 
 In the present Chapter, it was of interest that the combination of C-reactive protein 
and albumin (mGPS) had similar prognostic value to that of C-reactive protein and white cell 
count (PI).  Although few patients had a low albumin (5%) or a high white cell count (3%) in 
the presence of a normal C-reactive protein concentration (<10mg\l), both a low albumin 
concentration and a high white cell count both had prognostic value independent of C-
reactive protein.  These results would suggest that a white cell count, rather than the NLR or 
PLR, may be a useful addition to the comprehensively validated mGPS. 
 It was also of interest that a nutritional index previously shown to have prognostic 
value (PNI) and used extensively in Japan [Nozoe et al., 2002; Nozoe et al., 2010; Kanda et 
al., 2011], behaved, in terms of prognostic value, very similar to the systemic inflammation-
based prognostic scores (mGPS, NLR, PLR and PI).  The present results, while only 
demonstrating correlation and not causation, add further weight to the proposal that the 
systemic immune/inflammatory response is a major factor in the relationship between 
nutritional decline and poor outcome in patients with cancer [McMillan, 2008; McMillan, 
2009]. 
 Taken together, the results of the present Chapter highlight the associations between 
systemic inflammation and outcome in patients with cancer.  Therefore, we believe that the 
present results provide good evidence of systemic inflammation acting as a “common soil” 
[Fidler and Poste, 2008] promoting the fatal progression in most, if not all, cancers.  If this 
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proves to be the case then moderation of the systemic immune/inflammatory response will 
become, in the future, as important a therapeutic target as the tumour itself. 
 In this context it is of interest that Chechlinska, Kowalewska and co-workers 
[Chechlinska et al., 2010] have proposed that “systemic inflammation is a confounding factor 
in the interpretation of the biomarker profile of cancer patients” and “to assess the 
independent predictive value of a biomarker, it should be validated against its expression in 
inflammatory conditions, and examined in the context of unspecific parameters of systemic 
inflammation”.  Also, they have concluded that if this is not done “we will end up using 
advanced technologies to assess inflammatory reactions in cancer patients”, an opinion 
shared by the authors of the present body of work. 
 In summary, the results of the present Chapter show that systemic inflammation-based 
scores mGPS, NLR, PLR, PI and PNI have prognostic value in a variety of cancers.  
However, in terms of differentiating good from poor prognostic groups in a variety of tumour 
sites, the extensively validated mGPS is superior.  A measurement of systemic inflammation, 
in particular the mGPS, should be included in the routine assessment of all patients with 
cancer. 
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Table 6.1. Systemic inflammation-based prognostic scores 
The modified Glasgow Prognostic Score Score 
C-reactive protein ≤10 mg/l and albumin ≥35 g/l  0 
C-reactive protein ≤10 mg/l and albumin <35 g/l  0 
C-reactive protein >10 mg/l  1 
C-reactive protein >10 mg/l and albumin <35 g/l  2 
Neutrophil Lymphocyte Ratio  
Neutrophil count:lymphocyte count <5:1  0 
Neutrophil count:lymphocyte count ≥5:1  1 
Platelet Lymphocyte Ratio  
Platelet count:lymphocyte count <150:1  0 
Platelet count:lymphocyte count 150–300:1  1 
Platelet count:lymphocyte count >300:1  2 
Prognostic Index 
C-reactive protein ≤10 mg/l and white cell count <11×109/l 0 
C-reactive protein ≤10 mg/l and white cell count >11×109/l 1 
C-reactive protein >10 mg/l and white cell count <11×10
9
/l 1 
C-reactive protein >10 mg/l and white cell count >11×10
9
/l 2 
Prognostic Nutritional Index  
Albumin (g/L) + 5 × total lymphocyte count ×10
9
/l >45 0 
Albumin (g/L) + 5 × total lymphocyte count ×10
9
/l <45 1 
  
  124 
Table 6.2. The relationship between patient characteristics, tumour site, inflammatory-based 
prognostic scores and survival 
 Patients 
n=8759 
(%) 
Overall survival 
5 year 
% (n of deaths) 
n=5163 
p-
value 
Cancer survival 
5 year 
% (n of deaths) 
n=4417 
 
p-
value 
Age <65 years 4237 (48) 52 (1977) 
<0.001 
55 (1808) 
<0.001 
65–74 years 2620 (30) 33 (1703) 41 (1439) 
≥ 75 years 1902 (22) 21 (1483) 31 (1170) 
Sex  Male 4115 (47) 29 (2844) 
<0.001 
36 (2432) 
<0.001 Female 4644 (53) 49 (2319) 55 (1985) 
SIMD 2006 1 (least deprived) 1278 (15) 51 (609) 
<0.001 
57 (523) 
<0.001 
2 1138 (13) 48 (579) 54 (495) 
3 1391 (16) 43 (779) 48 (683) 
4 1786 (20) 37 (1110) 44 (940) 
5 (most deprived) 3166 (36) 33 (2086) 40 (1776) 
Tumour site Breast  1853 (21) 79 (361) 
<0.001 
85 (263) 
<0.001 
Bladder  437 (5) 48 (226) 63 (149) 
Gynaecological  460 (5) 45 (248) 51 (217) 
Prostate  456 (5) 53 (206) 64 (153) 
Gastroesophageal  874 (10) 12 (754) 15 (697) 
Haematological  817 (10) 48 (418) 57 (320) 
Renal  400 (5) 38 (242) 44 (214) 
Colorectal  996 (11) 39 (583) 45 (493) 
Head and Neck  555 (7) 34 (344) 51 (239) 
Hepatopancreaticobiliary  474 (5) 7 (430) 8 (410) 
Pulmonary  1437 (16) 5 (1351) 7 (1262) 
Inflammation 
based scores 
mGPS 0 3673 (42) 61 (1349) 
<0.001 
68 (1083) 
<0.001 
1 2436 (28) 32 (1640) 39 (1425) 
2 2650 (30) 16 (2174) 22 (1909) 
NLR 0 5151 (59) 51 (2401) 
<0.001 
58 (2021) 
<0.001 1 3608 (41) 23 (2762) 29 (2396) 
PLR 0 2734 (31) 52 (1253) 
<0.001 
60 (996) 
<0.001 
1 3522 (40) 42 (1993) 48 (1716) 
2 2503 (29) 23 (1917) 28 (1705) 
PI 0 3084 (35) 64 (1042) 
<0.001 
70 (832) 
<0.001 
1 3460 (40) 31 (2303) 38 (1994) 
2 2215 (25) 17 (1818) 23 (1591) 
PNI 0 4342 (50) 57 (1806) 
<0.001 
63 (1487) 
<0.001 1 4417 (50) 21 (3357) 27 (2930) 
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Table 6.3. The relationship between inflammation-based prognostic scores and survival.  
Adjusted for age, sex, deprivation and stratified by tumour site 
 
All patients (n=8759) 
 
 Overall survival Cancer specific survival 
 
HR p value 
 
HR p value 
mGPS 0 1 <0.001 1 <0.001 
1 1.74 <0.001 1.85 <0.001 
2 2.91 <0.001 3.06 <0.001 
NLR 0 1 <0.001 1 <0.001 
1 1.93 <0.001 1.97 <0.001 
PLR 0 1 <0.001 1 <0.001 
1 1.22 <0.001 1.31 <0.001 
2 1.89 <0.001 2.08 <0.001 
PI 0 1 <0.001 1 <0.001 
1 2.03 <0.001 2.15 <0.001 
2 2.87 <0.001 3.03 <0.001 
PNI 0 1 <0.001 1 <0.001 
1 2.24 <0.001 2.34 <0.001 
 
 
Patients sampled within two months following cancer diagnosis (n=4674) 
 
 
 
Overall survival Cancer specific survival 
 
HR p value 
 
HR p value 
mGPS 0 1 <0.001 1 <0.001 
1 1.65 <0.001 1.74 <0.001 
2 2.35 <0.001 2.44 <0.001 
NLR 0 1 <0.001 1 <0.001 
1 1.76 <0.001 1.77 <0.001 
PLR 0 1 <0.001 1 <0.001 
1 1.19 <0.001 1.24 <0.001 
2 1.71 <0.001 1.82 <0.001 
PI 0 1 <0.001 1 <0.001 
1 1.78 <0.001 1.87 <0.001 
2 2.44 <0.001 2.51 <0.001 
PNI 0 1 <0.001 1 <0.001 
1 1.98 <0.001 2.01 <0.001 
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Table 6.4. The relationship between inflammation-based prognostic scores and survival in 
colorectal cancer patients sampled within two months following cancer diagnosis.  Adjusted 
for age, sex, deprivation and Dukes stage 
 
 
n=374 
Overall survival Cancer specific survival 
HR p value HR p value 
     
mGPS 0 1 <0.001 1 <0.001 
1 1.81 0.004 1.91 <0.001 
2 2.30 <0.001 2.51 <0.001 
NLR 0 1 0.102 1 0.146 
1 1.27 0.102 1.25 0.146 
PLR 0 1 0.786 1 0.560 
1 1.16 0.487 1.30 0.281 
2 1.13 0.596 1.23 0.403 
PI 0 1 <0.001 1 <0.001 
1 1.69 0.012 1.92 <0.001 
2 2.83 <0.001 3.07 <0.001 
PNI 0 1 0.059 1 0.095 
1 1.33 0.059 1.31 0.095 
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Figure 6.1. The relationship between the mGPS (0-top, small dash line;   1-middle, large 
dash line;   2-bottom, solid line), NLR (0-top, large dash line;   1-bottom, solid line), 
PLR (0-top, small dash line;   1-middle, large dash line;   2-bottom, solid line), PI (0-top, 
small dash line;   1-middle, large dash line;   2-bottom, solid line), PNI (0-top, large dash 
line;   1-bottom, solid line) and cancer specific survival in all patients (all <0.001).  
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Prognostic Nutritional Index 
      
     
 
 
Figure 6.2.  
The relationship between the mGPS, NLR, PLR, PI and PNI and survival illustrated by 
Kaplan–Meier survival plots in each individual tumour type with only those 
demonstrating statistical significance (p<0.001) being shown. 
For the modified Glasgow Prognostic Score in each plot, the top (small dash) line 
represents mGPS of 0, the middle (large dash) line represents a mGPS of 1 and the 
bottom (solid) line represents a mGPS of 2. 
For the Neutrophil Lymphocyte Ratio in each plot, the top (large dash) line represents 
an NLR of 0 and the bottom (solid) line represents an NLR of 1. 
For the Platelet Lymphocyte Ratio in each plot, the top (small dash) line represents 
PLR of 0, the middle (large dash) line represents a NLR of 1 and the bottom (solid) line 
represents a NLR of 2. 
For the Prognostic Index in each plot, the top (small dash) line represents PNI of 0, the 
middle (large dash) line represents a PNI of 1 and the bottom (solid) line represents a 
PNI of 2. 
For the Prognostic Nutritional Index in each plot, the top (large dash) line represents an 
PNI of 0 and the bottom (solid) line represents an NLR of 1.  
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7.0. A DERIVED NEUTROPHIL TO LYMPHOCYTE RATIO PREDICTS 
SURVIVAL IN PATIENTS WITH CANCER 
7.1. ABSTRACT 
Introduction:  The Neutrophil Lymphocyte Ratio (NLR) has prognostic value in patients 
with a variety of cancers.  Many chemotherapeutic trial databases hold information on white 
cell and neutrophil counts only.  The aim of the present study was to compare the prognostic 
value of the NLR, with a derived score (dNLR), composed of white cell and neutrophil 
counts. 
Methods:  Patients (n=27,031) who were sampled incidentally between 2000 and 2007 for 
neutrophil, lymphocyte and white cell counts, and also had a diagnosis of cancer (Scottish 
Cancer Registry), were identified.  Of this group 12,118 patients who had been sampled 
within two years of their cancer diagnosis were studied. 
Results:  On follow up, there were 7366 deaths, of which 6198 (84%) were cancer deaths.  
The area under the Receiver Operating Characteristic (ROC) curve for cancer specific 
survival was 0.650 for the NLR and 0.640 for the dNLR.  The NLR and dNLR were 
independently associated with survival in all cancers studied (all p<0.001). 
Conclusion:  The results of the present study show that the dNLR, based on white cell and 
neutrophil counts, has similar prognostic value to the NLR.  Therefore, the universally 
available dNLR is to be commended for use in the risk stratification of patients undergoing 
chemotherapy. 
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7.2. INTRODUCTION 
 While it has been detailed that the host immune/inflammatory response plays an 
important role in carcinogenesis and disease progression there is increasing interest in simple, 
objective methods of measuring this response in patients with cancer.  The Neutrophil 
Lymphocyte Ratio (NLR), as detailed in Chapter 3 and 6, has been well established as a 
prognostic score in patients with a wide variety of cancers including those undergoing 
chemotherapy for cancer [Kao et al., 2010b; Chua et al., 2011b].  Although, apparently 
inferior to other measures of the systemic immune/inflammatory response, such as the mGPS 
[Proctor et al., 2011a], the NLR does have the advantage of its components being inexpensive 
and routinely measured in day to day oncological practice and in current chemotherapeutic 
cancer trials.  Clearly, if such extensive data were to confirm the prognostic value and clinical 
utility of the NLR this would be an important, relevant, clinical translational advance in the 
identification of cancer patients at high risk [Clarke et al., 2011]. 
 However, on patient entry to chemotherapeutic trials, despite having a differential 
white cell count carried out, only white cell and neutrophil counts are routinely entered into 
the clinical trial databases.  The differential white cell count is broadly composed of 
neutrophils (50-60%), lymphocyte (20-40%), monocytes (2-6%), eosinophils (1-4%) and 
basophils (0.5-1%)  In an attempt to allow the widespread utilisation of a similar 
inflammation-based score in such settings, we aimed to investigate the prognostic value of a 
derived NLR (dNLR), from a white cell and neutrophil count.  Therefore, the aim of the 
present study was to compare the prognostic value of the NLR and dNLR adjusted for age, 
sex, deprivation and tumour site in the Glasgow Inflammation Outcome Study. 
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7.3. MATERIALS AND METHODS 
 From a cohort previously described in Chapter 6 [Proctor et al., 2011a], patients in the 
North Glasgow who were sampled incidentally for C-reactive protein, albumin, calcium and a 
differential white cell count between the 1st January 2000 and the 31st December 2007 were 
included.  This time period was as such to correspond with the available follow-up data from 
the Scottish Cancer Registry at the time of analysis as previously detailed.  The NLR was 
constructed as follows: NLR = Neutrophil count to Lymphocyte count.  The dNLR was 
constructed as follows: dNLR = Neutrophil Count to (White Cell Count – Neutrophil count). 
 Patients with blood samples taken within two years of their cancer diagnosis were 
included in the analysis, and split into those sampled prior to and following cancer diagnosis.  
The dNLR was derived from the assumption that the white cell count is made up primarily of 
lymphocytes and neutrophils, and therefore, the white cell count minus the neutrophil count 
would be broadly similar to the lymphocyte count.  As different thresholds have been 
suggested in the past [Ding et al., 2010; Ohno et al., 2010; Kim et al., 2010; Sharaiha et al., 
2011], several were examined in order to ascertain the optimal NLR and dNLR. 
 Cohort linkage, with the Scottish Cancer Registry, classification of deaths and cancer 
coding were carried out as described in Chapter 5 and only those patients who had complete 
Cancer Registry follow-up were included [Proctor et al., 2011b].  Survival was calculated as 
described in Chapter 5 [Proctor et al., 2011b].  Patient inclusion criteria has been previously 
detailed and only cancer groups previously studied were included [Proctor et al., 2011a].  
Cancer groups with less than 150 cancer specific deaths were excluded to ensure statistical 
power.  Cancer stage was extracted from the registry where available. 
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 Deprivation was measured with the Scottish Index of Multiple Deprivation (SIMD) as 
detailed in Chapter 1.  Overall patient numbers were different in this Chapter, when 
compared to some previous, as the inclusion time period differed to some and longer cancer 
registry follow-up was available (until June 2009).  The study was approved by the Research 
Ethics Committee, North Glasgow NHS Trust. 
 Statistical analysis was carried out as follows.  Kaplan-Meier estimator was used to 
analyse the relationship between patient characteristics, tumour site and overall and cancer 
specific survival (Table 7.1).  Receiver Operating Characteristic (ROC) curve was used to 
determine the sensitivity and specificity similarities between the NLR and dNLR (Figure 
7.1).  Cox proportional multivariate regression analysis, corrected for age, sex, deprivation 
and tumour site, as well as area under the ROC curve, were used to determine the relationship 
between different NLR and dNLR thresholds (in whole numbers) and survival in patients 
sampled before and after diagnosis (Tables 7.2).  Box plot was used to demonstrate the 
relationship between the NLR, dNLR and Dukes stage in patients with colorectal cancer 
(Figure 7.2).  Cox proportional multivariate regression analysis, corrected for age, sex, 
deprivation and tumour site, as well as area under ROC curve, were used to determine the 
relationship between optimal NLR and dNLR thresholds and survival in patients with 
advanced (Dukes C and D) colorectal cancer (Table 7.3).  Analysis was performed using 
SPSS software (SPSS Inc., Chicago, IL, USA). 
7.4. RESULTS 
 From the Glasgow Inflammation Outcome Study cohort of 223,303 patients 
previously described in Chapter 4 [Proctor et al., 2010], 27,031 patients were identified as 
also having a diagnosis of cancer.  Within this group, 12,119 patients had been sampled 
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within two years of their cancer diagnosis.  Of this group, 3859 (32%) were sampled prior to 
a diagnosis and 8260 (68%) were sampled following diagnosis and the possible initiation of 
surgical or chemotherapeutic interventions. 
 The majority of patients were under the age of 75 years (n=9097, 75%), were female 
(n=6217, 51%) and were from the most deprived SIMD quintile (n=4692, 39%).  The 
minimum follow-up from cancer diagnosis was 18 months and the maximum 132 months 
(median 52 months for survivors). 
 The relationship between patient characteristics, tumour site, and overall and cancer 
specific survival in all patients is shown in Table 7.1.  In total 12,119 patients were studied.  
On follow-up, there were 7368 deaths of which 6200 (84%) were cancer related.  The median 
time from blood sampling to diagnosis was 1.6 months in those sampled prior to diagnosis 
and 2.2 months in those sampled following diagnosis, suggesting that most scores reflect 
status at diagnosis.  Increasing age, male gender, and increasing deprivation were associated 
with reduced 5 year overall and cancer specific survival (all p<0.001). 
 The ROC curves, using cancer specific death as an end-point (n=12,119), for NLR 
and dNLR is shown in Figure 7.1.  The ROC curves for NLR and dNLR were 0.650 
(p<0.001) and 0.640 (p<0.001) respectively.  The Spearman rank correlation between the 
NLR and dNLR was 0.962 (p<0.001). 
 The relationship between NLR and dNLR thresholds and survival in patients sampled 
prior to and following diagnosis, adjusted for age, sex, deprivation and stratified by tumour 
site, is shown in Table 7.2.  The optimal thresholds for the NLR (>4:1) and the dNLR (>2:1) 
in both patients sampled prior to and following diagnosis, as measured by the hazard ratios 
and area under the ROC curve, are highlighted. 
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 In the present cohort, a limited number of patients had stage related data available 
with only colorectal cancer having stage data for over 50% of patients.  Stage was only 
available in 29% (n=621) of patients with breast cancer and 10% (n=234) of patients with 
pulmonary cancer. Other cancer groups had no stage available.  Of the colorectal cancer 
patients with stage available, 90 (9%) were Dukes A, 264 (27%) were Dukes B, 327 (33%) 
were Dukes C and 312 (31%) were Dukes D. 
 The relationship between the NLR, dNLR and Dukes stage in all patients is shown in 
Figure 7.2.  The relationship between the NLR, dNLR and survival in patients with advanced 
colorectal cancer (Dukes C and D) adjusted for age, sex and deprivation is shown in Table 
7.3.  These patients were studied as they are likely to be similar to those entered into 
chemotherapeutic trials [Chua et al., 2011c].  On survival analysis (n=639), both the NLR and 
dNLR were associated with reduced overall and cancer specific survival independent of age, 
sex and deprivation (all p<0.001) with similar Hazard Ratios and area under the ROC curve 
(both p<0.001).  
7.5. DISCUSSION 
 The results of the present Chapter show clearly that the NLR and dNLR have similar 
prognostic value and that they can be used similarly to predict survival in a large cohort of 
unselected cancer patients.  Furthermore, the NLR and dNLR had similar predictive value, in 
all cancers as well as advanced colorectal cancer.  Recently, Chua and co-workers reported 
that the NLR, as a marker of the systemic immune/inflammatory response, predicted 
clinically meaningful outcomes in patients with advanced colorectal cancer receiving 
chemotherapy [Chua et al., 2011a].  Taken together, these results would indicate that the 
derived NLR is suitable for the risk stratification of patients in chemotherapeutic trials, in 
particular, colorectal cancer studies. 
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 In the present Chapter, although the ROC analysis of the NLR and dNLR were 
similar, the prognostic value of different thresholds was examined.  It was of interest that, in 
contrast to the most commonly used NLR threshold of 5:1 [Walsh et al., 2005; Halazun et al., 
2008; Gomez et al., 2008b], in the present Chapter 4:1 was found to have superior prognostic 
value in terms of Hazard Ratio and area under the ROC curve.  These results are consistent 
with the varying NLR threshold reported across and within different tumour types.  It is also 
of interest that the optimal threshold for the dNLR was 2:1, an expected shift from that of the 
NLR explained by the method of derivation.  The results of the present Chapter also suggest 
that the dNLR has considerable potential to be adopted universally as a stratification factor in 
all current cancer clinical trials.  Moreover, if it were shown to have such clinical utility, the 
dNLR would identify patients who may respond to anti-inflammatory interventions. 
 In the present Chapter it was of interest that there was a small but persistent 
superiority of the prognostic value of the NLR over the dNLR.  The basis of this observation 
is not clear.  However, in the dNLR the use of (WBC - neutrophil) as the denominator is 
broadly mixing two cell types, lymphocytes and monocytes, with possible opposing effects in 
terms of predictive value.  In the normal range the relative proportion of lymphocytes to 
monocytes is approximately 6:1.  In cancer patients there may be a fall in the absolute 
proportion of lymphocytes and an increase in the absolute proportion of monocytes.  Even so 
their relative proportion is unlikely to fall below 3:1 even in advanced disease [Leitch et al., 
2007].  Therefore (WBC – neutrophil) is dominated by lymphocytes and is likely to be a 
reasonable approximation to the lymphocyte fraction and the potential error introduced by the 
presence of monocytes in the fraction is therefore likely to be small.  Given that different 
aspects of the differential white cell count have been reported to predict survival [Leitch et 
al., 2007; Proctor et al., 2011b; Lee et al., 2012] it is possible to derive other ratios such as 
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the neutrophil: white cell count ratio.  However, of the differential white cell count 
parameters the neutrophil: lymphocyte ratio has been the most extensively validated and it 
was this that we were attempting to recapitulate when investigating the dNLR in the present 
Chapter.  Clearly, where the NLR is available it should be used.  However, there is a wealth 
of clinical trial data, where only white cell and neutrophil counts have been recorded in 
computer databases that could be used to examine the clinical value of the systemic 
immune/inflammatory response.  As the present Chapter validates the use of the dNLR, this 
may help unlock the residual value of such clinical trial databases, and encourage the 
widespread utilisation of a similarly based systemic inflammation-based scores in such 
settings. 
 The results of the present Chapter also confirm the hypothesis that a total white cell 
count may be a useful addition to currently established prognostic markers of the systemic 
immune/inflammatory response such as, C-reactive protein, albumin, neutrophil and 
lymphocytes counts and their combinations [Proctor et al., 2011a].  It was also of interest that 
the hazard ratios and areas under the curves were greater from patients sampled after 
diagnosis, compared to patients sampled prior to diagnosis.  These results would suggest that 
the systemic immune/inflammatory response is a more potent stimulator of cancer 
progression in established disease.  This is consistent with the long standing observations on 
the “seed and soil” nature of cancer progression and metastasis [Fidler and Poste, 2008].  
 The present cohort has a number of limitations.  The patients were selected on the 
presence of haematological and biochemical variables and were therefore not necessarily 
representative of all cancer patients in general.  Patients may also have concurrent morbidity, 
including infection, causing alterations in their haematological variables.  It is also recognised 
that demographic variables, such as race, that appear to influence neutrophil counts were not 
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available.  Nevertheless, the optimal prognostic threshold for the NLR in the range of 4-5:1 
has been consistently validated in different cancer cohorts (Clarke et al., 2011).  It remains to 
be determined whether a dNLR of 2:1 will be similarly validated in different cancer cohorts. 
 In summary, the results of the present Chapter show that a derived NLR, based on a 
white cell and neutrophil counts, has similar prognostic value to the NLR.  Therefore, the 
universally available dNLR is to be commended for use in the risk stratification of patients 
undergoing chemotherapy.  
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Table 7.1. The relationship between patient characteristics, tumour site, and overall and cancer 
specific survival in all patients 
 
 
n= 12,119 
(%) 
Overall survival 
5 year 
% (n of deaths) 
n= 7368 
p-
value 
Cancer survival 
5 year 
% (n of deaths) 
n= 6200 
p-
value 
Age <65 years 5425 (45) 50 (2573) 
<0.001 
54 (2316) 
<0.001 
65–74 years 3672 (30) 32 (2412) 39 (2041) 
≥ 75 years 3022 (25) 20 (2383) 30 (1843) 
Sex  Male 5902 (49) 28 (4096) 
<0.001 
35 (3437) 
<0.001 Female 6217 (51) 46 (3272) 52 (2763) 
SIMD 
2006 
1 (least deprived) 1698 (14) 48 (860) 
<0.001 
54 (732) 
<0.001 
2 1486 (12) 45 (781) 51 (655) 
3 1804 (15) 42 (1011) 48 (866) 
4 2439 (20) 34 (1541) 42 (1284) 
5 (most deprived) 4692 (39) 30 (3175) 38 (2663) 
Tumour 
site 
Breast 2147 (18) 78 (442) 
<0.001 
84 (304) 
<0.001 
Bladder 562 (5) 48 (286) 62 (195) 
Gynaecological 639 (5) 47 (325) 53 (281) 
Prostate 709 (6) 51 (323) 64 (222) 
Gastroesophageal 1085 (9) 11 (932) 14 (851) 
Haematological 1210 (10) 47 (627) 58 (456) 
Renal 552 (4) 39 (324) 44 (285) 
Colorectal 1413 (12) 39 (820) 46 (680) 
Head and Neck 738 (6) 35 (452) 52 (296) 
Hepatopancreaticobiliary 721 (6) 6 (660) 7 (626) 
Pulmonary  2343 (19) 6 (2177) 8 (2004) 
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Table 7.2. The relationship between NLR and dNLR thresholds and survival.  Adjusted for age, 
sex, deprivation and stratified by tumour site 
  Overall survival Cancer survival 
HR p-value AUC HR p-value AUC 
 
Patient sampled prior to cancer diagnosis   n=3859 
NLR 
 
<1:1 78 (2) 1   1   
>1:1 3781 (98) 1.03 0.840 0.507 0.967 0.859 0.507 
<2:1 589 (15) 1   1   
>2:1 3270 (85) 1.49 <0.001 0.563 1.48 <0.001 0.547 
<3:1 1354 (35) 1   1   
>3:1 2505 (65) 1.55 <0.001 0.593 1.52 <0.001 0.560 
<4:1 1987 (51) 1   1   
>4:1 1872 (49) 1.57 <0.001 0.598 1.52 <0.001 0.558 
<5:1 2435 (63) 1   1   
>5:1 1424 (37) 1.50 <0.001 0.579 1.44 <0.001 0.542 
dNLR 
 
<1:1 214 (6) 1   1   
>1:1 3645 (94) 1.17 0.098 0.518 1.16 0.163 0.516 
<2:1 1399 (36) 1   1   
>2:1 2460 (64) 1.54 <0.001 0.593 1.53 <0.001 0.563 
<3:1 2461 (64) 1   1   
>3:1 1398 (36) 1.47 <0.001 0.575 1.43 <0.001 0.543 
<4:1 2960 (77) 1   1   
>4:1 899 (23) 1.46 <0.001 0.552 1.41 <0.001 0.527 
<5:1 3267 (85) 1   1   
>5:1 592 (15) 1.40 <0.001 0.538 1.33 <0.001 0.517 
 
Patient sampled following cancer diagnosis  n=8260 
NLR 
 
<1:1 297 (4) 1   1   
>1:1 7963 (96) 1.16 0.094 0.505 1.89 0.069 0.506 
<2:1 1480 (18) 1   1   
>2:1 6779 (82) 1.63 <0.001 0.575 1.67 <0.001 0.566 
<3:1 2984 (36) 1   1   
>3:1 5275 (64) 1.85 <0.001 0.641 1.93 <0.001 0.629 
<4:1 4104 (50) 1   1   
>4:1 4155 (50) 1.86 <0.001 0.661 1.92 <0.001 0.646 
<5:1 4872 (59) 1   1   
>5:1 3387 (41) 1.82 <0.001 0.657 1.86 <0.001 0.642 
dNLR 
 
<1:1 656 (8) 1   1   
>1:1 7604 (92) 1.35 <0.001 0.521 1.39 <0.001 0.519 
<2:1 3083 (37) 1   1   
>2:1 5176 (63) 1.76 <0.001 0.630 1.83 <0.001 0.620 
<3:1 4978 (60) 1   1   
>3:1 3281 (40) 1.74 <0.001 0.644 1.78 <0.001 0.631 
<4:1 6034 (73) 1   1   
>4:1 2225 (27) 1.75 <0.001 0.619 1.78 <0.001 0.609 
<5:1 6632 (80) 1   1   
>5:1 1627 (20) 1.76 <0.001 0.595 1.80 <0.001 0.589 
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Table 7.3. The relationship between the NLR, dNLR and survival in patients with advanced 
colorectal cancer (Dukes C and D). Adjusted for age, sex and deprivation. 
  
n = 639 (%) 
Overall survival Cancer specific survival 
HR p-value AUC HR p-value AUC 
NLR 
 
<4:1 278 (44) 1   1   
>4:1 361 (56) 1.60 <0.001 0.584 1.60 <0.001 0.565 
dNLR 
 
<2:1 194 (30) 1   1   
>2:1 445 (70) 1.61 <0.001 0.575 1.67 <0.001 0.566 
 
  
 143 
 
 
Figure 7.1. Receiver Operating Characteristic curve for cancer specific survival. 
 
          
Figure 7.2. The relationship between NLR, dNLR and Dukes stage in patients with 
colorectal cancer. 
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CHAPTER 8. OPTIMISATION OF THE SYSTEMIC INFLAMMATION-BASED 
GLASGOW PROGNOSTIC SCORE IN PATIENTS WITH CANCER (oGPS) 
8.1. ABSTRACT 
Introduction:  The modified Glasgow Prognostic Score (mGPS), an inflammation-based 
prognostic score that uses thresholds  of C-reactive protein (>10mg/l) and albumin (<35g/l), 
is independently prognostic of survival in cancer.  The aim of the present chapter was to 
establish whether the addition of a differential white cell count and a high sensitivity C-
reactive protein measurement enhances the prognostic value of the mGPS. 
Methods:  Patients (n=12,119) who had an incidental blood sample taken between 2000 and 
2007 for C-reactive protein, albumin and a differential white cell count, as well as a diagnosis 
of cancer made within two years were identified.  This group were studied for the prognostic 
value of neutrophil, lymphocyte, and platelet counts.  Also, patients (n=2743) sampled 
following the introduction of high sensitivity C-reactive protein measurements were studied 
for the prognostic value of different thresholds. 
Results:  The prognostic value of the mGPS (HR 2.61, p<0.001, AUC 0.715), using cancer 
specific survival as an end-point, was improved by the addition of neutrophil and platelet 
counts (HR 4.86, p<0.001, AUC 0.734 ) and a high sensitivity C-reactive protein 
measurement (>3mg/l, HR 5.77, p<0.001, AUC 0.734). 
Conclusion:  The results of the present chapter showed that the addition of neutrophil and 
platelet counts, as well as a high sensitivity C-reactive protein measurement, enhanced the 
prognostic value of the Glasgow Prognostic Score. 
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8.2. INTRODUCTION 
 As has been detailed in previous Chapters, the host immune/inflammatory response 
plays an important role in carcinogenesis and disease progression.  It has also been 
demonstrated that a range of inflammation-based scores have prognostic value in patients 
with cancer [Proctor et al., 2011a].  Moreover, it appeared that the inclusion of a white cell 
count, may add prognostic value to the validated mGPS [Proctor et al., 2011a].  Also, the 
recent introduction of high sensitivity C-reactive protein measurements in routine clinical 
laboratory analysis has resulted in the threshold sensitivity being lowered from approximately 
5mg/l to 0.05mg/l.  This has raised the possibility that the combination of C-reactive protein 
and albumin may be further modified to take account of the potential additional prognostic 
value that could be derived from the components of a differential white cell count 
(neutrophil, lymphocyte, platelet counts) and high sensitivity C-reactive protein 
measurement. 
 The aim of the present Chapter was to establish whether the addition of a differential 
white cell count or a high sensitivity C-reactive protein measurement could enhance the 
prognostic value of the Glasgow Prognostic Score. 
8.3. MATERIALS AND METHODS 
 From a cohort previously described in Chapter 6 [Proctor et al., 2011a], patients in 
North Glasgow who were sampled incidentally for C-reactive protein, albumin, calcium and a 
differential white cell count between the 1st January 2000 and the 31st December 2007 were 
included.  This time period was as such to correspond with the available follow-up data from 
the Scottish Cancer Registry at the time of analysis.  Prior to the introduction of high-
sensitivity C-reactive protein measurements, the limit of detection was a concentration of less 
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than 5mg/L and 0.05mg/l thereafter.  Only those patients undergoing blood sampling after the 
introduction of the routine measurement of high sensitivity C-reactive protein (1st of August 
2006), were included in the analysis investigating the prognostic value of high sensitivity 
thresholds (<5mg/l).  Standardised thresholds for white cell count (>11×10
9
/l), neutrophil 
count (>7.5×10
9
/l), lymphocyte count (>3×10
9
/l) and platelet count (>400×10
9
/l) were used.  
High sensitivity C-reactive protein thresholds, <1mg/l and <3mg/l, previously reported to be 
associated with survival were investigated [Ridker, 2008].  The validated GPS and mGPS 
were constructed as described in Table 3.1.  Patients with blood samples taken within two 
years of their cancer diagnosis were included in the analysis, and split into those sampled 
prior to and following cancer diagnosis.  Cohort linkage, with the Scottish Cancer Registry, 
classification of deaths and cancer coding were carried out as described in Chapter 5 and only 
those patients who had complete Cancer Registry follow-up were included [Proctor et al., 
2011b].  Survival was calculated as described in Chapter 5 [Proctor et al., 2011b].  Cancer 
groups with less than 150 cancer specific deaths were excluded to ensure statistical power.  
Cancer stage was extracted from the registry where available. 
 Deprivation was measured with the Scottish Index of Multiple Deprivation (SIMD) as 
detailed in Chapter 1 [Proctor et al., 2010].  Patient inclusion criteria has been previously 
detailed and only cancer groups previously studied were included [Proctor et al., 2011a].  
Overall patient numbers were different in this Chapter, when compared to previous, as the 
inclusion time period differed to some and longer cancer registry follow-up was available 
(until July 2009).  The study was approved by the Research Ethics Committee, North 
Glasgow NHS Trust. 
 Statistical analysis was carried out as follows.  The relationship between patient 
demographics, tumour site, markers of the systemic immune/inflammatory response and 
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survival was assessed using the Kaplan-Meier and Cox proportional hazards methods and 
Area Under the receiver operating characteristic Curve (AUC).  Cox proportional hazards 
model stratified by tumour site, adjusted for age, sex, deprivation, time of sample and 
stratified by tumour site, and AUC was used to analyse the relationship between the 
components of a differential white cell count and high sensitivity C-reactive protein and 
survival.  In those patients with a high sensitivity C-reactive protein measurement, the 
prognostic value of the addition of the components of a differential white cell count and high 
sensitivity C-reactive protein to the GPS was examined with Cox proportional hazards model 
stratified for age, sex, deprivation, time of sample and stratified by tumour and the AUC.  
Given the number of statistical comparisons, a p value of <0.01 was considered to have 
statistical significance in the analysis.  Analysis was performed using SPSS software (SPSS, 
Chicago, IL, USA). 
8.4. RESULTS 
 From GIOS cohort of 223,303 patients originally described [Proctor et al., 2010], 
27,031 patients were identified as having a diagnosis of cancer in SCR and a blood sample 
for C-reactive protein, albumin and a differential white cell count taken between January 
2000 and December 2007.  Within this group, 12,119 patients had been sampled within two 
years of their cancer diagnosis, 3859 (32%) sampled prior to and 8260 (68%) following.  
Most patients were under 75 years of age (n=9097, 75%) and female (n=6217, 51%).  Thirty 
nine percent of patients (n=4692) were SIMD 5.  
 The relationship between patient demographics, tumour site, markers of systemic 
inflammation and five year survival in all patients (n=12,119) is shown in Table 8.1.  There 
were 7368 deaths in total with 6200 being cancer specific.  The median time from blood 
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sample to diagnosis was 2 months, suggesting that most scores reflect status at diagnosis.  
The minimum follow-up from cancer diagnosis for all patients was 18 months and the 
maximum 138 months (median 52 months for survivors).  Increasing age, male gender, and 
increasing deprivation were associated with reduced 5 year overall and cancer specific 
survival (all p<0.001).  High C-reactive protein (>10mg/l), white cell, neutrophil and platelet 
count and low albumin and lymphocyte count were associated with a reduced 5 year overall 
and cancer specific survival (all p<0.001). 
 The relationship between patient demographics, standard threshold C-reactive protein 
measurement (>10mg/l), albumin, white cell, lymphocyte, neutrophil and platelet count and 
survival, stratified by tumour site and time of sample, is shown in Table 8.2.  Increasing age, 
sample prior to diagnosis as well as high C-reactive protein (>10mg/l), neutrophil and platelet 
count, as well as low albumin were all independently associated with a reduction in overall 
and cancer specific survival (all p<0.01). 
 When the relationship between high sensitivity C-reactive protein thresholds and 
survival was investigated in patients sampled following the routine introduction of high 
sensitivity measurements (n=2742), no statistical difference between a high sensitivity C-
reactive protein concentration of <1mg/L and 1-3mg/L was found.  A threshold of >3mg/L 
was therefore used.   
 The relationship between patient demographics, high sensitivity C-reactive protein 
measurements (>3mg/l), albumin, white cell, lymphocyte, neutrophil and platelet counts and 
survival (n=2743): stratified by tumour site in only those patients sampled following the 
routine introduction of high sensitivity measurements is shown in Table 8.3.  Increasing age, 
sample prior to diagnosis as well as high C-reactive protein (>3mg/l), neutrophil and platelet 
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count, as well as low albumin were all independently associated with a reduction in overall 
and cancer specific survival (all p<0.01). 
 The hazard ratios and the areas under the receiver operator characteristic (ROC) curve 
in patients sampled following the introduction of high sensitivity C-reactive protein 
measurements (n=2743), adjusted for age, sex, deprivation, tumour site and time of sampling, 
for a high sensitivity C-reactive protein threshold of >3mg/l for overall and cancer specific 
mortality were calculated.  These were HR 2.47 (95% CI 2.08 - 2.94), AUC 0.636 (p<0.001) 
and HR 2.64 (95% CI 2.19-3.18), AUC 0.625 (p<0.001) respectively compared with the HR 
2.13 (95% CI 1.89-2.40), AUC 0.676 for overall (p<0.001) and cancer specific HR 2.22 (95% 
CI 1.96-2.52), AUC 0.665 (p<0.001) mortality using the standard threshold of 10mg/l.  
Therefore, since they were similar, when optimising the GPS, both the highly sensitive and 
standard threshold for C-reactive protein (10mg/l) were taken forward with other measures of 
the systemic immune/inflammatory response. 
 When the interrelationships between inflammatory markers in patients sampled 
following the introduction of high sensitivity C-reactive protein, were explored (n=2743), C-
reactive protein was inversely associated with albumin (rs=0.691, p<0.001), lymphocyte 
count (rs=0.334, p<0.001) and directly associated with white cell count (rs=0.334, p<0.001), 
neutrophil count (rs=0.399, p<0.001) and platelet count (rs=0.172, p<0.001).  Albumin was 
inversely associated with white cell count (rs=0.268, p<0.001), neutrophil count (rs=0.352, 
p<0.001), platelet count (rs=0.145, p<0.001) and directly associated with lymphocyte count 
(rs=0.332, p<0.001).  White cell count was directly associated with lymphocyte count 
(rs=0.0187, p<0.001), neutrophil count (rs=0.951, p<0.001) and platelet count (rs=0.346, 
p<0.001).  Lymphocyte count was inversely associated with neutrophil count (rs=0.049, 
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p<0.05) and directly associated with platelet count (rs=0.179, p<0.001). Neutrophil count was 
directly associated with platelet count (rs=0.335, p<0.001). 
 The optimisation of the Glasgow Prognostic Score in patients sampled following the 
introduction of high sensitivity C-reactive protein is shown in Table 8.4 (n=2743).  All 
combinations of inflammatory markers were predictive of overall and cancer specific survival 
(all p<0.001) independent of age, sex, time of sample and tumour site.  A score combining C-
reactive protein, albumin, and neutrophil count had an improved prognostic value, in terms of 
increased hazard ratio and area under the ROC curve, when compared to the GPS or mGPS.  
Further addition of a high sensitivity C-reactive improved the hazard ratio range, and thus 
offers the potential to better differentiate between those who will do well and those that will 
do badly.  However, it did not increase the area under the ROC curve and therefore did not 
improve its overall prognostic value. 
 The relationship between the Glasgow Prognostic Scores and survival in patients 
studied following the introduction of high sensitivity C-reactive protein, is shown in Figure 
8.1 (n=2743). 
8.5. DISCUSSION 
 The results of the present Chapter show that, in a large cohort (n=12,119) of patients 
with cancer, routine objective markers of the systemic immune/inflammatory response, 
elevated neutrophil and platelet counts, enhance the prognostic value of the Glasgow 
Prognostic Score independent of age, sex, deprivation, tumour site and time of sampling.  In a 
selected cohort of patients (n=2743) with high sensitivity C-reactive protein measurements, a 
lower threshold for C-reactive protein was associated with a larger range of hazard ratios, 
thus potential better differentiation of patients who will do particularly well, but no 
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improvement in the overall AUC of the Glasgow Prognostic Score, when combined with 
neutrophil and platelet counts. 
 Taken together, these additions to the GPS, have led to an increase in the hazard ratios 
associated with overall and cancer specific survival by approximately 100%.  Therefore, the 
refinement of the GPS with other components of the systemic immune/inflammatory 
response appears to have improved the prognostic value and clinical utility of the Glasgow 
Prognostic Score. 
 It is of interest that in the present Chapter of patients with cancer, it was identified 
that, high sensitivity C-reactive protein measurements >3mg/l were associated with reduced 
survival.  This is consistent with recent publications in cancer cohorts using the same 
threshold [Koenig et al., 2008; Ito et al., 2011; Nakamura et al., 2012].  The results of the 
present Chapter are also in agreement with previous workers [Gagnon et al., 2010] who 
reported, in patients with non-small cell lung cancer, that while an increase risk of mortality 
occurs with a C-reactive protein measurement above approximately 4mg/l, the risk increase is 
steeper between 8 and 16 mg/l.  Indeed, some workers have adopted other thresholds for C-
reactive protein such as >5mg/l into the GPS [Toiyama et al., 2011]. 
 The same high sensitivity C-reactive protein threshold (>3mg/l) has also been used to 
predict survival in non-cancer cohorts [Tuomisto et al., 2006; Zacho et al., 2010].  Taken 
together, the results would suggest that a C-reactive protein of 3mg/l is a potentially 
important threshold in both cancer and non-cancer cohorts.  It raises the possibility that 
inflammation-based prognostic scores such as those examined in the present Chapter will 
have prognostic value in non-cancer cohorts.  Further work in large non-cancer cohorts is 
required to examine the hypothesis that the Glasgow Prognostic Score, in combination with 
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neutrophil and platelet counts, as well as high sensitivity C-reactive protein, also 
independently predicts non-cancer specific survival. 
 Over the last decade, with the validation and establishment of simple, objective 
systemic inflammation-based prognostic scores it has become recognised that activation of 
the systemic immune/inflammatory response has a detrimental impact on the outcome of 
cancer patients [Roxburgh and McMillan, 2010].  More recently, there has been renewed 
interest on the beneficial impact of an activated local immune/inflammatory response on the 
outcome of cancer patients [Pinato et al., 2012].  Therefore, the relationship between the 
systemic and local immune/inflammatory responses is likely to be of considerable and 
increasing interest in future years. 
 The present cohort has a number of limitations.  The patients were selected on the 
basis that measurements of C-reactive protein, albumin and a differential white cell count had 
been performed and were therefore not necessarily representative of all cancer patients 
diagnosed and treated in the North Glasgow area. It is also recognised that patients with 
cancer may have concurrent morbidity causing a rise in their C-reactive protein and 
derangement of their albumin and other haematological parameters. 
 In summary, the addition of the constituents of a differential white cell count and high 
sensitivity C-reactive protein measurements can be used to improved the prognostic value 
and clinical utility of the Glasgow Prognostic Score.  This optimised Glasgow Prognostic 
Score can be adopted to predict cancer survival where differential white cell counts and high 
sensitivity C-reactive protein measurements are available. 
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Table 8.1. The relationship between patient demographics, tumour site, inflammatory markers and 
survival in all patients 
 
 
n=12,119 
Patients 
n=12 119 
(%) 
 
Overall survival 
5 year 
% (n of deaths) 
n= 7368 
p-
value 
Cancer survival 
5 year 
% (n of deaths) 
n= 6200 
p-
value 
Age <65 years 5425 (45) 50 (2573) 
<0.001 
54 (2316) 
<0.001 
65–74 years 3672 (30) 32 (2412) 39 (2041) 
≥ 75 years 3022 (25) 20 (2383) 30 (1843) 
Sex  Male 5902 (49) 28 (4096) 
<0.001 
35 (3437) 
<0.001 Female 6217 (51) 46 (3272) 52 (2763) 
SIMD 2006 1 (least deprived) 1698 (14) 48 (860) 
<0.001 
54 (732) 
<0.001 
2 1486 (12) 45 (781) 51 (655) 
3 1804 (15) 42 (1011) 48 (866) 
4 2439 (20) 34 (1541) 42 (1284) 
5 (most deprived) 4692 (39) 30 (3175) 38 (2663) 
Tumour site Breast 2147 (18) 78 (442) 
<0.001 
84 (304) 
<0.001 
Bladder  562 (5) 48 (286) 62 (195) 
Gynaecological  639 (5) 47 (325) 53 (281) 
Prostate 709 (6) 51 (323) 64 (222) 
Gastroesophageal 1085 (9) 11 (932) 14 (851) 
Haematological 1210 (10) 47 (627) 58 (456) 
Renal  552 (4) 39 (324) 44 (285) 
Colorectal 1413 (12) 39 (820) 46 (680) 
Head and Neck 738 (6) 35 (452) 52 (296) 
Hepatopancreaticobiliary 721 (6) 6 (660) 7 (626) 
Pulmonary 2343 (19) 6 (2177) 8 (2004) 
Inflammatory 
markers 
C-reactive 
protein 
<10mg/l 5146 (42) 56 (2143) 
<0.001 
63 (1708) 
<0.001 >10mg/l 6973 (58) 23 (5225) 30 (4492) 
Albumin >35g/l 8354 (69) 46 (4388) 
<0.001 
53 (3627) 
<0.001 <35g/l 3765 (31) 17 (2980) 23 (2573) 
White cell 
count 
<11×10
9
/l 9104 (75) 42 (5043) 
<0.001 
49 (4213) 
<0.001 >11×10
9
/l 3015 (25) 21 (2325) 28 (1987) 
Neutrophil 
count 
<7.5×10
9
/l 8334 (69) 44 (4444) 
<0.001 
51 (3699) 
<0.001 >7.5×10
9
/l 3785 (31) 21 (2924) 28 (2501) 
Lymphocyte 
count 
<3×10
9
/l 11 554 (95) 37 (7071) 
<0.001 
44 (5957) 
<0.001 >3×10
9
/l 565 (5) 44 (297) 51 (243) 
Platelet 
count 
<400×10
9
/l 10 254 (85) 40 (5889) 
<0.001 
48 (4884) 
<0.001 >400×10
9
/l 1865 (15) 19 (1479) 24 (1316) 
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Table 8.2. The relationship between patient demographics, C-reactive protein (>10mg/l), albumin, 
differential white cell count and survival.  Stratified by tumour site 
 
 
n=12,119 
Overall survival Cancer specific survival 
Univariate Multivariate  Univariate Multivariate  
HR p-
value 
HR p-
value 
AUC HR p-
value 
HR p-
value 
AUC 
Age <65/  1  1   1  1   
65-74 1.37 <0.001 1.28 <0.001  1.24 <0.001 1.17   
>75 2.09 <0.001 1.93 <0.001  1.73 <0.001 1.60 <0.001  
Sex Male 1     1     
Female 0.96 0.101    0.97 0.268    
SIMD 1  1    
 
1    
 
2 1.04 0.343   1.02 0.735   
3 1.05 0.226   1.04 0.471   
4 1.16 <0.001   1.11 0.029   
5  1.23 <0.001   1.17 <0.001   
Time of 
sample 
Pre diag 1  1 
<0.001  
1  1 
<0.001  Post diag 0.73 <0.001 0.67 0.78 <0.001 0.70 
C-reactive 
protein 
<10mg/l 1   
<0.001 0.671 
1  1 
<0.001 0.653 >10mg/l 1.94 <0.001 1.53 2.01 <0.001 1.61 
Albumin >35mg/l 1   
<0.001 0.620 
1  1 
<0.001 0.607 <35mg/l 1.82 <0.001 1.55 1.82 <0.001 1.53 
White cell 
count 
<11×10
9
/l 1  1 
0.166  
1  1 
0.237  >11×10
9
/l 1.49 <0.001 1.06 1.48 <0.001 1.05 
Lymphocyte 
count 
<3×10
9
/l 1  1 
0.012  
1  1 
0.010  >3×10
9
/l 0.77 <0.001 0.86 0.75 <0.001 0.84 
Neutrophil 
count 
<7.5×10
9
/l 1  1 
<0.001 0.608 
1  1 
<0.001 0.593 >7.5×10
9
/l 1.59 <0.001 1.28 1.58 <0.001 1.26 
Platelet count <400×10
9
/l 1  1 
<0.001 0.560 
1  1 
<0.001 0.560 >400×10
9
/l 1.37 <0.001 1.15 1.41 <0.001 1.17 
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Table 8.3. The relationship between patient demographics, high sensitivity C-reactive protein (>3mg/l), 
albumin, differential white cell count and survival.  Stratified by tumour site 
 
 
n=2743 
Overall survival Cancer specific survival 
Univariate Multivariate  Univariate Multivariate  
HR p-
value 
HR p-
value 
AUC HR p-
value 
HR p-
value 
AUC 
Age <65/  1  1   1  1   
65-74 1.20 0.003 1.11 0.104  1.12 0.085 1.03 0.657  
>75 1.73 <0.001 1.55 <0.001  1.50 <0.001 1.34 <0.001  
Sex Male 1     1     
Female 1.04 0.554    1.04 0.547    
SIMD 1 1    
 
1    
 
2 0.94 0.558   0.94 0.576   
3 1.07 0.513   1.08 0.490   
4 1.15 0.148   1.14 0.205   
5 1.21 0.034   1.17 0.093   
Time of 
sample 
Pre Diag 1  1 
<0.001  
1  1 
<0.001  Post Diag 0.86 <0.001 0.62 0.87 <0.001 0.63 
C-reactive 
protein 
<3mg/l 1  1 
<0.001 0.636 
1  1 
<0.001 0.625 >3mg/l 2.54 <0.001 1.63 2.68 <0.001 1.72 
Albumin >35mg/l 1  1 
<0.001 0.700 
1  1 
<0.001 0.685 <35mg/l 2.37 <0.001 1.97 2.42 <0.001 2.01 
White cell 
count 
<11×10
9
/l 1  1 
0.672  
1  1 
0.748  >11×10
9
/l 1.65 <0.001 1.04 1.65 <0.001 1.03 
Neutrophil 
count 
<7.5×10
9
/l 1  1 
<0.001 0.621 
1  1 
<0.001 0.609 >7.5×10
9
/l 1.78 <0.001 1.39 1.76 <0.001 1.35 
Lymphocyte 
count 
<3×10
9
/l 1   
  
1   
  >3×10
9
/l 0.76 0.043  0.69 0.012  
Platelet count <400×10
9
/l 1  1 
0.001 0.575 
1  1 
<0.001 0.578 >400×10
9
/l 1.58 <0.001 1.26 1.68 <0.001 1.31 
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Table 8.4. Optimisation of the Glasgow Prognostic Score in patients sampled following the 
introduction of high sensitivity C-reactive protein measurement.  Survival adjusted for age, sex, time 
of sample and stratified by tumour site 
n=2743  Cancer specific survival Overall survival 
  HR p-value AUC HR p-value AUC 
GPS 
 
0 955 (35) 1  
0.731 
1  
0.715 
1 621 (23) 1.86  1.88  
2 1166 (42) 3.18 <0.001 3.33 <0.001 
mGPS 0 1204 (44) 1  
0.707 
1  
0.695 
1 372 (14) 1.30  1.32  
2 1166 (42) 2.49 <0.001 2.61 <0.001 
CRP > 10mg/l 
+Albumin >35g/L 
+Neutrophils >7.5×109/l 
0 847 (30.9) 1  
0.746 
1  
 
1 537 (19.6) 1.64  1.70  
2 790 (28.8) 2.65  2.80  
3 568 (20.7) 3.96 <0.001 4.12 <0.001 0.726 
CRP > 10mg/l 
+ Albumin >35g/L 
+ Neutrophils>7.5×109/l 
+ Platelets >400×109/l 
0 813 (29.6) 1  
0.751 
1   
1 513 (18.7) 1.59  1.65   
2 706 (25.7) 2.49  2.63   
3 505 (18.4) 3.59  3.79   
4 205 (7.5) 4.58 <0.001 4.86 <0.001 0.734 
hs-CRP >3mg/l 
+ Albumin >35g/L 
+ Neutrophils>7.5×109/l 
+ Platelets >400×109/l 
0 508 (18.5) 1  
0.751 
1  
0.734 
1 635 (23.2) 1.61  1.62  
2 815 (29.7) 2.72  2.88  
3 571 (20.8) 4.14  4.32  
4 213 (7.8) 5.46 <0.001 5.77 <0.001 
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Figure 8.1. The relationship between the mGPS (0-top, small dash line;   1-middle, large 
dash line;   2-bottom, solid line) and the optimisation of the Glasgow Prognostic Score 
with high sensitivity CRP, albumin, neutrophil and platelet count (0-top, small dash 
line;   1-upper dot and dash line, 2-middle large dash line, 3-lower separated dot and 
dash line, 4-bottom, solid line) and survival.  
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CHAPTER 9. SYSTEMIC INFLAMMATION-BASED SCORE PREDICTS ALL-
CAUSE, CARDIOVASCULAR AND CEREBROVASCULAR MORTALITY 
9.1. ABSTRACT 
Introduction:  Markers of the systemic inflammatory response have been shown to be 
prognostic of survival in patients with cancer.  The aim of the present chapter was to examine 
the prognostic relationship between C-reactive protein, albumin, neutrophil, lymphocyte and 
platelet counts with all-cause, cancer, cardiovascular and cerebrovascular mortality. 
Methods:  Patients (n=160,481) who had an incidental blood sample taken between 2000 and 
2008 were studied for the prognostic value of  C-reactive protein (>10mg/l), albumin, 
neutrophil, lymphocyte and platelet counts.  Also, patients (n=52,091) sampled following the 
introduction of high sensitivity C-reactive protein (>3mg/l) measurements were studied.  A 
combination of these markers were used to make cumulative inflammation-based scores. 
Results:  In all patients (n=160,481) C-reactive protein (>10mg/l) (HR 2.71, p<0.001), 
albumin (>35mg/l) (HR 3.68, p<0.001) and neutrophil counts (HR 2.18, p<0.001) were 
independently predictive of all-cause mortality.  These associations were also observed in 
cancer, cardiovascular and cerebrovascular mortality before and after the introduction of high 
sensitivity C-reactive protein measurements (>3mg/l) (n=52,091).  A combination of high 
sensitivity C-reactive protein (>3mg/l), albumin and neutrophil count predicted all-cause (HR 
7.37, p<0.001, AUC 0.723), cancer (HR 9.32, p<0.001, AUC 0.731), cardiovascular (HR 
4.03, p<0.001, AUC 0.650) and cerebrovascular (HR 3.10, p<0.001, AUC 0.623) mortality. 
Conclusion:  The results of the present study showed that an inflammation-based prognostic 
score, combining high sensitivity C-reactive protein, albumin and neutrophil counts is 
prognostic of all-cause mortality. 
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9.2. INTRODUCTION 
 As has been detailed in previous Chapters, there is now good evidence that 
inflammation based prognostic scores have independent prognostic value in patients with a 
variety of cancers.  In Chapter 8, constituents of these scores, including high-sensitivity C-
reactive protein (>3mg/l), albumin (<35g/l), neutrophils (>7.5 x 10
9
) and platelets (>400 x 
10
9
), were combined to form the optimised Glasgow Prognostic Score (oGPS) that improved 
the prognostic value of the established Glasgow Prognostic Score [Proctor et al., 2013].  
Furthermore, Chapter 1 detailed the well established relationship between certain markers of 
systemic inflammation with atherosclerotic and all-cause mortality, with more recent studies 
demonstrating similar correlations [Zacho et al., 2010; Phillips et al., 2011; Zamani et al., 
2013].  However, it remains to be determined whether such markers, combined in an 
inflammation-based score, can reliably predict outcome and what the optimal constituents of 
this score would be. 
 Therefore, the aim of the present Chapter was to examine the relationship between 
markers of the systemic immune/inflammatory response and all cause, cancer, cardiovascular 
and cerebrovascular mortality in a large incidental cohort. 
9.3. MATERIALS AND METHODS 
 From the cohort previously described in Chapter 4, patients in North Glasgow, who 
had a single blood sample taken for C-reactive protein and albumin were considered [Proctor 
et al., 2010].  Only those patients who also had a differential white cell count available, 
including lymphocyte, neutrophil and platelet count were included.  Patients were sampled 
incidentally between January 2000 and November 2008.  The sample size was originally 
based on similar work investigating the association between C-reactive protein and all-cause 
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survival [Marsik et al., 2008].  If multiple samples had been taken during this time period, 
only the initial set was used.  Only those patients undergoing blood sampling after the 
introduction of the routine measurement of high sensitivity C-reactive protein (1st of August 
2006), were included in the analysis investigating the prognostic value of high sensitivity 
thresholds (<5mg/l).  Prior to the introduction of high-sensitivity C-reactive protein 
measurements, the limit of detection was a concentration of less than 5mg/L and 0.05mg/l 
thereafter.  Standardised thresholds for C-reactive protein (>10mg/l), white cell count 
(>11×10
9
/l), neutrophil count (>7.5×10
9
/l), lymphocyte count (>3×10
9
/l) and platelet count 
(>400×10
9
/l) were used.  High sensitivity C-reactive protein threshold >3mg/l, previously 
reported to be associated with survival [Ridker, 2003; Ridker, 2008; Lee et al., 2011; Ko et 
al., 2012] and shown to be the optimal threshold in this cohort [Proctor et al., 2013], was also 
studied.  
 As the presence of malignancy is known to be associated with activation of the 
systemic immune/inflammatory response [Proctor et al., 2010], all patients with a diagnosed 
malignancy any time prior to or within 14 days of blood sample were corrected for.  Whether 
the patient had been sampled as an inpatient or outpatient was also noted. 
 Patient outcome and mortality was established through linkage with the Information 
Services Division (ISD) for Scotland by exact matching surname, forename, sex and date of 
birth (Appendix 3).  If no match on surname then Daitch-Mokotoff followed by NYSIIS 
soundex algorithms were employed.  On remaining unmatched cases, forenames and 
surnames were switched followed by matching on previous surnames, reversing gender, 
using first initial opposed to full forename and finally on surname, gender and date of birth 
only.  On all those not with exact matches a manual check on whether to include or exclude 
was taken.  Of the 223,303 patients originally identified, 213,127 were successfully matched 
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through this linkage and 10 176 were not identified (5%).  Of the matched patients, 160 481 
patients had C-reactive protein and albumin as well as a complete differential white cell 
count.  The presence of SMR01 records were used to determine whether a patient was 
sampled during a hospital admission, the length of hospital stay and whether the patient had 
died.  Hospital admission was defined as having been sampled during an continuous inpatient 
stay.  SMRO6 records containing International Classification of Disease (ICD) codes were 
used to identify those with a diagnosis of cancer prior to, or within 14 days of blood 
sampling, as previously described [Proctor et al., 2010].  Cancer related mortality was 
defined as ICD10 codes C00 - C97, cardiovascular (ischaemic heart disease) related mortality 
was defined as ICD10 codes I20 - I25 and cerebrovascular disease related mortality was 
defined as ICD10 codes I60 - I69.  At the time of data collection, the ISD held complete 
SMR01 data on registered deaths until May 2011.  Survival was calculated from time of 
blood sample to date of death or censor date (31st of May 2011).  Patients were excluded if 
under the age of 16 years, demographic details were incomplete or if returned ISD fields were 
inaccurate or incomplete.  Overall patient numbers were different in this Chapter, when 
compared to previous, as the inclusion criteria and matching process differed for ISD 
compared to the Scottish Cancer Registry linkage. 
 Deprivation was measured with the Scottish Index of Multiple Deprivation (SIMD) as 
detailed in Chapter 1 [Proctor et al., 2010].  Ethical approval was granted for the present 
study by the Research Ethics Committee, North Glasgow NHS Trust. 
 Statistical analysis was performed as follows.  Cox proportional hazard model was 
used to analyse the relationship between patient demographics, hospital admission, the 
presence of cancer, C-reactive protein, albumin, neutrophil, lymphocyte and platelet counts 
with all-cause mortality.  Furthermore, cause specific mortality for those dying of cancer, 
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cardiovascular and cerebrovascular disease were also examined by individually entering these 
as the primary outcomes into the model. 
 In those patients with a high sensitivity C-reactive protein measurement, the 
prognostic value of the combination of C-reactive protein, albumin and neutrophils, adjusted 
for age, sex, deprivation, hospital admission and the presence of cancer, was analysed using 
the Cox proportional hazard model and the Area Under the receiver operating characteristic 
Curve (AUC).  During this analysis the proportionality assumptions in the Cox model were 
explored using a log minus log visual inspection and were found to be satisfactory.  The 
relationship between the optimised Glasgow Prognostic Score and survival was assessed 
using the Kaplan-Meier log rank.  A p value of <0.05 was considered to have statistical 
significance in the analysis.  Analysis was performed using SPSS software (SPSS, Chicago, 
IL, USA). 
9.4. RESULTS 
 From GIOS cohort of 223,303 patients originally described [Proctor et al., 2010], 
209,148 (94%) were matched with a unique patient record in the ISD dataset.  Of this group 
160,481 fitted the inclusion criteria and had a differential white cell count available, 
including neutrophil, lymphocyte and platelet counts.  Most patients were under 65 years of 
age (n=103,779, 65%) and female (n=85,308, 53%).  Forty four percent of patients 
(n=71,156) were SIMD 5 (most deprived).  Fifty four percent (n=86,339) of patients were 
sampled during an inpatient stay.  Following the introduction of high sensitivity C-reactive 
protein, 52,091 patients with high sensitivity C-reactive protein, albumin, neutrophil, 
lymphocyte and platelet counts, were present. 
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 On follow-up of all patients, there were 42,242 deaths in total of which 13,176 (31%) 
were cancer related, 6076 (14%) were cardiovascular related and 3638 (9%) were 
cerebrovascular related.  The minimum follow-up from blood sample for all patients was 31 
months and the maximum 134 months (median follow-up 69 months for survivors).  The 
relationship between patient demographics, hospital admission, history of cancer, C-reactive 
protein (>10mg/l), albumin, neutrophil, lymphocyte and platelet counts and survival 
(n=160,481) is shown in Table 9.1.  Increasing age, male gender, increasing deprivation, 
hospital admission, history of cancer, high C-reactive protein (>10mg/l), neutrophil and 
platelet counts, as well as low albumin and lymphocyte counts were independently associated 
with an increase is all-cause mortality (all p<0.001).  Increasing age, male gender, history of 
cancer, high C-reactive protein (>10mg/l), neutrophil and platelet counts as well as low 
albumin and lymphocytes were independently associated with an increase in cancer specific 
mortality (all p<0.001).  Increasing age, male gender, increasing deprivation, hospital 
admission, history of cancer, high C-reactive protein (>10mg/l), neutrophil and platelet 
counts as well as low albumin was independently associated with an increase in 
cardiovascular mortality (all p<0.001).  Increasing age, hospital admission, no history of 
cancer, high C-reactive protein (>10mg/l), neutrophil count as well as low albumin was 
independently associated with an increase in cerebrovascular mortality (all p<0.001).  The 
results of Table 9.1 show that activation of the immune/inflammatory response, as evidenced 
by an elevated C-reactive protein, predicts all-cause mortality but was most strongly 
associated with death from cancer (HR 1.85) when compared with cardiovascular (HR 1.54) 
or cerebrovascular (HR 1.31) disease. 
 The relationship between patient demographics, hospital admission, history of cancer, 
C-reactive protein (>3mg/l), albumin, neutrophil, lymphocyte and platelet counts and survival 
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in patients with a differential white cell count following the introduction of high sensitivity 
C-reactive protein (n=52,091) is shown in Table 9.2.  Increasing age, male gender, hospital 
admission, history of cancer, high C-reactive protein (>3mg/l), neutrophil and platelet counts 
as well as low albumin and lymphocyte counts were independently associated with an 
increase in all-cause mortality (all p<0.001).  Increasing age, male gender, history of cancer, 
high C-reactive protein (>3mg/l), neutrophil and platelet counts as well as low albumin and 
lymphocyte counts were independently associated with an increase in cancer mortality (all 
p<0.001).  Increasing age, male gender, hospital admission, history of cancer, high C-reactive 
protein (>3mg/l) and neutrophil counts as well as low albumin was independently associated 
with an increase in cardiovascular mortality (all p<0.001).  Increasing age, hospital 
admission, history of cancer, high C-reactive protein (>3mg/l) and neutrophil counts as well 
as low albumin was independently associated with an increase in cerebrovascular mortality 
(all p<0.05).  The results of Table 9.2 show that activation of the immune/inflammatory 
response, as evidenced by an elevated C-reactive protein (>3mg/l), predicts all-cause 
mortality but was most strongly associated with death from cancer (HR 1.81) when compared 
with cardiovascular (HR 1.66) or cerebrovascular (HR 1.25) disease. 
 As C-reactive protein, albumin and neutrophils were consistently predictive of all-
cause, cancer, cardiovascular and cerebrovascular specific mortality, these were taken 
forward to examine the prognostic value of their combination.  The relationship between 
cumulative markers of the systemic immune/inflammatory response (including high 
sensitivity C-reactive protein, albumin and neutrophil count) and mortality in an incidental 
cohort (n=52,091) is shown in Table 9.3.  The model was built up in a similar manner as 
previously demonstrated [Proctor et al., 2013] with the area under the curve representing the 
full model for each outcome.  All combinations of these systemic inflammatory markers were 
 165 
 
predictive of all-cause, cancer, cardiovascular and cerebrovascular specific survival (all 
p<0.01) independent of age, sex deprivation, hospital admission and the presence of cancer 
(Figure 9.1).  The Kaplan-Meier plot, for a score of 3, shows initial steep curves that 
subsequently do not diverge.  This suggests that systemic inflammation is particularly 
predictive of early all-cause mortality.  The areas under the curve represent the full model for 
each of the three outcomes. 
9.5. DISCUSSION 
 The results of the present Chapter show that, in a large incidentally sampled cohort of 
patients (n=160,481), a number of routine objective markers of the systemic 
immune/inflammatory response examined were independently associated with all-cause 
mortality.  Furthermore, of these C-reactive protein, albumin and neutrophils were confirmed 
to have independent prognostic value not only in patients with cancer but also in patients with 
cardiovascular and cerebrovascular disease.  While these variables do not predict cause of 
death, there are correlations between lethal pathological processes, such as cancer and 
atherosclerotic disease, and activation of the systemic immune/inflammatory response.  These 
results implicate the activation of the systemic immune/inflammatory response as a key and 
common factor in the shortened survival in the most common lethal disease states. 
 The results of the present Chapter are consistent with previous work using individual 
markers of the systemic immune/inflammatory response to predict all-cause mortality 
[Goldwasser and Feldman, 1997; Gillum et al., 2005; Marsik et al., 2008; Grimm et al., 2009; 
Zacho et al., 2010] and goes further to demonstrate that the combination of C-reactive 
protein, albumin, neutrophils can further improve the prognostic value of the systemic 
immune/inflammatory response.  Furthermore, these associations remained following 
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adjustment for hospital admission and a previous diagnosis of cancer, events likely to be 
associated with raised inflammatory markers and reduced survival. 
 With reference to cancer, there has been growing interest in the role of markers of the 
systemic immune/inflammatory response in predicting outcome [McMillan, 2012; Guthrie et 
al., 2013] and the clinical utility of combining such markers with tumour based factors to 
provide improved patient counselling and personalised treatment is becoming increasingly 
recognised [Gakis et al., 2011; Lamb et al., 2012; Inoue et al., 2013; McMillan, 2013].  The 
present results provide a framework for the further development of a paradigm that uses both 
patient and tumour based objective factors to assess patient prognosis. 
 With reference to cardiovascular and cerebrovascular disease the prognostic value of 
C-reactive protein is well established [Kaptoge et al., 2012].  Indeed, high sensitivity C-
reactive protein has been recommended for use in cardiovascular risk stratification in 
moderate risk, asymptomatic patients [Greenland et al., 2010].  Therefore, the present results 
also provide further evidence for the clinical utility of systemic inflammation-based scoring 
systems in predicting outcome in cardiovascular and cerebrovascular disease.  Indeed, this 
approach with C-reactive protein and albumin as core factors has recently been validated in 
the NHANES III cohort [Van Hemelrijck et al., 2012].   
 The present Chapter shows that activation of the immune/inflammatory response 
predicts all-cause mortality, predominantly within the first year following sample, with the 
strongest association in cancer, followed by cardiovascular and cerebrovascular disease.  The 
basis of the independent prognostic value of C-reactive protein, albumin and neutrophil count 
over all disease states (and platelets in cancer) is not clear and likely to be complex.  
However, it is likely that these factors are associated with aspects of the 
immune/inflammatory response and in particular the innate immune/inflammatory response.  
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Therefore, it may be hypothesised that the complementary prognostic value of these factors 
reflects an upregulation of the innate immune/inflammatory response and is likely to identify 
those with an ongoing pathological process who may die early as a consequence.  The 
consistency of observations across different tumour types and now different disease states 
suggests that this hypothesis is worthy of further study. 
 In the present Chapter, the cohort has a number of limitations.  The patients were 
selected on the basis that measurements of C-reactive protein, albumin and a differential 
white cell count had been performed and were therefore not necessarily representative of all 
patients treated in the North Glasgow area.  It is also recognised that patients may have 
concurrent morbidity causing a rise in their C-reactive protein and derangement of their 
albumin and other haematological parameters. 
 In summary, a number of markers of the systemic immune/inflammatory response, 
reflecting an optimised Glasgow Prognostic Score, have prognostic utility not only in cancer, 
but also in cardiovascular and cerebrovascular disease.  Further work to validate such 
findings in other large cohorts is warranted. 
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Table 9.1. The relationship between patient demographics, markers of the systemic immune/inflammatory response and mortality 
 
 
 
 All-cause mortality 
Deaths = 42,242 
Cancer mortality 
Deaths = 13,176 
Cardiovascular mortality 
Deaths = 6076 
Cerebrovascular mortality 
Deaths = 3638 
n (%) Univariate Multivariate Univariate Multivariate Univariate Multivariate Univariate Multivariate 
n=160 481 HR p-value HR p-value HR p-value HR p-value HR p-value HR p-value HR p-value HR p-value 
Age <65/  103,779 (65) 1  1  1  1  1  1  1  1  
65-74 26,989(17) 4.00 <0.001 3.31 <0.001 3.76 <0.001 2.21 <0.001 5.80 <0.001 5.64 <0.001 8.45 <0.001 8.18 <0.001 
>75 29,716 (18) 8.27 <0.001 6.51 <0.001 4.36 <0.001 2.41 <0.001 12.58 <0.001 12.36 <0.001 28.41 <0.001 26.10 <0.001 
Sex Male 75,173 (47) 1  1  1  1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
0.232 Female 85,308 (53) 0.86 <0.001 0.77 <0.001 0.76 <0.001 0.70 0.72 0.63 1.18 0.94 
SIMD 1 21,362 (13) 1  1  1    1  1  1    
2 17,778 (11) 1.03 0.216 1.11 <0.001 1.03 0.459   1.10 0.104 1.21 0.001 0.84 0.012   
3 20,432 (13) 1.16 <0.001 1.20 <0.001 1.18 <0.001   1.18 0.002 1.28 <0.001 0.91 0.139   
4 29,753 (19) 1.28 <0.001 1.30 <0.001 1.23 <0.001   1.42 <0.001 1.47 <0.001 1.00 0.986   
5 71,156 (44) 1.25 <0.001 1.36 <0.001 1.00 0.882   1.32 <0.001 1.45 <0.001 1.16 0.004   
Hospital 
Admission 
No 74,142 (46) 1  1  1  1  1  1  1  1  
Yes 86,339 (54) 1.75 <0.001 1.21 <0.001 1.55 <0.001 1.00 0.861 1.81 <0.001 1.33 <0.001 2.00 <0.001 1.49 <0.001 
History of 
Cancer 
None 139,080 (87) 1  1  1  1  1  1  1  1  
Present 21,401 (13) 3.40 <0.001 2.13 <0.001 12.01 <0.001 8.94 <0.001 1.45 <0.001 0.84 <0.001 1.58 <0.001 0.84 <0.001 
C-reactive 
protein 
<10mg/l 94,544 (59) 1  1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 >10mg/l 65,937 (41) 2.71 <0.001 1.60 3.16 1.85 2.33 1.54 2.17 1.31 
Albumin >35mg/l 135,087 (84) 1  1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 <35mg/l 25,394 (16) 3.68 <0.001 2.02 4.25 2.08 2.36 1.33 2.54 1.41 
Neutrophil 
count 
<7.5×10
9
/l 127,736 (80) 1  1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 >7.5×10
9
/l 32,745 (20) 2.18 <0.001 1.49 2.51 1.41 1.89 1.51 1.89 1.52 
Lymphocyte 
count 
>3×10
9
/l 12,542 (8) 1  1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
0.564 
1 
<0.001 
1 
0.272 <3×10
9
/l 147,939 (92) 1.87 <0.001 1.21 1.84 1.19 1.58 0.97 2.00 1.11 
Platelet 
count 
<400×10
9
/l 143,431 (89) 1  1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
0.584 >400×10
9
/l 17,050 (11) 1.64 <0.001 1.07 2.03 1.39 1.17 0.81 1.51 1.03 
 169 
 
Table 9.2. The relationship between patient demographics, markers of the systemic immune/inflammatory response (including high sensitivity C-
reactive protein) and mortality 
 
 
 
 All-cause mortality 
Deaths = 8243 
Cancer mortality 
Deaths = 3480 
Cardiovascular mortality 
Deaths = 929 
Cerebrovascular mortality 
Deaths = 553 
 Univariate Multivariate Univariate Multivariate Univariate Multivariate Univariate Multivariate 
n (%) 
n=52 091 
HR p-value HR p-value HR p-value HR p-value HR p-value HR p-value HR p-value HR p-value 
Age <65/  36,834 (71) 1  1  1  1  1  1  1  1  
65-74 7277 (14) 4.28 <0.001 2.95 <0.001 4.36 <0.001 2.12 <0.001 6.26 <0.001 5.73 <0.001 7.75 <0.001 7.39 <0.001 
>75 7880 (15) 8.10 <0.001 5.24 <0.001 4.82 <0.001 2.20 <0.001 14.36 <0.001 13.18 <0.001 24.31 <0.001 22.20 <0.001 
Sex Male 25,411 (49) 1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
0.058 
 
 Female 26,680 (51) 0.87 0.77 0.86 0.76 0.72 0.61 1.18  
SIMD 1 6943 (13) 1    1    1    1    
2 5972 (12) 1.07 0.141   1.02 0.768   1.36 0.024   0.92 0.639   
3 6749 (13) 1.16 0.001   1.19 0.004   1.23 0.133   0.81 0.199   
4 9583 (18) 1.17 <0.001   1.07 0.275   1.58 <0.001   0.87 0.355   
5  22 844 (44) 1.06 0.129   0.83 <0.001   1.21 0.092   0.96 0.777   
Hospital 
Admission 
No 23,616 (45) 1  1  1  1  1  1  1  1  
Yes 28,475 (55) 1.76 <0.001 1.16 <0.001 1.56 <0.001 0.96 0.229 1.82 <0.001 1.29 <0.001 2.31 <0.001 1.74 <0.001 
History of 
Cancer 
None 20,917 (40) 1  1  1  1  1  1  1  1  
Present 31,174 (60) 4.74 <0.001 2.49 <0.001 12.75 <0.001 8.00 <0.001 1.57 <0.001 0.74 0.002 1.78 <0.001 0.77 0.032 
C-reactive 
protein 
<3mg/l 20,917 (40) 1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
0.032 >3mg/l 31,174 (60) 3.05 1.55 3.88 1.81 2.78 1.66 2.10 1.25 
Albumin >35mg/l 41,010 (79) 1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
0.010 <35mg/l 11,081 (21) 5.19 2.68 6.40 2.95 3.57 1.87 2.69 1.28 
Neutrophil 
count 
<7.5×10
9
/l 41,617 (80) 1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 >7.5×10
9
/l 10,474 (20) 2.41 1.63 2.66 1.47 1.80 1.49 2.14 1.89 
Lymphocyte 
count 
>3×10
9
/l 5391 (10) 1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
0.008 
1 
0.083 
1 
0.001 
1 
0.992 <3×109/l 46,700 (90) 2.06 1.25 2.42 1.42 1.37 0.80 1.78 1.02 
Platelet 
count 
<400×10
9
/l 47,160 (91) 1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
<0.001 
1 
0.001 
1 
0.055 
1 
<0.001 
1 
0.950 >400×10
9
/l 4931 (9) 2.05 1.16 2.70 1.54 1.39 0.82 1.66 1.01 
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Table 9.3. The relationship between markers of the systemic immune/inflammatory response (including high sensitivity C-reactive protein) and 
mortality:  Adjusted for age, sex, deprivation, hospital admission and the presence of cancer 
 
 
 
 
 
 
n (%) 
n=52,091 
All-cause mortality 
Deaths = 8243 
Cancer mortality 
Deaths = 3480 
Cardiovascular mortality 
Deaths =929 
Cerebrovascular mortality 
Deaths =553 
HR p-value AUC HR p-value AUC HR p-value AUC HR p-value AUC 
 
CRP > 10mg/l 
+Albumin >35g/L 
+Neutrophils >7.5×10
9
/l 
0 26,603 (51) 1  
0.720 
1  
0.728 
1  
0.645 
1  
0.612 
1 13,734 (26) 1.92 <0.001 1.99 <0.001 1.66 <0.001 1.53 <0.001 
2 8635 (17) 3.45 <0.001 4.27 <0.001 2.67 <0.001 1.76 <0.001 
3 3119 (6) 6.45 <0.001 7.95 <0.001 3.49 <0.001 2.50 <0.001 
 
hs-CRP >3mg/l 
+ Albumin >35g/L 
+ Neutrophils>7.5×10
9
/l 
0 17,542 (34) 1  
0.723 
1  
0.731 
1  
0.650 
1  
0.623 
1 19,880 (38) 1.76 <0.001 1.94 <0.001 1.62 <0.001 1.40 0.006 
2 11,158 (21) 3.58 <0.001 4.44 <0.001 2.92 <0.001 1.90 <0.001 
3 3511 (7) 7.37 <0.001 9.32 <0.001 4.03 <0.001 3.10 <0.001 
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Figure 9.1. The relationship between cumulative markers of the systemic 
immune/inflammatory response and all-cause mortality (including high sensitivity C-reactive 
protein, albumin and neutrophil count) and survival (0-top, solid line;   1-upper separated dot 
and dash line, 2-middle large dash line, 3-lower close dot and dash line, n=52,091) 
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10.0. CONCLUSION 
 At the beginning of this period of research, as detailed in Chapter 1, it was clear that 
inflammation played an integral role in the pathogenesis and progression of malignancy and 
atherosclerotic disease.  It had also been shown that activation of the systemic 
immune/inflammatory response, as measured by an objective systemic inflammatory-based 
score, was associated with reduced survival in particular cohorts with cancer, cardiovascular 
disease and stroke.  However, it was unclear as to whether this was a universal phenomenon 
affecting all cancer types and what the optimal serum constituents of an inflammation based 
prognostic score would be for patients with cancer.  It had also not been determined whether 
the link between inflammation and survival in arteriosclerotic disease was measurable by a 
similar inflammation-based score.  The aim of this body of work was to address these issues 
in a single cohort of patients. 
 In Chapter 4, the relationships between the presence of cancer, serum levels of 
markers of systemic inflammation (mGPS) and other routinely sampled biochemical 
variables were investigated.  Indeed, people with cancer were more likely to have an elevated 
mGPS and derangement of serum biochemical markers, both factors that had previously been 
associated with mortality.  Interestingly, there were also significant interrelationships 
between markers of the systemic immune/inflammatory response and biochemical variables, 
suggesting that inflammation may be the underlying pathophysiological mechanism.  It was 
also demonstrated that systemic inflammation (mGPS) across tumour types differed with the 
proportion of non-inflamed patients correlating with nationally reported five-year survival 
rates. 
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 In Chapter 5, the relationship between the mGPS, biological parameters, tumour site 
and survival in patients with malignancy was investigated.  It was discovered that that serum 
C-reactive protein, albumin, liver function tests and calcium were all shown to have 
independent prognostic value in patients with a recent history of malignancy.  Moreover, the 
relationship between the mGPS and survival was independent of tumour site and thus 
provided evidence that the systemic immune/inflammatory response is a universal marker of 
poor outcome in patients with malignancy.  It was indicated that further work investigating 
the potential of combining a measure of the host immune/inflammatory response with 
conventional TNM staging would be worthwhile. 
 In Chapter 6, a comparison of the prognostic value of commonly reported systemic 
inflammation-based prognostic scores was carried out.  The mGPS, NLR, PLR, PI and PNI 
were all shown to be associated with survival in patients with a recent diagnosis of cancer and 
it was argued that these scores were essentially measuring a common pathological process.  
Scores incorporating C-reactive protein were identified as having superior predictive nature 
and it was proposed that the widely validated mGPS should be used in the routine assessment 
of all patients with cancer.  It was also noted that the addition of a white cell count to the 
mGPS may improve its prognostic value and further work on this issue was recommended. 
 In Chapter 7, the prognostic value of a derived systemic inflammation-based score 
(derived Neutrophil to Lymphocyte Ratio) using a white cell and neutrophil count widely 
available in chemotherapy trial databases was evaluated.  The derived Neutrophil to 
Lymphocyte Ratio (neutrophil count/ white cell count - neutrophil count) had comparable 
prognostic value to the NLR and was shown to be predictive independent of tumour site.  It 
was suggested that large oncology datasets be analysed, using the derived Neutrophil to 
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Lymphocyte Ratio, to assess further the clinical utility of this systemic inflammation-based 
prognostic score. 
 In Chapter 8, the aim was to examine whether it was possible to improve the 
prognostic value of the mGPS by including other markers of the systemic inflammatory 
response.  The addition of a high sensitivity C-reactive protein measurement, neutrophil and 
platelet counts were found to enhance the predictive value (AUC) of the Glasgow Prognostic 
Score as well as improving the differentiation of patients at different levels of risk.  These 
results were consistent with the concept that the systemic inflammatory response in patients 
with cancer was primarily due to an upregulation of the innate immune/ inflammatory 
response. 
 Given the universal utility of inflammation-based prognostic scores in patients with 
cancer, it was of interest as to whether a comparable score would be associated with all-
cause, cardiovascular and cerebrovascular survival mortality.  In Chapter 9, the prognostic 
value of C-reactive protein and albumin together with neutrophil, lymphocyte and platelet 
counts were investigated in a large unselected cohort.  It was concluded that a similar 
systemic inflammation-based prognostic score to that used in cancer, containing high 
sensitivity C-reactive protein, albumin and neutrophils, was also independently associated 
with all-cause, cardiovascular and cerebrovascular mortality. 
 There are several areas for future study and potential clinical application of the 
inflammation-based scores presented in this body of work.  Biomarkers are a topic of current 
interest as they can not only play an important role in disease detection and risk stratification, 
but can also assist in the personalisation of treatment [La Thangue and Kerr, 2011].  
Biomarkers offer advantages over traditional clinical, radiological and pathological 
prognostic modalities given their objective nature [Strimbu and Tavel, 2010]. Furthermore it 
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has been suggested that the optimal biomarker, as is the case with the scores presented in the 
current body of work, would accurately predict outcome and could assist in the tailoring of 
appropriate treatment while being universally available and financially viable [Paoletti et al., 
2004]. 
 With regards to cancer screening, it has been suggested that genetic profiling may 
assist in the identification of high risk groups that will benefit from intensive surveillance 
[Dunlop et al., 2013].  However, to date genetic variants associated with an increased risk of 
colorectal cancer have not been shown to have a detrimental effect on survival [Tenesa et al., 
2010].  It is of significance, when considered with the results of the current work, that Tao 
and co-workers have reported C-reactive protein levels in conjunction with Faecal Occult 
Blood Tests to improve the sensitivity and specificity of colonoscopy for colorectal cancer 
screening [Tao et al., 2012].  This clearly raises the possibility that the addition of an 
inflammation-based prognostic score may help improve this further.  When screening for 
cardiovascular disease it has been recommended that C-reactive protein is also used to 
identify those at risk as well as help determine who will benefit from Statin therapy 
[Greenland et al., 2010; Kaptoge et al., 2012].  Interestingly, in those treated, a reduction in 
C-reactive protein concentrations has also been shown to correlate with improved outcomes 
independent of cholesterol reduction [Rao and Milbrandt, 2010; Tsai et al., 2012].  This raises 
the possibility that inflammation-based scores, including a sensitive C-reactive protein 
measurement, may have clinical utility in the screening and risk stratification of patients with 
atherosclerotic disease. 
 As the present body of work has shown, systemic inflammation-based prognostic 
scores have the potential to predict outcome in patients with cancer.  A large number of other 
predictive biochemical biomarkers have been suggested, including carbonic anhydrase IX in 
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clear cell renal cancer [Stillebroer et al., 2010] and IMP3 in colorectal cancer [Lin et al., 
2013].  Work has also been carried out investigating tumour indicators of survival in cancers 
with evidence demonstrating particular genetic signatures to be associated with survival 
[Ogino et al., 2009].  However, these tests are highly specialised with limited clinical 
availability and significant financial cost.  Indeed, Kerr and Midgley stated: 
The genetic model for colorectal (CRC) tumourigenesis proposal by Fearon and 
Vogelstein two decades ago, although broadly correct, has yielded to a much 
more complex and multifaceted paradigm. This has led to the clinical 
community being tantalized, but somewhat lacking in practical examples of 
biomarkers that can be applied for obvious patient benefit.  There is, of course, 
the example of seeming resistance to anti–epidermal growth factor receptor 
(EGFR) antibody therapy in tumours carrying mutant K-ras, which has gained 
clinical traction, but there are no other biomarkers in CRC that are routinely 
incorporated into any treatment guidelines or algorithms. Many candidates have 
come and gone (p53,3 thymidylate synthase, loss of heterozygosity of 18q, to 
name but a few), lost in the fog of underpowered studies, technical variation in 
means of measurement, and absence of validating data sets with adequate 
controls [Kerr and Midgley, 2010]. 
It therefore follows that the simple, widely available, systemic inflammation-based scores 
presented in the current work may be a superior alternative. 
 Another potential use for systemic inflammation-based prognostic scores is to assist 
in the identification of patients that will benefit from particular treatment modalities.  For 
example, anti-inflammatory chemotherapeutic agents, such as aspirin and cyclooxygenase-2 
(COX-2) inhibitors, have been suggested to reduce risk of cancer as well as the subsequent 
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development of metastasis [Rothwell et al., 2012; Chan and Detering, 2013].  It is however 
worth noting that while Cox-2 inhibitors have a selective anti-inflammatory action, they also 
inhibit the production of prostacyclin, a prostaglandin that reduces platelet aggregation and 
arterial vasodilatation.  This therefore allows the unchallenged promotion of platelet 
aggregation and vasoconstriction exerted by COX-1 induces thromboxane A2, and a 
subsequent increased incidence of heart attack and stroke [Niederberger et al., 2004]. 
 Non-steroidal anti-inflammatory drugs have also been shown to play a potential role 
in patients with advanced malignancy and cancer cachexia [Solheim et al., 2013].  It is 
possible that inflammation-based prognostic scores may be useful in identifying those who 
are systemically inflamed and would benefit from treatment, as well as measure the potential 
response [McMillan, 2013].  It has also been suggested that, in colorectal cancer patients with 
stage II disease, an inflammation-based prognostic score (GPS) could help identify patients 
who will gain a survival benefit from adjuvant chemotherapy [Toiyama et al., 2011].  
Similarly, in patients with incurable cancer cachexia, the GPS has been able to identify those 
that would benefit from supportive parenteral nutrition [Bozzetti et al., 2014].  Also, the NLR 
has been shown to select those with metastatic prostate cancer that will benefit from 
Abiraterone hormonal therapy [Leibowitz-Amit et al., 2014]. 
 There is also a growing pool of evidence regarding the use of markers of the systemic 
immune/inflammatory response when determining who will tolerate potentially toxic 
systemic therapies, such as palliative chemotherapy.  In patients with advanced NSCLC, 
hypoalbuminaemia has been associated with anaemia, neuropathy, apatite loss, nausea and 
fatigue [Arrieta et al., 2010].  Furthermore, Gioulbasanis and co-workers demonstrated an 
association with mucositis, neurotoxicity, neutropenia, requirement for treatment termination 
and chemotherapy-related toxic deaths in patients with a raised inflammatory status (GPS) 
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receiving palliative chemotherapy for lung cancer [Gioulbasanis et al., 2012].  Similarly, in 
patients with advanced nasopharyngeal cancer, the presence of a non-normalising elevated C-
reactive protein level after chemotherapy, has been associated with a poor outcome [Xia et 
al., 2013].  Also, patients receiving trans-arterial chemoembolisation for unresectable 
hepatocellular carcinoma were found to have worse outcomes in the presence of an activated 
immune/inflammatory response [Pinato and Sharma, 2012].  The current results show that 
inflammation-based prognostic scores have universal predictive value across all tumour types 
studied.  They also offer an objective measurement of a patient’s physical state, where 
performance status and physician opinion may vary.  Moreover, activation of the systemic 
immune/inflammatory response has been shown to correlate with the majority of cancer 
symptoms [Laird et al., 2013] and accordingly, a standardised inflammation-based score, may 
assist traditional modalities in selecting patients who will benefit from further oncological 
therapies. 
 Another potential use for inflammation-based prognostic scores would be to monitor 
response to treatment.  It has been suggested that targeted, immunomodulating therapies may 
confer a survival advantage and there is ongoing work to investigate such therapies, including 
anti-angiogenic TNF-α [Balkwill and Mantovani, 2010; Sasi et al., 2012].  It also been put 
forward been suggested that biomarkers are required to identify those appropriate for such 
targeted therapies and it is possible that inflammation-based scores may have a role to play in 
this process [Clarke et al., 2011].  Indeed, Ruxolitinib, a selective Janus kinase inhibitor 
(JAK1 and JAK2), has recently been shown to offer a survival advantage in patients with 
metastatic pancreatic cancer, but only in those patients with evidence of an active systemic 
inflation as measured by a mGPS of 1 or 2 [Hurwitz H et al., 2014].  Moreover, there is also 
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some evidence that similar immune/inflammatory modification may be employed in 
cardiovascular disease [Frangogiannis, 2012]. 
 The current piece of work gives an insight into the particular aspect of the 
immune/inflammatory response that is detrimental in cancer.  Of the prognostic indices 
examined, it was noted that those associated with a reduced survival, including C-reactive 
protein as well as neutrophil and platelet counts, were predominantly linked to the innate 
immune response.  Indeed, it is becoming clear that up-regulation of the innate response is 
detrimental as it facilitates angiogenesis and subsequent tumour dissemination [Tazzyman et 
al., 2013] and prognostic scores focusing on constituents of the innate immune response 
could be of future benefit. 
 In summary, this piece of research has demonstrated that a variety of inflammation-
based prognostic scores, which essentially measure the same process, to be of universal 
predictive value in patients with cancer, cardiovascular disease and stroke.  It also indicates 
that the basis of the relationship between the systemic immune/inflammatory response and 
outcome, particularly in cancer, is primarily due to activation of the innate 
immune/inflammatory response rather that the down regulation of the adaptive 
immune/inflammatory response. 
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APPENDIX 1:  GIOS Pathology Dataset 
 
Inflammation Outcome Study - North of Glasgow Biochemical, Haematological and 
Pathological linkage with creation of GIOS database 
 
Document date: 10th October 2009  
 
(1.) Dataset (ProcExtract 1-6.exe) containing all primary single samples of C-reactive protein, 
albumin and Calcium between 1st January 2000 and 1st November 2008 in North Glasgow 
Hospital laboratories - Including Glasgow Royal Infirmary, Stobhill hospital, Gartnavel 
hospital and the Western Infirmary -extracted from TELEPATH systems with coded 
algorithm.  Other variables extracted where available.  269 959 records extracted with 26 328 
having temporary emergency hospital numbers not compatible with cross linkage. 
 
(2.) Dataset (comp_histo_proc_extract 1-6.exe) containing all pathological diagnosis with 
malignant SNOMED codes in North Glasgow Hospital laboratories - Including Glasgow 
Royal Infirmary, Stobhill hospital, Gartnavel hospital and the Western Infirmary - extracted 
from telepath systems with coded algorithm. 
 
(3.) Data cross linked to provide dataset with 223 303 patient (conforming to aforementioned 
criteria in Chapter 3) identifiers including hospital number gender, DOB, and postcode 
subsequent check referencing of >500 random samples to ensure accuracy. 
 
(4.) SNOMED Clinical Terms (www.nlm.nih.gov/research/umls/Snomed/snomed_main) 
converted to ICD codes, subsequent clinical terms and then manual combination of 
morphology and topography terms to meaningful cancer diagnosis. 
 
(5.) Converted to anonymised password-protected .zip file with the following fields: 
 
Acquired fields: 
 *  ID at time of anonymisation 
 *  DOB date of birth 
 *  SEX gender 
 *  POSTCODE of address at time of blood sample 
*  DATEOFREQUEST of blood test 
 *  Universal required variables: CRP (C-reactive Protein), ALB (Albumin), CCAL(Calcium) 
 *  Biochemical variables where available: BIL (Bilirubin), ALP (Alkaline Phosphatase),  
     AST (aspartate transaminase), ALT (alanine transaminase) and γ-glutamyl transferase  
     (GGT) 
 *  Haematological variables were available: WCC (White Cell), NEUT (Neutrophil),  
     LYMPH (Lymphocyte), PLT (Platelet count) 
 *  DATEOFSAMPLE of neoplastic pathology diagnosis (1-4 where present) 
 *  Sample SNOMED topography (CATSITE) and morphology (CATTYPE) codes for each  
     individual sample 1-4 
 
Calculated fields: 
 *  AGE 
 *  SIMD 2006 Quintiles 
 *  CARSTAIRS Index 
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 *  Blood sample "normal" classification depending on aformentioned range classification  
    (Chapter3) 
 *  Inflammatory score mGPS 
 *  CATYPE1 type of primary malignancy and CASITE1 site of primary malignancy 
 *  NO presence of multiple malignancy or METYPEmetastatic malignancy 
 *  DIFFDATEDAYS difference in days between diagnosis of malignancy and blood test 
 *  CAGROUP broad group of malignancy 
  
See attached file: GIOS Dataset.SAV 
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APPENDIX 2:  GIOS Cancer Registry Dataset 
 
Inflammation Outcome Study - North of Glasgow Biochemical, Haematological and Scottish 
Cancer Registry linkage to create GIOS database of patients with cancer and follow-up 
 
Document date: 13th September 2010 with update linkage 12th July 2011 
 
(1.) GIOS Dataset.SAV containing identifying variables as well as all primary single samples 
of C-reactive protein, albumin and Calcium between 1st January 2000 and 1st November 
2008 in North Glasgow Hospital laboratories - Including Glasgow Royal Infirmary, Stobhill 
hospital, Gartnavel hospital and the Western Infirmary - as described in Appendix 1.   
 
(2.)  223 303 records cross linked with Scottish Cancer Registry Data base held at West of 
Scotland Cancer Surveillance Unit, Faculty of Medicine, University of Glasgow, Glasgow 
G12 8RZ. Using exact matches of patients’ forename, surname and date of birth followed by 
Daitch-Mokotoff and NYSIIS soundex algorithms were employed.  On remaining unmatched 
cases, forenames and surnames were switched followed by matching on previous surnames, 
reversing gender, using first initial opposed to full forename and finally on surname gender 
and date of birth only.  On all those not with exact matches a manual check on whether to 
include or exclude was taken.  All unmatched cases were reviewed for manual match.   
 
(3.) Anonymised data set returned to provide 21 668 patient conforming to aforementioned 
criteria in Chapter 4 with a various mix of ICD 9/10/Oncology codes 
(www.who.int/classifications/icd/en/) for diagnosis and death where appropriate.  A selection 
of matched cases were reviewed for manual quality check (>500).  ICD code manual 
combination of morphology and topography terms to meaningful cancer diagnosis and cause 
of death. 
 
(5.) Converted to anonymised password-protected .zip file with the following fields: 
 
Acquired fields: 
 *  ID anonymisation 
 *  AGEATREQ age at blood sample request 
 *  SEX gender 
 *  SIMD as GIOS dataset 
 *  CARSTAIRS Index as GIOS dataset 
 *  Universal required variables: CRP (C-reactive Protein), ALB (Albumin), CCAL(Calcium)  
     as GIOS dataset 
 *  Biochemical variables where available: BIL (Bilirubin), ALP (Alkaline Phosphatase),  
     AST (aspartate transaminase), ALT (alanine transaminase) and γ-glutamyl transferase  
     (GGT) as GIOS dataset 
 *  Haematological variables were available: WCC (White Cell), NEUT (Neutrophil),  
     LYMPH (Lymphocyte), PLT (Platelet count) as GIOS dataset 
*  SITEICD10, SITEICDO, TYPEICDO regarding cancer diagnosis 
*  DAYSINCIDENCE from blood sample to cancer incidence 
*  SURVIVALREQ from cancer incidence to death or censor date 
*  DESCCAUSE the primary cause of death 
*  DUKES classification for colorectal cancer patients 
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Calculated fields: 
*  Blood sample "normal" classification depending on aformentioned range classification  
    (Chapter3) 
 *  Inflammatory score mGPS, GPS, NLR, PLR, PI 
 *  DESCICD10, DESCICDO3, DESCTYPEICDO2, DESCSITEICDO2 descriptions of  
     cancer type for each code supplied. 
*  TUMOURGROUPCR the categorical group of tumour type as detailed in Chapter 4. 
 *  DESCDEATHCAUSE the description of the ICD code of death 
 *  DEATHCAT the categorical cause of death 
 
See attached file: GIOS Cancer Registry Dataset.SAV 
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APPENDIX 3:  GIOS ISD dataset 
 
Inflammation Outcome Study - ISD Linkage 
 
Document date: 19th August 2011 
 
(1.) GIOS Dataset.SAV containing identifying variables as well as all primary single samples 
of C-reactive protein, albumin and Calcium between 1st January 2000 and 1st November 
2008 in North Glasgow Hospital laboratories - Including Glasgow Royal Infirmary, Stobhill 
hospital, Gartnavel hospital and the Western Infirmary - as described in Appendix 1. 
 
(2.) 223 303 records cross linked with ISD, NHS National Services Scotland, Gyle Square, 1 
South Gyle Crescent, Edinburgh, EH12 9EB, by exact matching surname, forename, sex and 
date of birth.  If no match on surname then Daitch-Mokotoff followed by NYSIIS soundex 
algorithms were employed.  On remaining unmatched cases, forenames and surnames were 
switched followed by matching on previous surnames, reversing gender, using first initial 
opposed to full forename and finally on surname gender and date of birth only.  On all those 
not with exact matches a manual check on whether to include or exclude was taken.  
Successful match of 209 148 cases. 
 
(3.) Anonymised data set returned to provide patient conforming to aforementioned criteria in 
Chapter 4 with a various mix of ICD 10 (www.who.int/classifications/icd/en/) for death 
where appropriate.  ICD code manual combination of morphology and topography terms to 
meaningful cause of death. 
 
(5.) Converted to anonymised password-protected .zip file with the following fields: 
 
Acquired fields: 
 *  ID anonymisation 
 *  AGEATREQ age at blood sample request 
 *  SEX gender 
 *  SIMD as GIOS dataset 
  *  Universal required variables: CRP (C-reactive Protein), ALB (Albumin), 
CCAL(Calcium)  
     as GIOS dataset 
 *  Biochemical variables where available: BIL (Bilirubin), ALP (Alkaline Phosphatase),  
     AST (aspartate transaminase), ALT (alanine transaminase) and γ-glutamyl transferase  
     (GGT) as GIOS dataset 
 *  Haematological variables were available: WCC (White Cell), NEUT (Neutrophil),  
     LYMPH (Lymphocyte), PLT (Platelet count) as GIOS dataset 
 *  ISD_10_CODE of cause of death 
 *  ISD_CIS NUMBER of days continuous in patient hospital stay 
 *  ISD_ADMTYPE at time of blood sample emergency vs elective 
 *  ISD_DAYSFROMADMTOREQUEST days from admission to blood sample 
 *  ISD_INFECTIVECAUSE as primary reason of admission 
 *  ISD_SURVIVALFROMREQ from cancer incidence to death or censor date 
 
Calculated fields: 
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*  Blood sample "normal" classification depending on aformentioned range classification  
    (Chapter3) 
 *  Inflammatory score mGPS, GPS, NLR, PLR, PI 
 *  DESC_ISD_10 descriptions of cancer type for each code supplied. 
 
See attached file: GIOS ISD Dataset.SAV 
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13.0 LIST OF ABBREVIATIONS 
 
Abbreviation Definition 
ACS Acute coronary syndrome 
Alb Albumin 
Alk phos Alkaline phosphatase 
ALT Alanine transaminase 
AST Aspartate transaminase 
AUC Area under the curve (ROC) 
Bili Bilirubin 
Ca
2+
 Adjusted calcium 
CABG Coronary Artery Bypass Graft 
CI Confidence interval 
DNA Deoxyribonucleic acid 
dNLR derived Neutrophil Lymphocyte Ratio 
ECOG Eastern Cooperative Oncology Group 
GGT γ-glutamyl transferase 
g/l Grams per litre 
GPS Glasgow Prognostic Score 
HR Hazard Ratio 
hs-CRP High sensitivity C-reactive protein 
ICD International Classification of Diseases 
IL Interleukin 
ISD Information Services Division for Scotland 
LDH Low density lipoprotein 
LFT Liver function test 
mg/l Milligrams per litre 
mGPS modified Glasgow Prognostic Score 
mmol/l millimoles per litre 
NLR Neutrophil Lymphocyte Ratio 
NS Not significant 
oGPS optimised Glasgow Prognostic Score 
PCA Percutaneous Coronary Angioplasty 
PI Prognostic Index 
PLR Platelet Lymphocyte Ratio 
PNI Prognostic Nutritional Index 
p-value Probability value 
ROC Receiver operating characteristic 
SCR Scottish Cancer Registry 
SIMD Scottish Index of Multiple Deprivation 
SNOMED CT Systematized Nomenclature of Medicine – Clinical Terms 
STEMI ST elevation myocardial infarction 
TNM Tumour Node Metastasis 
U/l Units per litre 
μmol/l micromoles/litre 
WBC/WCC White blood cell count 
 
